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Chapter 1 
The systemic vasculitides 
Vasculitides are “chronic inflammatory diseases in which blood vessels are targeted by an 
immune insult” [1]. They can occur as primary disease (primary vasculitis), but also in response to 
several drugs, or in the context of an underlying disease, such as various malignancies, 
myelodysplasia, and several bacterial and viral infections (secondary vasculitis). 
Historically, the classification of vasculitides is predominantly based upon histopathological and 
immunohistochemical characteristics, such as the size of the vessels that are involved, and the 
presence or absence of immune-complexes. Until 1994, it was very difficult to obtain a uniform, 
widely accepted, classification system. In 1994 however, a classification scheme for systemic 
idiopathic (primary) vasculitides was presented as a result of the Chapel Hill Consensus 
Conference [2]. This classification scheme is now widely used, and importantly facilitates the 
diagnosis, treatment as well as research in this category of diseases. In Figure 1-1, the primary 
systemic vasculitides are arranged according to their main site of occurrence in the vascular 
system, as proposed by the Chapel Hill Consensus conference. This thesis focuses on a subgroup 
of small vessel vasculitides that is associated with the presence of anti-neutrophil cytoplasmic 
autoantibodies (ANCA). 
 
Figure 1-1: Preferred sites of vascular involvement by selected vasculitides. The widths of the trapezoids indicate the 
frequencies of involvement of various portions of the vasculature. LCA: leukocytoclastic angiitis (adapted from 
Jennette et al., 1997 [3]) 
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ANCA-associated vasculitis 
Wegener’s Granulomatosis (WG), Churg-Strauss Syndrome (CSS) microscopic polyangiitis 
(MPA), and idiopathic necrotizing crescentic glomerulonephritis (NCGN) have several 
characteristics in common. First, their diagnosis is based histopathologically on the presence of 
destructive inflammation of the arterioles, capillaries and postcapillary venules without extensive 
depositions of immune components such as complement and immunoglobulins (pauci-immune). 
Second, they are often accompanied by elevated levels of anti-neutrophil cytoplasmic 
autoantibodies (ANCA), predominantly specific for proteinase 3 (PR3-ANCA) and 
myeloperoxidase (MPO-ANCA). Therefore, they are collectively referred to as ANCA-associated 
small-vessel vasculitides [2-6]. 
 
 
Figure 1-2: The presence of ANCA can be visualized by indirect immunofluorescence on normal human PMNs. (a) 
Cytoplasmic (C-ANCA) staining observed after incubation with serum positive for PR3-ANCA; (b) Perinuclear (P-
ANCA) pattern observed after incubation with serum positive for MPO-ANCA. 
 
As shown in Figure 1-2, the presence of ANCA in serum can be visualized by indirect 
immunofluorescence (IIF). In most cases, MPO-ANCA show a perinuclear staining pattern on 
human PMNs (P-ANCA), whereas PR3-ANCA result in a cytoplasmic staining pattern (C-
ANCA). Testing for ANCA specificities is done by ELISA using purified antigens. For their 
association with the above-mentioned diseases, determination of ANCA-titers is not only of great 
value in the diagnosis, but also in the prediction and prevention of relapses during follow-up [7]. 
Although every organ can be affected by ANCA-associated vasculitis (Table 1-1; reviewed in [5]), 
severe renal failure and pulmonary hemorrhage in particular result in severe morbidity, and may 
be fatal if left untreated. Current standard therapy consists of immunosuppression with high dose 
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corticosteroids and cyclophosphamide during the first 3-6 months, and azathioprine for 18 
months as maintenance therapy [8]. Plasma exchange should be added in case of severe 
histopathological signs of crescentic glomerulonephritis or fulminant extrarenal disease 
manifestations. Although this regimen leads to remission in the majority of patients, considerable 
treatment-related morbidity and failure to induce or maintain remission underline the importance 
of less toxic and more effective therapies. 
 
Table 1-1: Approximate frequency (%) of organ-system manifestations in several forms of small-vessel vasculitis 
(Adapted from Jennette et al., NEJM 1997). 
Organ system 
Henoch-
Schönlein 
purpura 
Cryoglobulinemic 
vasculitis 
Microscopic 
polyangiitis 
Wegener’s 
granulomatosis 
Churg-
Strauss 
syndrome 
Cutaneous 90 90 40 40 60 
Renal 50 55 90 80 45 
Pulmonary <5 <5 50 90 70 
Ear, nose, and 
throat 
<5 <5 35 90 50 
Musculoskeletal 75 70 60 60 50 
Neurological 10 40 30 50 70 
Gastrointestinal 60 30 50 50 50 
 
The pathogenesis of ANCA-associated vasculitis – in vitro 
studies 
The association between small-vessel vasculitides and ANCA has been well established, and a 
role for the latter in the pathogenesis of disease has been long suggested by multiple in vitro 
observations. Sera or purified IgG from ANCA-positive patients, as well as monoclonal 
antibodies directed against MPO or PR3, have been found to induce an oxidative burst in healthy 
human neutrophils that are pretreated with inflammatory cytokines such as tumor necrosis factor 
alpha (TNFα) [9-13] and IL-18 [14]. Furthermore, ANCA-activated PMNs are capable of 
damaging cultured human umbilical vein endothelial cells (HUVECs) [15], and firm adhesion of 
PMNs to a monolayer of TNFα-treated HUVECs is greatly increased after pretreatment with 
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ANCA-IgG [16]. Such studies might provide a link between ANCA-positivity and the occurrence 
of vascular disease. Indeed, freshly isolated and untreated PMNs from patients with ANCA-
associated vasculitis are found to produce significantly more superoxide than PMNs from normal 
controls [17]. From these data, a hypothesis can be deducted, in which three key-players act 
together to generate full-blown ANCA-mediated disease (Figure 1-3 [18]). The first one is the 
polymorphonuclear neutrophil (PMN), being the most prominent source of the ANCA antigens, 
MPO and PR3. The second one, a proinflammatory environment, typically created in vitro by 
adding a priming concentration of TNFα to the system, is required to “pre-activate” the PMNs, 
leading to the upregulation of adhesion molecules and, importantly, to an increased availability of 
the ANCA antigens on the outer membrane of circulating PMNs and monocytes. ANCA then 
act as the third player by binding to the monocyte and PMN cell membrane, resulting in their 
activation and the release of lytic granule constituents and reactive oxygen radicals. Finally, 
activated neutrophils adhere to susceptible endothelium, where they initiate an inflammatory 
cascade that ultimately results in symptomatology as clinically observed [18]. 
Although the clinical symptoms of vasculitis patients positive for PR3-ANCA and patients with 
MPO-ANCA are similar, they differ in a number of ways. This might be consequential to 
differences in immunogenicity, tissue retention, and binding or functional behavior of the 
respective autoantigens [5, 19, 20]. MPO is a 140 kD heme protein that is predominantly stored 
in the lysosomes of monocytes and in the azurophilic granules of resting PMNs. Its capacity to 
catalyze the formation of hypochlorite (HOCl) out of hydrogen peroxide (H2O2) and chloride-
ions makes it a powerful tool in the bactericidal armament of these cells. In vitro, MPO however 
also mediates CD11b/CD18- (MAC-1) mediated binding of PMNs [21] and more importantly, 
this specific binding of MPO to CD11b/CD18 has recently been shown to result in PMN 
activation [22]. In addition, there is convincing in vitro and in vivo evidence for a role of MPO in 
apoptosis [23-25], as well as in direct activation of the complement system [26, 27]. Interestingly, 
it has been shown that MPO-ANCA are capable of inhibiting the binding of MPO to its natural 
inhibitor, ceruloplasmin [28, 29]. The resultant state of uninhibited activity of MPO should not 
be ignored as a possible pathogenic factor in MPO-ANCA associated vasculitis. 
To summarize, during the last decade many factors involved in the pathogenesis of ANCA-
associated vasculitis have been elucidated. However, to definitively prove that ANCA are 
pathogenic, and to further assess their precise role so that new, more targeted and less toxic 
therapies can be developed, animal models are indispensable. 
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Figure 1-3: Representation of ANCA-mediated neutrophil responses that are putatively involved in the pathogenesis 
of ANCA-associated small vessel vasculitis. (a) Proinflammatory cytokines and chemokines (e.g. tumor necrosis 
factor α) released as a result of local or systemic infection cause upregulation of endothelial adhesion molecules (e.g. 
selectins, ICAM-1, and VCAM) and prime the neutrophil. (b) Neutrophil priming causes upregulation of neutrophil 
adhesion molecules (CD11b) and translocation of the ANCA antigens from their lysosomal compartments to the cell 
surface. (c) Engagement of the F(ab’)2 portion of ANCA with ANCA antigens on the cell surface and interaction of 
the Fc part of the antibody with Fc receptors activates the neutrophil, causing increased neutrophil–vessel wall 
adherence and transmigration. (d) ANCA-mediated neutrophil activation also triggers reactive oxygen radical 
production and possibly causes neutrophil degranulation, with consequent release of proteolytic enzymes, leading to 
vasculitis [18] 
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The theory of autoantigen complementarity 
Although the role of autoantibodies in a variety of autoimmune diseases is already well 
established, it is still largely unclear by which mechanism self-tolerance of the human immune 
system is evaded, and how this leads to the initiation of an autoimmune response. In ANCA-
associated vasculitis, a role for molecular mimicry between the autoantigen and an infectious 
microorganism has been long suspected in this respect (reviewed in [30] and [4]). Indeed, 
correlations have been found between the occurrence of infection and the development of 
ANCA-associated vasculitis, but the evidence for molecular mimicry between infectious agents 
and ANCA antigens being the driving force behind the induction of ANCA has remained weak. 
With an interesting modification on the theory of idiotypic manipulation (reviewed in [31]), 
Pendergraft and colleagues recently proposed an alternative mechanism responsible for ANCA 
induction [32]. In their study, immunization of mice with a peptide translated from the DNA 
strand complementary to the gene encoding for human PR3 (complementary PR3, cPR3), initially 
induced an immune response against this peptide (anti-cPR3 IgG). This is followed by an anti-
idiotypic immune response, that is directed against the antigen-specific part of anti-cPR3 IgG 
(anti-anti-cPR3 IgG), but also cross-reacts with human PR3, the ANCA autoantigen (Figure 1-4 
[32]). Interestingly, the cPR3 peptide bears considerable homology with proteins expressed by a 
variety of microorganisms, several of which have already been associated with PR3-ANCA 
associated disease in previous studies. In particular the homology between cPR3 and 
Staphylococcus aureus proteins is of note, since in several studies, an association is suggested 
between Staphylococcus aureus positivity and WG (reviewed in [33]). 
The most remarkable aspect of the study described above, is the finding that translation of a 
complementary DNA strand results in a protein that can has the capacity to function as a 
complementary protein in an idiotype/anti-idiotype network. It remains to be seen whether this 
is a phenomenon that is more or less unique to PR3, or whether this mechanism is also involved 
in the generation of other autoantibodies, in particular MPO-ANCA. Nevertheless, although in 
this non-homologous system the pathogenic role of PR3-ANCA can not be addressed, the theory 
of autoantigen complementarity provides an attractive explanation for the initiation of the anti-
PR3 immune response in PR3-ANCA associated vasculitis. 
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Figure 1-4: Schematic of a new mechanism for the development of autoimmunity, termed the theory of autoantigen 
complementarity. Autoimmunity is a consequence of an immune response to a protein whose amino acid sequence is 
complementary to that of a self protein. The immunogen, which elicits the initial immune response (idiotypic 
response), is complementary in amino acid sequence to the autoantigen. This idiotypic antibody elicits a second 
immune response (anti-idiotypic response), in which anti-idiotypic antibodies are produced. The anti-idiotypic 
antibodies are now autoantibodies that react with ‘self’ [32] 
 
Animal studies of ANCA-associated vasculitis 
A) RATS 
In a rat model of autoimmunity [34], the administration of mercuric chloride (HgCl2) to Brown 
Norway (BN) rats leads to a syndrome characterized by the presence of autoantibodies against a 
variety of antigens, including DNA, collagen, thyroglobulin, glomerular basement membrane 
(GBM) components, and MPO [35]. On pathological examination of the animals after sacrifice at 
days 12-18, moderate acute tubular necrosis and lymphocytic infiltration, in the interstitium as 
well as perivascularly, can be observed. In addition, in some animals a mild interstitial 
pneumonitis is seen in the lungs, and multiple other organs contain sites of lymphocytic 
infiltration. The disease can be divided into an early, T-cell independent, and a late, T-cell 
dependent phase [36]. The importance of T-cell activation in this model has been confirmed and 
extended by Macphee et al [37]. They recently showed that blocking CD80 (B7.1) and CD86 
(B7.2) on B-lymphocytes inhibits T-lymphocyte activation through inhibition of costimulation via 
CD28, resulting in decreased caecal vasculitis scores. The above-described model seems well 
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applicable to the study of immune responses that are mainly driven by T-cells, such as graft-
versus-host disease. In contrast, there is still much dispute on the importance of T-lymphocytes 
in human ANCA-associated vasculitis [38-42], and Xiao et al [43] clearly show the importance of 
humoral immunity in a study that will be described later in this chapter. To our knowledge, the 
capability of HgCl2-induced ANCA to induce an oxidative burst in rat PMNs has not been 
demonstrated thus far, although the observation that administration of antioxidants attenuates 
HgCl2-induced vasculitis suggests an important role for oxidative stress in this model [44]. The 
absence of crescentic glomerulonephritis and/or pulmonary granuloma formation, and the 
multitude of different autoantibodies that are found in this model comprise other important 
limitations for the use of this model for the study of ANCA-associated vasculitis. 
Antibodies against human MPO that cross-react with rat MPO, are observed in BN rats 
immunized with human MPO [45, 46]. In such rats, administration of human MPO and H2O2, 
the substrate of MPO, via the right jugular vein, leads to pulmonary and gastrointestinal 
vasculitis, but not glomerulonephritis [46]. In contrast, severe NCGN occurs when kidneys from 
BN rats that are immunized with human MPO are perfused with human neutrophil lysosomal 
extract and H2O2 [47]. In this study, renal perfusion of MPO-immunized rats with H2O2 only, or 
renal perfusion of non-immunized rats, did not lead to glomerulonephritis, whereas perfusion of 
immunized rats with MPO led to moderate immune complex glomerulonephritis. Interestingly, 
on pathological evaluation deposits of IgG are found in kidneys of rats sacrificed 4 or 24 hours 
after perfusion, but are absent at later timepoints. This suggests that in fact immune complexes 
could play a role in the pathogenesis of NCGN, but that they might already have disappeared by 
the time kidney biopsies are generally taken. However, in contrast to these results considerable 
immune depositions were found by Yang et al. in BN rats as well as in spontaneously 
hypertensive rats at day 10 after perfusion [48]. 
Recently, a novel rat model of ANCA-associated vasculitis is presented that provides strong 
evidence for pathogenicity of the anti-MPO immune response in this disease [49]. In this model, 
immunization of Wistar Kyoto (WKY) rats with human MPO leads to the generation of 
antibodies against human MPO, that cross-react with rat neutrophils. In addition, on pathologic 
examination after 8 weeks, MPO-immunized rats display mild pauci-immune crescentic 
glomerulonephritis that is histopathologically similar to human ANCA-associated 
glomerulonephritis. In the lungs, signs of alveolar hemorrhage, perivascular cuffing by leukocytes 
and fibrin deposits are also found. The close resemblance between the histopathology seen in this 
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model and in humans, makes this a promising model for the study of ANCA-associated vasculitis 
and its pathogenesis. 
Also in Wistar rats, the role of bacterial infection in ANCA-associated vasculitis (reviewed in [4] 
and [30]) was recently investigated [50]. Immunization with pasteurized and sonicated 
preparations of S. aureus or E. coli led to segmental glomerular sclerosis, albeit in a very limited 
number of animals. Rats were given injections of the preparation together with Complete or 
Incomplete Freund’s Adjuvant at 10 day intervals and sacrificed at day 60 or 70. The affected E. 
coli-immunized rat was found to be C-ANCA positive, but antigen specificity could not be 
determined, nor could T-cell reactivity be observed in response to MPO or PR3. 
B) MICE 
In 1995, Blank et al. reported the development of a novel animal model in which PR3-ANCA-
associated vasculitis can be studied [51]. Based on the theory of idiotypic manipulation, mice 
were immunized with human anti-PR3, resulting in the development of murine antibodies to 
human PR3 at 4 months. Anti-PR3 IgG-immunized, but not normal human IgG-immunized 
mice sacrificed at 8 months showed massive sterile micro-abscesses or perivascular lymphocytic 
infiltration, but not necrotizing vasculitis, in the lungs. Remarkably, immunization with human 
PR3-ANCA also led to elevated titers of mouse antibodies against human MPO and endothelial 
cells. Reactivity of murine sera to murine antigens was not examined. In contrast, Jenne et al. 
found that autoantibodies from 40 different WG patients do not bind to the murine homologue 
of PR3 [52]. It is therefore unlikely that the histopathology observed by Blank et al. can be 
attributed to the presence of mouse anti-human PR3. 
Rauova et al [53] reported the development of antibodies to human MPO in wild type (WT) mice 
after immunization with live or apoptotic human PMNs. Incubation of unprimed human PMNs 
with these antibodies led to an increased respiratory burst compared to control mouse IgG. It is 
however unclear whether these antibodies bind to and activate murine PMNs, and histological 
examination after sacrifice at several timepoints revealed no pathologic alterations. Nevertheless, 
this study underlines the potential role of apoptosis in the initiation of ANCA production, a 
notion that was confirmed in other animal studies (e.g. ref [54]; discussed in more detail in 
Chapter 7). In this respect, a study by Clayton et al. showed that apoptotic neutrophils are 
phagocytosed by dendritic cells (DCs), an effect that was enhanced by incubation with ANCA 
[55]. This however did not lead to sensitization of DCs, but to reduced allogeneic T cell 
responses, an effect that was abolished by coincubation with TNFα. 
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SCG/Kj mice are the product of breeding with (BXSB x MRL/Mp-lpr/lpr) F1 mice that are 
selected for having parents with the most severe crescentic glomerulonephritis (CGN) [56]. 
BXSB is a mouse strain that spontaneously develops autoimmune disease and immune complex 
glomerulonephritis [57], and MRL/Mp-lpr/lpr mice spontaneously develop neutrophilic 
vasculitis with histological features of microscopic angiitis [58, 59]. Interestingly, in the latter 
strain some mice also develop anti-MPO autoantibodies, and their presence is strongly associated 
with the occurrence of clinical vasculitis. SCG/Kj mice however spontaneously develop CGN 
and proteinuria to a higher degree than MRL/Mp-lpr/lpr or BXSB mice [56]. Systemic vasculitis 
is also observed, although the kidneys are not frequently affected. Immunohistochemically, 
deposits of IgG, IgM and C3 in the glomeruli are scanty, and serum levels of immune complexes 
and anti-DNA antibodies were equal to, or lower than the levels observed in MRL/Mp-lpr/lpr 
mice. However, Neumann et al. recently reported significant glomerular immune deposits in all 
animals with CGN, and found no evidence for ANCA [60]. The contrast with small-vessel 
vasculitis in humans, a disease predominantly characterized by paucity of immune reactants, is 
evident, and makes the SCG/Kj model not representative for human ANCA-associated 
vasculitis. 
The mouse model of anti-MPO IgG-induced 
glomerulonephritis 
Recently, Xiao et al. provided strong evidence that MPO-ANCA play a pivotal role in the 
development of MPO-ANCA-associated vasculitis [43]. They described an animal model in 
which an immune response against murine MPO is raised in mice lacking MPO [61], by 
immunization with murine MPO (muMPO) isolated from WEHI-3, a murine myeloid cell line. 
Adoptive transfer of splenocytes from muMPO-immunized Mpo-/- mice to RAG2 knockout 
(Rag2-/-) mice, that lack mature B and T lymphocytes, induces a dose-dependent elevation of anti-
muMPO titers, that kept rising until sacrifice at day 13. In mice receiving ≥5x107 anti-muMPO 
splenocytes, markedly elevated BUN and serum creatinine levels, as well as hematuria, proteinuria 
and leukocyturia were seen. Moreover, on pathologic evaluation, extensive focal necrotizing 
glomerulonephritis could be observed, with crescent formation and/or necrosis in 80% of 
glomeruli. Also in other organs such as the lungs, spleen, and lymph nodes, manifestations of 
vascular inflammation were found. Transfer of splenocytes from mice immunized with bovine 
serum albumin (BSA) to Rag2-/- mice, as well as the transfer of muMPO-immunized splenocytes 
to Mpo-/- mice, only led to a mild immune complex glomerulonephritis. 
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Figure 1-5: Transfer of IgG from Mpo-/- mice immunized with murine MPO to wildtype or immune-deficient (Rag2-/-) 
mice results in NCGN, whereas splenocytes or IgG from sham (BSA-) immunized Mpo-/- mice do not [43] 
 
In addition to the above-described adoptive transfer experiments, the effect of a passive transfer 
of IgG from muMPO-immunized Mpo-/- mice to WT or Rag2-/- mice was investigated. Sera from 
immunized mice were pooled and IgG was isolated and injected intravenously into WT and 
Rag2-/- mice (see Figure 1-5 for a schematic representation of the mouse model). After three days, 
both groups had comparable anti-MPO titers. Both groups also developed urine abnormalities, 
although Rag2-/- mice tended to be somewhat more affected than WT mice. On pathologic 
evaluation at 6 days, WT as well as Rag2-/- mice had mild focal necrotizing glomerulonephritis 
with crescents. Notably, the percentages of crescentic and necrotic glomeruli were considerably 
higher in Rag2-/- than in WT mice. Control mice from both groups that received IgG isolated 
from BSA-immunized Mpo-/- mice, developed no urine or pathologic abnormalities. Remarkably, 
when compared to the adoptive transfer of anti-muMPO splenocytes, passive transfer led to less 
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severe urine abnormalities and lower levels of necrosis and crescent formation. In addition, BUN 
and serum creatinine levels were not increased in the passive transfer experiments. 
The mouse model described above elegantly proves that MPO-ANCA play an important role in 
the pathogenesis of ANCA-associated vasculitis and NCGN. However, it is remarkable that, 
although ANCA titers after passive transfer and adoptive transfer are comparable, disease 
manifestations are much more severe after adoptive transfer. This might be an effect of the 
described presence of low to moderate amounts of immune complex depositions in the kidneys 
of Rag2-/- mice receiving splenocytes [62]. Moreover, it suggests considerable contributions of 
other factors that are introduced by the transfer of splenocytes. There is support from human 
studies for a role of autoreactive T-cells in the development of vasculitis [39-42]. T-cell 
proliferation in response to MPO is also increased in rats immunized with human MPO, as 
determined by delayed-type hypersensitivity (DTH) reaction and T-cell proliferation assay [47, 
50]. Therefore, it might be interesting to identify muMPO-reactive T-lymphocytes in the spleens 
of muMPO-immunized Mpo-/- mice, and to investigate whether adoptive transfer of these cells 
leads to disease. In addition, to extend the in vitro observed effect of neutrophil priming on 
ANCA-induced neutrophil oxidative burst [9-13], the animal model provides the opportunity to 
study the effect of pro-inflammatory stimuli on MPO-ANCA induced glomerulonephritis. 
It might seem highly artificial to induce disease through the transfer of murine MPO-specific 
IgG. It is therefore interesting to note in this respect a recently published case report, in which 
the newborn from an MPO-ANCA positive mother develops severe pulmonary hemorrhage, 
associated with MPO-ANCA positivity [63]. Upon the initiation of therapy with corticosteroids 
and exchange transfusion, the symptoms subsided, and the neonate has remained in remission 
during one year of follow-up. Although only casuistic, this report is the first to convincingly show 
pathogenicity of MPO-ANCA alone, and provides strong support for the clinical relevance of the 
observations in the murine transfer model as discussed above. 
The success of the transfer models of vasculitis mediated by MPO-ANCA raised the question 
whether it was possible to establish a similar mouse model of PR3-ANCA associated disease. To 
address this question, Pfister and colleagues immunized mice double-deficient for PR3 and 
neutrophil elastase (NE) with recombinant murine PR3, and transferred their sera to WT mice 
[64]. The administration of serum from mPR3-immunized PR3-/NE-double-deficient mice was 
shown to significantly augment TNFα-induced local panniculitis in WT mice. Remarkably 
however, neither healthy WT mice, nor WT mice pretreated with bacterial lipopolysaccharide 
(LPS) as a proinflammatory stimulus, developed vasculitis or glomerulonephritis upon serum 
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transfer. Whether the apparent discrepancy between the murine model of anti-MPO IgG-induced 
NCGN and its PR3 equivalent is consequential to differences in the administered titer, or caused 
by biochemical or biophysical differences between murine MPO and murine PR3 is as yet 
unexplained. It can however be concluded that a suitable animal model of this disease should be 
awaited before a valid conclusion can be drawn regarding the pathogenicity of PR3-ANCA in 
clinical disease. 
Conclusion 
During the past two decades, a number of animal models have been used to study ANCA-
associated vasculitis. Based on in vitro observations, it was suggested that ANCA play an 
important role in the pathogenesis of this disease, although direct evidence for a causal relation 
between ANCA and disease was absent. The transfer studies performed by Xiao et al., in which 
the administration of IgG from muMPO-immunized Mpo-/- mice to MPO-positive mice causes a 
disease remarkably similar to human NCGN and vasculitis [43], provide an animal model that is 
excellently suitable to investigate the link between the anti-MPO immune response and the 
occurrence of disease.  
To summarize, recently developed animal models of ANCA-associated vasculitis provide 
promising tools to study the pathogenesis of this disease. As a result, they might be beneficial to 
the development of novel therapies. As long as a validated animal model of PR3-ANCA-
associated vasculitis is absent, progress in this regard needs to be awaited. 
Outline of this thesis 
The main goal of this thesis is to create insight in the various factors involved in the initial phase 
of the development of ANCA-associated vasculitis. To this end, we utilized the mouse model of 
anti-MPO IgG-induced glomerulonephritis as described above, and as schematically represented 
in Figure 1-5. In Chapter 2, a study is presented in which we test the hypothesis obtained from in 
vitro studies, that proinflammatory stimuli enhance the pathogenic effect of anti-MPO antibodies. 
We show that LPS increases the severity of anti-MPO IgG-induced NCGN. This resulted in a 
modified model that better expresses the severity of human MPO-ANCA associated disease. In 
Chapter 3, the rationale for TNFα bioactivity-inhibiting therapy in humans with ANCA-
associated vasculitis is discussed, bearing in mind in vitro observations, the results of various 
animal studies, and mounting data from clinical studies on the efficacy of various TNFα-
inhibiting drugs.  
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General introduction 
A recent study, performed in various complement-deficient mouse strains, shows a crucial role 
for the complement system in anti-MPO IgG-induced NCGN. Chapter 4 describes a study in 
which the mouse model of anti-MPO IgG-induced NCGN is used to investigate whether 
complement factor C5 could be a therapeutic target in ANCA-associated vasculitis. 
In the mouse model of anti-MPO IgG-induced NCGN, disease is induced with polyclonal anti-
MPO IgG, isolated from the sera of Mpo-/- mice immunized with murine MPO. In Chapter 5, we 
describe the generation and characterization of a panel of monoclonal antibodies (moAbs) 
specific for murine MPO, and test their pathogenicity in the context of a systemic 
proinflammatory stimulus induced by the administration of LPS, as well as in the context of a 
local proinflammatory environment created by the administration of a low dose of heterologous 
antibodies specific for the glomerular basement membrane (GBM).  
As discussed above, the symptomatology of MPO-ANCA associated vasculitis might be 
explained in part by the biological function of MPO itself. Consequently, a better understanding 
of the function of MPO in inflammation might provide additional insight into the pathogenesis 
of MPO-ANCA associated glomerulonephritis as well. Since it is impossible to study MPO-
ANCA associated NCGN in Mpo-/- mice, we employed a murine model of renal warm 
ischemia/reperfusion injury to provide more insight in the role of MPO in renal inflammation. 
The results of this study are presented in Chapter 6. Finally, in Chapter 7 the results of ongoing 
investigations, obtained by our group as well as others, in the field of ANCA-associated vasculitis 
are summarized, discussed, and implemented in a modified theory, covering the 
pathophysiological mechanisms involved in the initial development of disease as well as the 
mechanisms that might be responsible for its perpetuation. 
 
  
 Chapter 2 – Aggravation of  anti-myeloperoxidase 
antibody-induced glomerulonephritis by bacterial 
lipopolysaccharide: role of  tumor necrosis factor α 
Huugen D, Xiao H, van Esch A, Falk RJ, Peutz-Kootstra CJ, Buurman WA, Tervaert JW, 
Jennette JC, Heeringa P. Am J Pathol. 2005 Jul;167(1):47-58. 
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Abstract 
Wegener’s granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome, and idiopathic pauci-immune 
necrotizing crescentic glomerulonephritis (NCGN) are associated with anti-neutrophil cytoplasmic autoantibodies 
(ANCA). There is clinical and experimental evidence indicating that ANCA and pro-inflammatory stimuli of 
infectious origin act synergistically in causing vasculitis. Here, we tested this hypothesis using a recently developed 
mouse model of anti-MPO IgG induced glomerulonephritis and bacterial lipopolysaccharide (LPS), as a model 
proinflammatory stimulus. 
Systemic administration of LPS dose-dependently increased renal injury induced by anti-MPO IgG as demonstrated 
by increased glomerular crescent formation and glomerular necrosis. In the early phase, LPS enhanced anti-MPO 
IgG induced glomerular neutrophil accumulation. Furthermore, a transient induction of circulating levels of TNFα, 
followed by a marked increase in circulating levels of myeloperoxidase was observed upon administration of LPS. In 
vitro, anti-MPO IgG induced a respiratory burst in murine neutrophils only after priming with TNFα. Finally, anti-
TNFα treatment attenuated, but did not prevent, the LPS mediated aggravation of anti-MPO IgG induced 
glomerulonephritis. 
In conclusion, our study demonstrates that ANCA and pro-inflammatory stimuli act synergistically in inducing 
vasculitic disease and point to a potentially beneficial effect of TNFα-bioactivity inhibiting treatment modalities on 
human ANCA-associated NCGN. 
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Introduction 
Wegener’s granulomatosis (WG), microscopic polyangiitis (MPA), Churg-Strauss syndrome and 
idiopathic pauci-immune necrotizing crescentic glomerulonephritis (NCGN) are forms of small-
vessel vasculitis of unknown etiology that are strongly associated with anti-neutrophil cytoplasmic 
autoantibodies (ANCA) [3]. ANCA comprise a group of autoantibodies directed against proteins 
contained in the lysosomal compartments of neutrophils and monocytes. The primary target 
antigens have been identified as proteinase 3 (Pr3), a 29 kD neutral serine proteinase, and 
myeloperoxidase (MPO), a 140 kD protein involved in the generation of reactive oxygen species 
[65]. To date, detection of ANCA has proven to be a helpful diagnostic tool and many clinical 
studies have confirmed that Pr3-ANCA and MPO-ANCA are highly specific for WG and MPA, 
respectively [65] 
Since the discovery of ANCA, numerous clinical and laboratory studies have been performed to 
determine whether ANCA are directly involved in the pathogenesis of vasculitis and 
glomerulonephritis. The overall concept derived from these studies is that ANCA induced 
vasculitis is a ‘two-hit’ process in which ANCA together with pro-inflammatory stimuli, most 
likely of infectious origin, are required for the induction of full-blown disease. In support of this 
model are clinical observations demonstrating that relapses in disease activity are often preceded 
by rising ANCA levels [66-68]. Furthermore, the frequent observation of infectious episodes 
prior to diagnosis and/or relapse suggests that these may play a role in the pathogenesis of 
ANCA-associated disease [69-72]. Consistent with these clinical observations are in vitro studies 
that have shown that ANCA are capable of activating neutrophils and monocytes primed with 
pro-inflammatory cytokines, resulting in an oxidative burst, degranulation, production of 
cytokines and endothelial cell damage [9-13, 73]. 
Recently, an experimental animal model of anti-MPO induced NCGN was developed that 
involves the adoptive transfer of mouse MPO-reactive splenocytes into immune-deficient mice 
[43]. These mice developed severe NCGN with pathological features that were remarkably 
similar to human anti-MPO associated glomerulonephritis. In addition, it was demonstrated that 
passive transfer of murine anti-mouse MPO antibodies alone into either immune-deficient or 
wildtype mice also induces NCGN, although of a substantially milder form. 
Thus, the association between ANCA, small vessel vasculitis, and infections suggests that, besides 
ANCA, a second (nonspecific) pro-inflammatory signal is necessary to induce full-blown disease. 
To test this hypothesis, we used the experimental mouse model of anti-MPO antibody induced 
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NCGN and investigated the effects of bacterial lipopolysaccharide (LPS), as a model (pro-) 
inflammatory stimulus, on disease severity. 
Material and methods 
MICE 
MPO-/- mice, backcrossed to a C57Bl/6 background for 6 times, were genotyped using PCR-
amplified DNA from tail clippings [61]. Wildtype (WT) female C57Bl/6 (8-12 weeks of age) were 
obtained from Harlan (Horst, the Netherlands). Mice were kept according to University of 
Maastricht animal facility regulations, and all experiments were approved by the local Animal 
Care and Experimentation Committee. 
PURIFICATION OF MURINE MPO 
Murine MPO (muMPO) was purified from WEHI-3, a myeloid cell line, that was grown in 
HEPES-buffered McCoy5A medium containing penicillin/streptomycin and 10% FCS. When a 
density of 1.5x106 cells/ml was reached, cells were harvested, resuspended in buffer A containing 
6.7 mM sodium acetate, 3.0 mM MgCl2, 3.0 mM NaCl, 0.5 mM PMSF and 1% CTAB, and lysed 
by Dounce homogenization on ice. After stirring (2 hours, 4°C), insoluble particles were removed 
by centrifugation (14.000 g, 30 minutes, 4°C), and the supernatant was dialyzed overnight at 4°C 
against buffer B containing 100 mM sodium acetate (pH 6.3) and 100 mM NaCl. Next, CaCl2, 
MgCl2 and MnCl2 were added to a final concentration of 1 mM each, and the solution was mixed 
with concanavalin A-Sepharose (Amersham Biosciences, Roosendaal, Netherlands). After 
centrifugation and removal of supernatant, the con A was resuspended in several washes of 
buffer B with 750 mM methyl a-D-mannopyranoside to elute the MPO (overnight, 4°C). The 
samples of buffer B containing MPO (as judged by OD at 428 nm) were then dialyzed against 
buffer C, containing 50 mM sodium acetate (pH 8.5-9) and 100 mM NaCl, loaded onto a Mono S 
cation exchange column (Biorad, Veenendaal, the Netherlands), eluted with 1 M NaCl, and 
dialyzed against PBS. Purity was checked by SDS-PAGE. 
PREPARATION OF PATHOGENIC MOUSE ANTI-MURINE MPO IGG AND CONTROL 
MOUSE ANTI-BSA IGG. 
MPO-/- mice were immunized as reported previously[43] with minor modifications. Briefly, mice 
received an intraperitoneal injection of 10 µg of muMPO in complete Freund’s adjuvant (Difco) 
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on day 0, followed by intraperitoneal booster injections in incomplete Freund’s adjuvant on days 
21 and 36. On day 42, blood was obtained and mice were sacrificed. Antibody titers were 
monitored by enzyme-linked immunosorbent assay (ELISA) as described previously [43]. In 
short, microtiter plates were coated overnight with muMPO (0.5 µg/ml) and blocked with bovine 
serum albumin (BSA). Then plates were incubated with mouse sera (1:100 starting dilution), 
followed by incubation with alkaline phosphatase-conjugated goat-anti-mouse IgG antibodies. 4-
nitrophenyl phosphate (pNPP) was used as substrate, and wells were analyzed 
spectrophotometrically at 405 nm. 
To obtain anti-BSA IgG, a separate group of MPO-/- mice was immunized with BSA following 
the protocol described above. Normal serum from C57Bl/6 mice was obtained from Harlan. IgG 
was isolated from pooled sera by 50% ammonium sulphate precipitation followed by protein G 
column affinity chromatography. IgG containing fractions were concentrated by ultrafiltration 
(Centriplus, Millipore, Amsterdam, the Netherlands) and dialyzed against PBS. Protein 
concentrations were determined using the bicinchoninic acid protein assay kit (Pierce, Rockford, 
IL). The anti-MPO titer of each batch was checked by ELISA as described above, using a sample 
of anti-MPO IgG with previously established pathogenicity as a reference. Endotoxin 
concentrations were determined by the limulus amebocyte lysate assay (Bio Whittaker, 
Walkersville, MD) and depending on the isolation ranged from 0.04 ng/ml to 1.2 ng/ml. 
INDUCTION OF GLOMERULONEPHRITIS BY PASSIVE TRANSFER OF ANTI-MPO IGG 
C57Bl/6 mice received a dose of 100 µg/g body weight of sterile-filtered (0.2 µm filter, 
Schleicher&Schuell, Dassel, Germany) anti-MPO IgG by intraperitoneal injection. Where stated, 
groups of mice additionally received a single intraperitoneal injection of 5.0, 0.5, or 0.05 µg/g of 
LPS (E. coli, serotype 026-B6, Sigma St. Louis MO, n=4-5 in each group) dissolved in sterile PBS 
one hour after the administration of IgG. Control mice were injected with anti-BSA IgG (100 
µg/g, n=5) followed by 5.0 µg/g of LPS one hour later, or with LPS (5.0 µg/g, n=4) alone. 
Circulating anti-MPO IgG was monitored by ELISA as described above, using a serum pool 
from MPO-immunized MPO-/- mice as reference. Results are expressed as a percentage of the 
absorbance units (OD 405 nm) of a positive control pool serum.  
MEASUREMENT OF SERUM MPO AND TNFα LEVELS 
In a separate experiment, the effect of intraperitoneal injection of LPS on serum TNFα- and 
MPO levels was determined. Blood was taken from mice 1 week before, 1 hour after and 1 and 6 
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days after the administration of 0.05, 0.5 or 5.0 µg/g LPS (n=4 in each group) in endotoxin-free 
0.9% saline. Samples were centrifuged and serum was taken and stored at -20°C. 
To detect circulating MPO, we generated a mouse-anti-mouse MPO monoclonal antibody 
(moab) from splenocytes obtained from muMPO-immunized MPO-/- mice using standard 
procedures. The resulting moab (IgG1, designated 8F4) recognized murine MPO and cross-
reacted with rat but not human MPO as determined by direct ELISA and immunohistochemistry 
on normal spleen sections (data not shown). Using this antibody, a catching ELISA was 
developed for the detection of murine MPO in sera as follows. Microtiter plates were coated with 
Fcγ fragment-specific goat anti mouse-IgG (3.2 µg/ml, 100 µl/well; Jackson ImmunoResearch), 
incubated for 48 hours at 4°C, and blocked with 1% BSA in PBS for 30 minutes at room 
temperature. Plates were then incubated with 8F4 (1.0 µg/ml, 100 µl/well) for 1 hour at room 
temperature. Next, plates were incubated with appropriately diluted serum samples for 1 hour at 
room temperature, followed by incubation with polyclonal rabbit anti-human MPO (14 µg/ml, 
DakoCytomation, Glostrup, Denmark) for 1 hour at room temperature and incubation with 
alkaline phosphatase-labeled polyclonal goat anti-rabbit IgG for 1 hour at room temperature. 
Finally, plates were incubated with pNPP for 30 minutes, and results were analyzed 
spectrophotometrically at 405 nm. Concentrations were calculated from a standard curve of 
purified murine MPO (range 2.5-100 ng/ml).  
TNFα levels were determined by capture ELISA as described previously [74]. Briefly, plates were 
coated overnight with TN3 (5 µg/ml). After blocking with BSA, samples were added to the plate 
for 1 hour at room temperature. Plates were then incubated for 1h with rabbit anti-mouse TNF 
polyclonal antibody followed by incubation with peroxidase-labeled goat anti-rabbit IgG for 1 
hour. The assay was developed with O-Phenylene Diamine (OPD), the reaction was stopped 
with 4N H2SO4, and the OD was measured at 490 nm. Concentrations were calculated from a 
standard curve of recombinant murine TNFα (range 0.02-40 ng/ml). 
ANTI-TNFα TREATMENT 
To investigate the effects of TNFα depletion on disease induction, groups of mice received a 
single intraperitoneal dose of the anti-murine TNFα antibody TN3 (500 µg/mouse, endotoxin 
concentration < 10 pg/ml), a complementarity-determining regions-grafted murine IgG2a (kindly 
provided by Celltech, Slough, UK, n=8) or isotype control (moab L2-3D9, endotoxin 
concentration < 10 pg/ml, n=7), [75, 76] in sterile PBS, 24 hours before anti-MPO IgG and LPS 
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(0.5 µg/g) administration. When given 24 hours in advance, this dose of TN3 completely 
inhibited TNFα activity in sera of mice taken one hour after intraperitoneal injection of 0.5 µg/g 
LPS, as determined by cytotoxicity assay using the murine fibrosarcoma cell line WEHI 164 as 
described previously [77]. All mice were sacrificed six days after disease induction. 
LABORATORY AND PATHOLOGICAL EVALUATION OF DISEASE INDUCTION 
At the times indicated, mice were bled and sacrificed. Urine samples were tested by dipstick 
(Bayer, Mijdrecht, the Netherlands) for hematuria, proteinuria, and leukocyturia and scored on 0-
4+ scale. Blood urea nitrogen (BUN) and creatinine levels were determined in sera collected at 
the time of sacrifice by an enzymatic degradation assay on a Synchron LX20 PRO (Beckman 
Coulter Inc., Fullerton CA). 
Tissue samples were taken from both kidneys and processed for light microscopy, 
immunofluorescence, and immunohistochemistry. For light microscopy, renal tissue samples 
were fixed in 4% formaldehyde and embedded in paraffin. 1.5 µm sections were cut and 
hematoxylin/eosin and periodic acid Schiff staining were performed. For each animal, a crescent 
score was determined by evaluating crescent formation in 50 consecutive glomerular cross 
sections. Only glomeruli that had two or more layers of cells in Bowman’s space were considered 
crescentic. Similarly, a glomerular necrosis score was determined for each animal by evaluating 
segmental or global glomerular capillary necrosis in 50 consecutive glomerular cross sections. 
Analysis was performed in a blinded fashion using coded slides. 
Phenotypic analysis of the inflammatory cell infiltrate was performed on 4 µm cryostat sections 
fixed in 100% acetone at room temperature. The following primary antibodies were used: rat 
anti-mouse CD45, rat anti-mouse neutrophils (clone NIMP-R14)[78]; rat anti-mouse CD68 
(macrophages, clone FA11)[79]; rat anti-mouse CD3 (clone KT3). Endogenous peroxidase 
activity was blocked with 0.05% H2O2 in PBS. Rabbit anti-rat IgG-PO and goat anti-rabbit IgG-
PO (both DakoCytomation) were used as secondary and tertiary antibodies, respectively. 
Antibody binding was visualized using 3-amino-9-ethylcarbazole (AEC) and H2O2 as substrates. 
Sections were counterstained with hematoxylin. Glomerular cell infiltrates were determined by 
counting the number of positive cells in 30 glomerular cross sections per kidney section. In 
experiments where effects of LPS on early (day 1) neutrophil recruitment were studied the 
number of glomeruli containing neutrophil aggregates was also scored. An aggregate was defined 
as a homotypic aggregate of 3 or more neutrophils and was evaluated in 30 glomerular cross 
sections. 
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Mouse IgG and fibrin deposits were detected by immunofluorescence using rabbit anti-mouse 
IgG-Alexa Fluor 488 (Molecular probes, Leiden, the Netherlands) and rabbit anti-human 
fibrinogen-FITC (DakoCytomation). MPO deposits were detected using biotinylated mouse anti-
mouse MPO (8F4) followed by streptavidin-Alexa 488 (Molecular probes). Endogenous avidin 
and biotin were blocked using a streptavidin-/biotin blocking kit (Vector Laboratories, 
Burlingame, CA). 
SUPEROXIDE ANION ASSAY 
To determine the in vitro capacity of polyclonal mouse-anti murine MPO antibodies to induce an 
oxidative burst in murine neutrophils, we used the superoxide dismutase inhibitable (SOD) 
ferricytochrome C assay [80]. Peritoneal exudate cells (PECs) were obtained by flushing of the 
peritoneal cavities of 3 to 4 WT or MPO-/- mice with sterile Hank’s balanced salt solution (HBSS) 
four hours after intraperitoneal administration of 1 ml 3% thioglycollate. As determined on May 
Grünwald Giemsa-stained cytospots, the percentage of neutrophils in these cell preparations was 
≥ 55% . Cells were centrifuged and resuspended at a concentration of 2x106 cells/ml in HBSS. 
The remainder of the procedure was performed at 37°C. Cells were incubated with cytochalasin 
B (5 µg/ml, Serva, Heidelberg, Germany) for 5 minutes, followed by incubation with 
recombinant murine TNFα (10 ng/ml, R&D, Abingdon, UK) or an equal volume of HBSS for 
10 minutes. Next, 96-well microtiter plates were incubated with 200 µl cell suspension (4 x 105 
cells/well), ferricytochrome C (70 µM, Sigma, Zwijndrecht, the Netherlands), stimulus, and either 
SOD (42 U/ml, Sigma) or an equal volume of HBSS. As stimulus, 250 µg/ml anti-muMPO IgG 
or normal mouse IgG was used. Phorbol ester myristate acetate (PMA, 200 ng/ml, Sigma) served 
as a positive control. Optical density at 550 nm was measured every 15 minutes for 60 minutes 
and SOD-inhibitable production of superoxide was determined as ∆OD at 550 nm. Each test 
was performed in triplicate and experiments were repeated 3 (MPO-/- cells) to 4 (WT cells) times. 
STATISTICAL ANALYSIS 
Data are expressed as means ± SD and were analyzed using the unpaired two-tailed Student’s t 
test using Graphpad Prism 4.01 for Windows (Graphpad Software, San Diego CA, USA). For 
semiquantitative data from dipstick analysis, a ranked ANOVA test was used to evaluate 
differences across all groups. When significant differences were detected with ANOVA, the 
Duncan test was used to evaluate statistical differences between specific groups. A p-value ≤ 0.05 
was considered statistically significant. 
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Results 
DEVELOPMENT OF CIRCULATING MPO-ANCA AND URINARY ABNORMALITIES 
AFTER PASSIVE TRANSFER OF ANTI-MPO IGG 
Upon passive transfer of anti-MPO IgG, circulating anti-MPO antibodies were detected in all 
subjected mice. The level of circulating anti-MPO was highest on day 1 and had declined at the 
time of sacrifice (day 6). On day 1, no differences were detected in levels of circulating anti-MPO 
antibodies between the experimental groups (Table 2-1). However, on day 6, mice that received 
the highest dose of LPS (5 µg/g) had a significantly lower anti-MPO titer compared to mice 
receiving anti-MPO alone (Table 2-1). No anti-MPO reactivity was detected in sera from mice 
treated with anti-BSA IgG and LPS (0.5 µg/g) or LPS alone. 
 
Table 2-1: Anti-MPO antibody titers after passive transfer of anti-MPO IgG. 
Groups n 
Anti-MPO antibody titer 
(% AU (OD 405nm) of positive control) 
  Day 1 Day 6 
anti-MPO 5 85.2 ± 10.0 54.4 ± 12.2 
anti-MPO + 
5 µg/g LPS 
5 77.4 ± 13.5 38.2 ± 8.1* 
anti-MPO + 
0.5 µg/g LPS 
5 83.6 ± 2.7 45.0 ± 16.2 
anti-MPO + 
0.05 µg/g LPS 
4 82.5 ± 3.1 59.0 ± 6.8 
Anti-BSA + 
LPS 5 µg/g 
5 0 0 
                                                 
* p<0.04 compared to anti-MPO alone 
 
By day 1, hematuria had developed in all mice that received anti-MPO antibodies with or without 
LPS which persisted until the time of sacrifice at day 6 (Table 2-2). Most of these mice also had 
proteinuria and leukocyturia at day 6. Hematuria and leukocyturia measured at day 6 tended to be 
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more severe in mice treated with anti-MPO IgG and 5.0 µg/g or 0.5 µg/g LPS, than in mice 
treated with anti-MPO IgG alone (Table 2-2). At day 6, serum creatinine and blood urea nitrogen 
levels were within normal range in all mice. No urinary abnormalities above background could be 
detected in mice treated with anti-BSA and 5.0 µg/g LPS, or with LPS alone (Table 2-2). 
 
Table 2-2: Urinalysis and renal function at 6 days after disease induction 
Groups n Hematuria Proteinuria Leukocyturia 
Creatinine 
(µmol/L) 
BUN 
(mmol/L) 
anti-MPO 5 2.7 (1-3) 2.8 (2-4) 0.8 (0-2) 15.6 ± 7.0 8.1 ± 2.9 
anti-MPO + 
5 µg/g LPS 
5 3.4*(3-4) 2.6 (2-3) 1.4 (0-2) 19.2 ± 2.6 8.0 ± 0.9 
anti-MPO + 
0.5 µg/g LPS 
5 3.8* (3-4) 3.2 (2-4) 2.6 (2-3) 18.2 ± 2.4 7.5 ± 1.8 
anti-MPO + 
0.05 µg/g LPS 
4 2.3 (1-3) 2.3 (1-3) 1.0 (1-2) 21.3 ± 2.6 7.0 ± 1.6 
Anti-BSA + 
5 µg/g LPS 
5 0 1.4 (1-2) 0 18.5 ± 2.4 8.6 ± 1.1 
Hematuria, proteinuria and leukocyturia were tested by dipstick and scored on 0-4+ scale. Values represent mean 
scores per group. Samples taken before antibody injection showed mean proteinuria 1.0+, hematuria 0+, and 
leukocyturia 0+. 
                                                 
* p< 0.005 
 
LPS AGGRAVATES ANTI-MPO IGG INDUCED NECROTIZING CRESCENTIC 
GLOMERULONEPHRITIS 
Intraperitoneal administration of anti-MPO IgG into WT mice induced a focal and segmental 
necrotizing crescentic glomerulonephritis in all subjected mice at day 6, with a mean of 5.6% 
(range 2-10) crescentic and 9.0% (range 7-12) necrotic glomeruli (Figure 2-1 and Figure 2-2). 
Administration of 5.0 or 0.5 µg/g LPS one hour after administration of anti-MPO IgG resulted 
in a marked increase in the severity of glomerulonephritis, as judged by the percentage of 
glomeruli containing crescents or fibrinoid necrosis. Addition of 5.0 µg/g LPS resulted in 20.4% 
(range 16-26) crescentic and 22.8% (range 12-36) necrotic glomeruli, whereas addition of 0.5 
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µg/g LPS resulted in 20.8% (range 14-26) crescentic and 28.4% (range 22-34) necrotic glomeruli 
(Figure 2-1 and Figure 2-2). Addition of 0.05 µg/g LPS did not lead to more severe disease 
compared to anti-MPO IgG alone, and administration of 100 µg/g anti-BSA IgG and 5.0 µg/g 
LPS, or LPS aloe, did not result in any histological abnormalities (Figure 2-1 and Figure 2-2). 
 
Phenotypic analysis of the inflammatory cell infiltrate 6 days after administration of anti-MPO 
IgG demonstrated intraglomerular influx of CD45+ve leukocytes, the majority of which were 
found to be FA11+ macrophages (Figure 2-3, a and b, Table 2-3). A further increase in the 
number of glomerular infiltrating CD45+ leukocytes and FA11+ macrophages was observed 
upon addition of 5.0 or 0.5 µg/g LPS (Figure 2-3, c-f, Table 2-3). At this time point, numbers of 
intraglomerular CD3+ T cells and neutrophils were only slightly elevated in anti-MPO treated 
mice with or without LPS as compared to non-treated C57Bl/6 mice or mice that had received 
LPS (5.0 µg/g) alone. 
Figure 2-1: Effect of LPS on pathologic findings in 
C57Bl/6 mice 6 days after passive transfer of anti-
MPO IgG. a: Glomerular crescent formation 
expressed as a percentage of glomerular crescents in 
each animal. * p=0.0005, ** p=0.0002 compared to 
anti-MPO IgG alone b: Glomerular necrosis 
expressed as a percentage of glomeruli with necrosis 
in each animal. Horizontal lines represent mean 
percentages in each group. * p=0.02, ** p=0.001 
compared to anti-MPO IgG alone. 
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Figure 2-2: Effect of LPS on renal tissue injury in C57Bl/6 mice 6 days after passive transfer of anti-MPO IgG. a: 
Overview of renal tissue of a mouse that received anti-MPO IgG. One small crescentic glomerulus is shown (arrow). 
b: Overview of renal tissue in a mouse that received anti-MPO IgG and 0.5 µg/g LPS. Increased numbers of 
crescentic glomeruli are observed (arrows). c: Segmental fibrinoid necrosis in a glomerulus from a mouse that 
received anti-MPO IgG d: Small cellular crescent in mouse that received anti-MPO IgG. e: Glomerulus with 
segmental fibrinoid necrosis and crescent formation in a mouse that received anti-MPO IgG. f: Segmental fibrinoid 
necrosis in a glomerulus from a mouse that received anti-MPO IgG and 0.5 µg/g LPS. g: Large cellular crescent in 
mouse that received anti-MPO IgG and 0.5 µg/g LPS. h: Large cellular crescent with breaks in Bowman’s capsule 
and periglomerular accumulation of inflammatory cells in a mouse that received anti-MPO IgG and 0.5 µg/g LPS. 
a,b,d,e,g,h: PAS stain. c,f: H&E stain. Magnification a,b: x320; c-h: x400. 
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Immunofluorescence revealed marked focal and segmental glomerular deposition of fibrin in 
anti-MPO treated mice with or without LPS at day 6 that corresponded with sites of segmental 
necrosis or crescent formation (Figure 2-3, i). In contrast, on day 6 glomerular staining for MPO 
and IgG was absent or scanty (Figure 2-3, g and h). 
 
Figure 2-3: Effect of LPS on inflammatory cell recruitment in C57Bl/6 mice 6 days after passive transfer of anti-
MPO IgG. a: Moderate intraglomerular and interstitial infiltration of CD45 +ve leukocytes in a mouse that received 
anti-MPO IgG. b: Intra- and periglomerular influx of FA11 +ve macrophages in a mouse that received anti-MPO 
IgG. c and d: Marked intra- and periglomerular and interstitial influx of CD45 +ve leukocytes in a mouse that 
received anti-MPO IgG and 0.5 µg/g LPS. e and f: Marked intra- and periglomerular and interstitial influx of FA11 
+ve macrophages in a mouse that received anti-MPO IgG and 0.5 µg/g LPS. g: Immunofluorescent staining for 
MPO in a mouse that received anti-MPO IgG and 0.5 µg/g LPS. h: Immunofluorescent staining for mouse IgG in a 
mouse that received anti-MPO IgG and 0.5 µg/g LPS. i: Immunofluorescent staining for fibrin in a mouse that 
received anti-MPO IgG and 0.5 µg/g LPS showing prominent staining corresponding to crescent formation. 
Magnification: a,b,d,e x200, c,f x630, g-i x400. 
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Table 2-3: Immunophenotyping of intraglomerular inflammatory cell infiltrate at 6 days after disease induction 
Groups n 
CD45 + 
Leukocytes 
FA11 + 
macrophages 
CD3 + 
T cells 
PMNs 
anti-MPO 5 1.82 ± 0.19 1.34 ± 0.13 0.44 ± 0.20 0.39 ± 0.10 
anti-MPO + 
5 µg/g LPS 
5 3.72 ± 0.51* 2.24 ± 0.07* 0.55 ± 0.14 
0.48 ± 0.19 
anti-MPO + 
0.5 µg/g LPS 
5 3.56 ± 0.41* 2.45 ± 0.19* 0.43 ± 0.14 
0.39 ± 0.10 
anti-MPO + 
0.05 µg/g LPS 
4 1.95 ± 0.14 1.48 ± 0.22 0.23 ± 0.03 
0.21 ± 0.07 
LPS 5 µg/g 4 1.08 ± 0.10 0.44 ± 0.15 0.31 ± 0.13 0.22 ± 0.08 
WT 4 0.77 ± 0.26 0.36 ± 0.20 0.17 ± 0.06 0.09 ± 0.07 
                                                 
* p<0.0001 compared to anti-MPO alone. Numbers represent mean numbers ± SD of positive cells per glomerular 
cross section. 
LPS ENHANCES ANTI-MPO IGG INDUCED EARLY NEUTROPHIL RECRUITMENT 
At day 1, anti-MPO IgG treated mice showed increased glomerular influx of neutrophils that 
occasionally appeared as small neutrophilic aggregates (Figure 2-4, b). This early glomerular influx 
of neutrophils was markedly enhanced upon addition of 0.5 µg/g LPS resulting in large 
neutrophilic aggregates (Figure 2-4, c). In contrast, injection of 0.5 µg/g LPS alone induced only 
a slight increase in the number of intraglomerular neutrophils, whereas glomerular neutrophil 
aggregation was not observed (Figure 2-4). 
LPS INCREASES SERUM MPO AND TNFα LEVELS 
In a separate experiment, the effect of a single dose of 5.0, 0.5, or 0.05 µg/g LPS on serum MPO 
and TNFα levels was determined. As shown in Figure 2-5, intraperitoneal administration of 5.0, 
0.5 and 0.05 µg/g LPS led to a rise in serum TNFα levels one hour after injection. In case of the 
high (5.0 µg/g) and medium (0.5 µg/g) dose of LPS, this was followed by a rise in serum MPO 
levels at day 1. TNFα levels were undetectable at day 1 and day 6 after administration, whereas at 
the latter time point MPO levels had returned to baseline. Administration of saline alone did not 
lead to alterations in TNFα and MPO levels (data not shown). 
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Figure 2-4: Effect of LPS on neutrophil influx and 
aggregation in C57Bl/6 mice 1 day after passive transfer of 
anti-MPO IgG. a: Glomerulus from a mouse that received 
anti-MPO IgG showing segmental neutrophil influx and 
formation of a small neutrophilic aggregate. b: Glomerulus 
from a mouse that received anti-MPO and 0.5 µg/g LPS 
showing massive neutrophil influx and homotypic 
aggregation. c and d: Quantification of glomerular 
neutrophil influx (c) and the percentage of glomeruli that 
contained homotypic neutrophil aggregates (d) in mice (n=3 
in each group) that received LPS (0.5 µg/g) alone, anti-
MPO IgG alone or anti-MPO and LPS (0.5 µg/g). gcs, 
glomerular cross section. Magnification a and b: x400. * 
p=0.008. 
 
Figure 2-5: Serum MPO and TNFα levels in 
C57Bl/6 mice that received 0.05 (white bars), 
0.5 (grey bars) or 5 µg/g (black bars) of LPS by 
intraperitoneal injection. The horizontal line 
indicates the mean serum MPO levels in serum 
samples taken before treatment. In these 
pretreatment samples, no TNFα could be 
detected. 
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PRETREATMENT WITH ANTI-TNFα ANTIBODY ATTENUATES 
GLOMERULONEPHRITIS INDUCED BY ANTI-MPO IGG AND LPS 
To investigate the involvement of TNFα in the LPS-mediated aggravation of anti-MPO IgG 
induced glomerulonephritis, a neutralizing anti-murine TNFα antibody (TN3) was used. In these 
experiments, mice received an intraperitoneal injection of 500 µg TN3 or isotype control on day -
1, followed by administration of anti-MPO IgG and 0.5 µg/g LPS on day 0. In both groups, mice 
developed hematuria and leukocyturia to a similar degree as measured by dipstick analysis. 
However, pathologic analysis at day 6 revealed that pretreatment with TN3 significantly 
attenuated glomerular crescent formation, whereas no difference was found in the extent of 
glomerular necrosis (Figure 2-6). In both groups, renal function on day 6 was unimpaired (BUN 
7.8 ± 1.4 vs. 7.4 ± 2.1 and creatinine 19.±4.1 vs. 19.3±1.9 in TN3 and isotype control antibody 
treated mice, respectively). 
 
 
Figure 2-6: Effect of anti-TNFα treatment on necrotizing crescentic glomerulonephritis induced by anti-MPO IgG 
and LPS (0.5 µg/g). a: Quantification of glomerular crescent formation upon anti-TNFα or isotype control 
treatment. Glomerular crescent formation is expressed as a percentage of glomerular crescents in each animal. b: 
Quantification of glomerular necrosis upon anti-TNFα or isotype control treatment. Glomerular necrosis is 
expressed as a percentage of glomeruli with necrosis in each animal. 
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Immunohistochemical analysis showed that pretreatment with TN3 significantly attenuated 
glomerular influx of CD45+ total leukocytes and FA11+ macrophages (Table 2-4). No 
differences were observed in intraglomerular numbers of neutrophils and T cells (Table 2-4). By 
immunofluorescence, glomerular IgG staining was absent or scanty in both groups. 
 
Table 2-4: Immunophenotyping of intraglomerular inflammatory cell infiltrate at 6 days after anti-TNFα antibody or 
isotype control antibody (L2-3D9) treatment 
Groups n 
CD45 + 
Leukocytes 
FA11 + 
macrophages 
CD3 + 
T cells 
PMNs 
anti-MPO + 
0.5 µg/g LPS 
+ L2-3D9 
8 3.03 ± 0.52* 2.26 ± 0.62* 0.33 ± 0.14 0.37 ± 0.10 
anti-MPO + 
0.5 µg/g LPS 
+ TN3 
7 2.23 ± 0.41 1.53 ± 0.29 0.37 ± 0.08 0.35 ± 0.14 
                                                 
* p<0.005 compared to anti-MPO + 0.5 µg/g LPS + TN3. Numbers represent mean numbers ± SD of positive cells 
per glomerular cross section. 
 
ANTI-MPO IGG INDUCES SUPEROXIDE ANION PRODUCTION IN TNFα-PRIMED 
PERITONEAL EXUDATE CELLS IN VITRO 
The capacity of anti-MPO antibodies to induce neutrophil activation in vitro was determined using 
the SOD inhibitable ferricytochrome C assay. Incubation of unprimed peritoneal exudate cells 
with normal mouse IgG or anti-MPO IgG did not induce superoxide production above 
background (data not shown). However, when peritoneal exudate cells were pretreated with 10 
ng/ml murine TNFα for 10 minutes, incubation with anti-MPO IgG resulted in a modest but 
significant increase in superoxide production as compared to normal mouse IgG or buffer alone 
(Figure 2-7, a and b). Importantly, anti-MPO IgG did not induce superoxide anion production in 
TNFα primed, MPO deficient peritoneal exudate cells (Figure 2-7, a and c). PMA induced 
superoxide anion production in these cells was, however, similar to that observed in wildtype 
peritoneal exudate cells (Figure 2-7, a). 
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Figure 2-7a: Superoxide anion production in TNFα (10 ng/ml) primed peritoneal exudate cells (4x105 cells/well) 
derived from wildtype C57Bl/6 or MPO-/- mice as measured by the SOD inhibitable ferricytochrome C assay. Anti-
MPO IgG (250 µg/ml) induces significant superoxide anion production in TNFα primed peritoneal exudate cells 
from wildtype C57Bl/6 mice (black bars) as compared to normal mouse IgG (250 µg/ml) or buffer alone. In 
contrast, no superoxide anion production was detected in TNFα primed peritoneal exudate cells from MPO-/- mice 
(white bars) upon stimulation with anti-MPO IgG. Results represent mean ∆OD 550 nm ± SD of 3 to 4 
experiments performed in triplicate. * p=0.02 compared to anti-MPO IgG on MPO deficient cells. b and c: Time 
course of superoxide anion production in response to PMA (◊, 200 ng/ml), anti-MPO IgG (▲, 250 µg/ml), normal 
mouse IgG (▼, 250 µg/ml) or buffer alone (●) using TNFα primed peritoneal exudates cells from wildtype C57Bl/6 
(b) or MPO-/- (c) mice. Results represent mean ∆OD 550 nm from single experiments performed in triplicate. 
 
 43 
LPS aggravates anti-MPO-induced GN 
Discussion 
In the present study, three main findings are reported that are relevant to the pathogenesis of 
MPO-ANCA induced glomerulonephritis. First, it was demonstrated that systemic administration 
of bacterial LPS markedly aggravates anti-MPO induced NCGN. This effect was dependent on 
the dose of LPS administered and appeared to be related to LPS-induced circulating levels of 
TNFα and MPO. Second, LPS-mediated aggravation of anti-MPO IgG induced 
glomerulonephritis was attenuated, but not prevented, by pretreatment with neutralizing anti-
TNFα antibodies. Finally, in vitro experiments showed that murine anti-MPO IgG induces an 
oxidative burst in TNFα-primed peritoneal exudate cells, an observation that is consistent with 
human data showing ANCA mediated neutrophil activation. 
In our studies, glomerulonephritis induction by anti-MPO IgG alone is less severe compared to 
similar groups of mice reported in the companion paper by Xiao et al. The most plausible 
explanation for this difference in disease severity is the route of injection of the anti-MPO 
antibodies. In our studies, anti-MPO antibodies were injected intraperitoneally whereas in the 
companion paper the antibodies were administered intravenously. This could potentially lead to 
different levels of circulating anti-MPO antibodies but we have not formally tested this. Another 
explanation may be that the antibody batches used in these two studies differed in the amount of 
pathogenic anti-MPO antibodies. Importantly, however, in both studies, transfer of anti-MPO 
antibodies induced crescentic glomerulonephritis in all of the tested mice which emphasizes the 
pathogenic potential of these autoantibodies. 
Our observation that LPS dose-dependently aggravates anti-MPO induced glomerulonephritis 
provides support for the hypothesis that ANCA and proinflammatory stimuli act synergistically 
in inducing full-blown disease in humans. With respect to the mechanisms underlying this effect 
several possibilities may be considered and will be discussed below. 
First, as shown here and by many others, systemic administration of LPS results in an immediate, 
transient increase in serum TNFα levels. From in vitro experiments on human PMNs, it is well 
known that priming with TNFα is necessary for the induction of a respiratory burst by sera or 
purified IgG from ANCA-positive patients [9-13, 73]. We confirmed this in our mouse model by 
showing that anti-MPO IgG induced an oxidative burst in peritoneal exudate cells only after 
pretreatment with TNFα, and only when those cells were obtained from MPO-competent mice. 
Second, we observed that administration of LPS synergistically increased anti-MPO IgG induced 
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early glomerular neutrophil recruitment. The number of infiltrating PMNs was significantly 
increased in anti-MPO treated mice with or without LPS that were sacrificed one day after 
disease induction. These results suggest an important role for PMNs in the initiation of anti-
MPO IgG-induced disease. The number of lesional PMNs had decreased on day 6 which most 
likely is a reflection of the progression of the inflammatory response that is dominated by 
macrophages. This is in line with in vitro data, demonstrating an important role for priming of 
endothelial cells with TNFα[16] or LPS[81] in anti-MPO IgG induced neutrophil adhesion. 
Subsequently, these adherent neutrophils may become activated by MPO-ANCA causing 
endothelial cell injury [15]. Despite aggravation of renal injury by LPS as observed by 
histopathological analysis, renal function in these mice was not impaired. Apparently, the number 
of affected glomeruli was not sufficient to cause elevations in serum creatinine and BUN levels. 
The requirement for TNFα priming in ANCA-mediated neutrophil activation is in part explained 
by the observation that primed neutrophils translocate the ANCA antigens to their cell surface 
making them accessible for interaction with the autoantibodies. In the case of MPO-ANCA, 
studies have clearly demonstrated that expression of MPO is essential for MPO-ANCA mediated 
neutrophil activation because neutrophils obtained from MPO deficient individuals are non-
responsive [82]. However, inconsistent data exist on whether MPO-ANCA mediated neutrophil 
activation involves MPO expressed on the cell surface of primed neutrophils. Whereas some 
authors describe an enhanced surface expression of MPO on primed neutrophils, others have 
been unable to demonstrate this effect [9, 11, 12, 73]. In preliminary experiments using flow 
cytometry, we have not been able to convincingly demonstrate surface MPO expression on either 
peripheral neutrophils from LPS-treated mice or peritoneal exudate cells treated with LPS in vitro. 
One possibility is that priming induces cell surface MPO expression in minute amounts that are 
below the detection limits of our assay system but this clearly needs further investigation. 
Alternatively, other mechanisms may be involved in MPO-ANCA mediated neutrophil 
activation. Studies by Hess and colleagues have shown that resting human neutrophils exposed to 
supernatants of degranulated autologous neutrophils expressed MPO, but not Pr3, on their cell 
surface and became responsive to anti-MPO autoantibodies [11]. Interestingly, high levels of 
circulating MPO correlate with disease severity in human MPO-ANCA associated 
glomerulonephritis [71]. In the present study, we found that doses of LPS that aggravated anti-
MPO IgG induced glomerulonephritis also gave rise to increased levels of circulating MPO. 
Based on these observations we speculate that circulating MPO, in the presence of high levels of 
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anti-MPO antibodies, may disperse MPO-ANCA mediated activation to resting neutrophils 
resulting in amplification of the inflammatory response. 
As described above, ANCA induced neutrophil activation is enhanced upon priming with pro-
inflammatory stimuli, in particular TNFα. This is a potent pro-inflammatory cytokine produced 
by many cell types, and there is mounting evidence that TNFα plays a major role in glomerular 
inflammation and scarring [83]. The actions of TNFα are numerous and include the stimulation 
of release of other cytokines and chemokines, and the induction of adhesion molecule expression 
on the endothelium [84]. To directly investigate the contribution of TNFα on the LPS-mediated 
aggravation of anti-MPO IgG induced glomerulonephritis, we treated mice with a neutralizing 
anti-TNFα antibody prior to disease induction. It was found that TNFα-inhibition reduced 
glomerular crescent formation whereas development of glomerular necrosis was unaffected. 
These results are in agreement with studies in TNFα-deficient mice, in which the development of 
accelerated anti-glomerular basement antibody (GBM) glomerulonephritis is also attenuated but 
not completely prevented [85]. On the other hand, complete prevention of glomerular crescent 
formation has been observed in a rat model of anti-GBM glomerulonephritis upon treatment 
with the soluble TNFα receptor P55 [86]. Our observations suggest that, as yet unknown, TNFα 
independent effects also play a role in the LPS-mediated aggravation of anti-MPO IgG induced 
glomerulonephritis but this clearly needs to be investigated in more detail. 
In conclusion, the results of the present study are in agreement with the hypothesis that in 
ANCA-associated diseases, autoantibody mediated effects and proinflammatory signals synergize 
in causing vascular inflammation by promoting neutrophil adhesion to the endothelium and 
enhancing neutrophil activation. Furthermore, our findings indicate that therapeutic strategies 
aimed at neutralizing TNFα bioactivity could be beneficial in the treatment of ANCA- associated 
diseases. In fact, such clinical studies have already been initiated and in a first preliminary 
publication, promising results have been reported [87]. 
 
 
 Chapter 3 – Tumor necrosis factor-alpha bioactivity-
inhibiting therapy in ANCA-associated vasculitis – 
clinical and experimental considerations 
Huugen D, Cohen Tervaert JW, Heeringa P. Clin. J. Am. Soc. Nephrol. 2006 Sep;1:1100-1107. 
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Abstract 
Wegener’s granulomatosis, microscopic polyangiitis, idiopathic necrotizing crescentic glomerulonephritis, and Churg-
Strauss syndrome are associated with the presence of anti-neutrophil cytoplasmic autoantibodies (ANCA) with 
specificity for myeloperoxidase (MPO-ANCA) or proteinase 3 (PR3-ANCA). Current therapy consists mainly of 
corticosteroids and cyclophosphamide, but since this treatment regimen is associated with considerable morbidity, 
other treatment modalities remain desirable. 
There is compelling evidence that tumor necrosis factor-alpha (TNFα) plays an important role in the pathogenesis of 
ANCA-associated vasculitis. Consequentially, inhibition of TNFα bioactivity potentially results in attenuation of 
disease. In this review, we discuss whether TNFα bioactivity-inhibiting drugs are useful in the treatment of ANCA-
associated vasculitis. The results of in vitro and in vivo experiments, as well as clinical studies are evaluated. Although 
the importance of TNFα during lesion development is evident, clinical trials using TNFα blockers in patients with 
ANCA-associated vasculitis give mixed results. Importantly, in a large-scale randomized trial treatment with 
etanercept was found to be not effective and resulted in an excess of treatment-related morbidity. It remains to be 
investigated whether inhibition of TNFα bioactivity is effective in a subgroup of patients. 
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Introduction 
Wegener’s granulomatosis (WG), microscopic polyangiitis (MPA), idiopathic necrotizing 
crescentic glomerulonephritis (NCGN), and Churg-Strauss syndrome (CSS) are associated with 
anti-neutrophil cytoplasmic autoantibodies (ANCA) [5]. They are not only widely used as serum 
markers for the diagnosis of systemic vasculitis, but also for follow-up, since ANCA-levels 
predict disease reactivation in most patients [7]. In vasculitis and glomerulonephritis, the main 
ANCA-antigens are the myeloid enzymes myeloperoxidase (MPO) and proteinase 3 (PR3), but in 
a minority of patients, ANCA are specific for other neutrophil proteins such as elastase. 
To date, therapy for ANCA-associated disease consists mainly of immunosuppression with high-
dose glucocorticoids and cyclophosphamide during the induction phase and azathioprine in 
combination with low-dose steroids as maintenance therapy. This therapeutic regimen is 
associated with considerable morbidity, and often proves to be insufficient for the induction of a 
sustained remission, since most patients develop relapsing disease activity during follow-up. 
Consequently, renal, pulmonary, and/or other organ damage is encountered [88]. 
In various immune-mediated diseases, including rheumatoid arthritis [89-91], Crohn’s disease [92] 
and ankylosing spondylitis [93, 94], the efficacy of TNFα-inhibiting treatment is well established. 
Also in several forms of vasculitis, such as Takayasu arteritis [95] and Behçet’s disease [96-98], 
there is evidence that inhibition of TNFα bioactivity-inhibition is beneficial. 
Here, we review the literature on the role of TNFα in ANCA-associated vasculitides. In vitro 
studies as well as in vivo experimental data and clinical trials on the feasibility of TNFα bioactivity 
inhibition will be discussed, as well as their consequences for the future use of this treatment 
modality in patients with ANCA-associated disease. 
The role of TNFα in ANCA-associated vasculitis – in vitro 
observations 
There is a considerable amount of data obtained from in vitro experiments pointing towards a role 
for TNFα in the pathogenesis of ANCA-associated disease. Importantly, ANCA-induced 
neutrophil activation is greatly enhanced by TNFα, leading to an increased release of oxygen 
radicals and toxic granule constituents [9-13]. The exact mechanism of this effect is uncertain, but 
several reports demonstrate an increased presence of MPO and/or PR3 on the outer membrane 
of neutrophils after incubation with TNFα [11, 12, 99, 100]. This increases the availability of the 
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ANCA-antigens for binding of the autoantibodies. In addition, neutrophil priming with TNFα 
causes upregulation of various molecules involved in adhesion of neutrophils to the endothelium 
[101], and it has been convincingly demonstrated that in particular one of these molecules, the β2 
integrin CD11b/CD18 (CR3), is critically involved in ANCA-induced neutrophil activation [73]. 
In vitro, TNFα pretreatment of endothelial cells makes them more susceptible to damage induced 
by incubation with ANCA-stimulated neutrophils, in particular if those neutrophils are also 
preincubated with TNFα [15, 102]. Moreover, pretreatment of human umbilical cord vascular 
endothelial cells with TNFα is necessary for the establishment of firm adhesion of ANCA-
stimulated neutrophils to those cells [16]. 
Taken together, in vitro data point towards a mechanism in which TNFα and ANCA together 
induce the activation of neutrophils. These activated neutrophils attach to the endothelium, 
release their toxic granule constituents and oxygen radicals, and thus cause vascular damage. 
TNFα in animal models of autoimmune crescentic 
glomerulonephritis 
In crescentic glomerulonephritis, the role of TNFα has been investigated most thoroughly in 
animal models of anti-glomerular basement membrane (GBM) glomerulonephritis. In these 
models, heterologous antibodies to the GBM are administered to mice or rats, respectively, either 
with (in the accelerated model) or without (in the heterologous model) preceding immunization 
with unspecific heterologous antibodies. This results in crescentic glomerulonephritis 
characterized by massive early neutrophil-influx and an abundance of immune complexes. 
Le Hir et al. studied the role of TNFα in the accelerated model of anti-GBM glomerulonephritis 
using TNFα-knockout (TNFα-/-) mice, and found that TNFα-deficiency led to attenuation, but 
no complete inhibition, of disease as reflected by delayed onset of proteinuria and attenuation of 
histopathological and immunohistochemical alterations [85]. Importantly, no significant decrease 
in early neutrophil influx could be observed in the TNFα-/--mice. 
Whereas TNFα-/--mice are only partially protected from disease in the accelerated model of anti-
GBM GN, treatment with daily doses of a soluble TNFα receptor (sTNFr) from day –1 
onwards, completely prevents the development of crescents in the heterologous rat model of 
anti-GBM GN [86]. An explanation for the discrepancy between this study and the study in 
TNFα-/--mice by le Hir et al. is not provided, but it is conceivable that TNFα plays a more 
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profound role in the heterologous, neutrophil-dependent, than in the accelerated model of anti-
GBM disease. Alternatively, TNFα-/--mice, due to their lifelong lack of endogenous TNFα, may 
have developed a compensatory mechanism for this deficiency, thus increasing the levels of 
alternative proinflammatory cytokines that play a role in the development of anti-GBM GN. 
Interestingly, in the rat model, treatment of established anti-GBM disease (from day +4 onwards) 
with sTNFr resulted in a marked attenuation of disease 10 days after disease induction, reflected 
by reduced proteinuria, crescent formation, fibrinoid necrosis, and glomerular influx of 
monocytes and cytotoxic T-cells [86]. This implies that TNFα does not only play a role in the 
initial phase of disease development, but also in maintaining the disease, a notion that is further 
supported by a more recent study from the same group, in which the effect of a TNFα-inhibiting 
monoclonal antibody (moAb) on the course of (heterologous) anti-GBM GN is studied in rats 
that are followed for as long as 28 days [103]. In this study, treatment of established anti-GBM 
GN with anti-TNFα moAb from day 4 or day 14 until sacrifice at day 28 significantly attenuated 
disease as measured by glomerular and tubulointerstitial scarring and serum creatinine level. 
Investigation of the role of TNFα in ANCA-associated GN has long been hampered by the lack 
of an animal model in which the pathogenicity of ANCA could be convincingly demonstrated. In 
a mouse model of spontaneous crescentic glomerulonephritis in SCG/Kj mice [56], TNFα levels 
were shown to be elevated compared to healthy C57Bl/6 mice [104]. Although MPO-ANCA are 
detected in these mice, they also display massive glomerular immune complex depositions and 
elevated titers of anti-nuclear autoantibodies [60]. Therefore, the contribution of MPO-ANCA to 
the pathology observed in this model is questionable. 
An alternative mouse model of MPO-ANCA associated vasculitis is provided by Xiao and 
colleagues, showing that transfer of IgG or splenocytes from murine MPO-immunized MPO-
knockout (MPO-/-) mice to wildtype or immune-deficient mice induces disease manifestations 
similar to those observed in human MPO-ANCA associated disease [43]. Using the passive 
transfer model of anti-MPO IgG-induced glomerulonephritis, we recently demonstrated that a 
‘second hit’ with lipopolysaccharide (LPS) significantly increased the severity of anti-MPO IgG 
induced lesions [105]. Furthermore, in this accelerated model of MPO-ANCA induced GN, we 
found that administration of a single dose of TNFα bioactivity-inhibiting moAb one day prior to 
disease induction led to a significant decrease, but no complete inhibition, of renal disease as 
measured by the degree of urinary abnormalities and the percentage of crescentic glomeruli. This 
study suggests that TNFα plays an important, although not pivotal, role in the pathogenesis of 
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NCGN induced by anti-MPO IgG and LPS. However, the fact that these results are obtained 
after preemptive anti-TNFα treatment, might limit their applicability for the clinical situation. 
Interestingly, the effect of TNFα bioactivity-inhibiting therapy was recently also investigated in a 
novel rat model of MPO-ANCA-associated NCGN. In this model, the immunization of 
WKY/NCrlBR rats with human MPO leads to the generation of anti-human MPO antibodies 
that cross-react with rat MPO, resulting in pulmonary vasculitis and pauci-immune NCGN in 
some animals [49]. Additionally, treatment of established disease with a TNFα-inhibiting moAb 
strongly reduced albuminuria and completely reversed crescent formation [106]. 
Taken together, data obtained from animal models of anti-GBM as well as MPO-ANCA-
associated NCGN clearly indicate that TNFα plays an important role in disease induction and 
progression and suggest a beneficial role for TNFα bioactivity inhibition in humans. Due caution 
should, however, be taken when extrapolating the results from animal experiments to the human 
situation. 
TNFα-inhibition – human studies 
The efficacy of two TNFα-inhibiting drugs has been investigated in patients with ANCA-
associated NCGN. Firstly, etanercept (Enbrel) is a fusion protein of two p75 subunits of the 
TNFα receptor, linked to the Fc portion of human IgG1. Secondly, infliximab (Remicade) is a 
chimeric IgG1 monoclonal antibody that binds and inhibits soluble as well as membrane-bound 
TNFα. The efficacy of both treatments in patients with rheumatoid arthritis seems to be 
comparable [107], but in patients with Crohn’s disease, etanercept, in contrast to infliximab, 
seems to be not effective [108]. The role of adalimumab (Humira), a novel, fully human TNFα-
inhibiting monoclonal antibody [109], that has been shown to be effective in rheumatoid arthritis 
and Crohn’s disease when the response to etanercept or infliximab is lost [110, 111], in the 
treatment of ANCA-associated vasculitis remains to be established. 
From the in vitro and in vivo studies on the role of TNFα in ANCA-associated vasculitis discussed 
above, it may be hypothesized that an effect of anti-TNFα treatment would be the result of 
inhibition of TNFα-induced preactivation of PMNs. This would lead to decreased membrane 
expression of the ANCA-antigens, what makes it impossible for the autoantibodies to exert their 
pathogenic effect. 
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Several clinical studies provide indirect evidence for a role of TNFα in ANCA-associated 
vasculitis. First, plasma levels of TNFα are increased in patients with ANCA-associated 
glomerulonephritis, and increased amounts of TNFα can be found by immunohistochemistry 
[112]. Second, the fractional excretion of TNFα is increased in patients with ANCA-associated 
glomerulonephritis, suggesting local production by renal cells or infiltrating leukocytes [113]. 
Third, response to treatment with intravenous immunoglobulins is accompanied by a decrease in 
serum TNFα level [114]. Finally, it has been shown in rheumatoid arthritis that TNFα is 
pivotally involved in a tightly regulated network of proinflammatory cytokines, and is responsible 
for the increased production of the interleukins 1, 6, and 8, and granulocyte-macrophage colony-
stimulating factor (reviewed in [115]). Consequently, inhibition of TNFα bioactivity in patients 
with ANCA-associated vasculitis would also result in decreased levels of those cytokines, and 
thereby decrease vascular inflammation. 
The human studies on TNFα bioinhibition in ANCA-associated vasculitis are briefly summarized 
in Table 3-1. In the first study, infliximab was added in an uncontrolled fashion to standard 
treatment consisting of corticosteroids and cyclophosphamide in six patients with treatment-
resistant Wegener’s granulomatosis [116]. This led to remission in five cases, lasting for six to 24 
months. Addition of infliximab to standard immunosuppressive therapy also led to remission in a 
more recently published case of Wegener’s disease [117]. 
A large, prospective, but also uncontrolled, trial among patients with MPO- or PR3-ANCA-
positive vasculitis has been published in 2004 [87]. Addition of infliximab to standard therapy at 
initial presentation, during relapse, or during persistent disease activity, was followed by a clinical 
response in 28 out of 32 patients, as measured with the Birmingham Vasculitis Activity Score 
[118] and reflected by a decrease in C-reactive protein, serum creatinine, and required steroid 
dose. Unfortunately, however, many side-effects were observed, including several cases of 
infection, thrombotic events and a case of B cell lymphoma, complicating clinical response. In 
addition, despite ongoing treatment with infliximab, relapses were observed frequently. This 
suggests an escape mechanism, that might be partly mediated by the development of anti-
infliximab antibodies [91, 119-122], although this was not investigated in detail. In an 
accompanying paper, the administration of infliximab significantly improved endothelial function 
in 10 patients with active ANCA-associated disease, as measured by endothelium-dependent 
vasodilation, and also in these patients, a clinical response was observed [123]. 
Until now, studies have mainly been focusing on the addition of infliximab to standard 
immunosuppressive therapy, and there is only limited information on infliximab replacing 
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standard treatment. In an uncontrolled study on 10 patients with conventional therapy-resistant 
systemic vasculitis, seven of which had WG, Bartolucci et al. found that treatment with 
corticosteroids and infliximab led to a considerable resolution of disease symptoms and 
corticosteroid requirement at 42 days and six months [124]. Although limited in size and 
uncontrolled, this study encourages further research into the replacement of conventional 
treatment by infliximab in individuals with ANCA-associated vasculitis that fail to enter 
remission under standard therapy. A case report, in which remission induction was achieved in a 
patient with MPA after primary treatment with prednisolone, cotrimoxazole/trimethoprim and 4 
infusions of infliximab, supports this notion [125]. 
 
Table 3-1: Human studies on TNFα inhibition 
Ref. Study type n Diagnosis (n) Intervention 
Remission 
(n) 
Follow-up 
(months) 
[116] Uncontrolled 
trial 
6 WG CS, CTX, IFX 5 6-24 
[117] Case study 1 WG CS, CTX, IFX 1 7 
[87] Uncontrolled 
trial 
32 WG/MPA CS, S/T, CTX, AZ, 
MTX, MMF, IFX 
28 Max. 12 
[124] Uncontrolled 
trial 
10 WG (7)/ 
other (3) 
CS, IFX* CR: 5 
PR: 5 
6 
[125] Case report 1 Pauci-
immune 
NCGN 
CS, S/T, IFX 1 12 
[126] Controlled 
trial 
181 WG CS, CTX or MTX, 
AZ, S/T, ETA or 
placebo 
Exp: 
69.7% 
Ctrl: 75.3% 
>9 (mean: 
27 months) 
Abbreviations: CS, corticosteroids; CTX, cyclophosphamide; IFX, infliximab; S/T, sulfamethoxazole/trimethoprim; 
AZ, azathioprine; MTX, methotrexate; MMF, mycophenolate mofetil; CR, complete remission; PR, partial remission; 
ETA, etanercept 
                                                 
* Two patients with severe disease received additional therapy with CTX, and MTX and MMF, respectively 
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In contrast to data on the use of infliximab, the effect of etanercept in patients with WG is less 
promising. In the only double-blind placebo-controlled multicenter trial on the use of TNFα-
inhibiting therapy in ANCA-associated vasculitis presented thus far, the Wegener’s 
Granulomatosis Etanercept Trial (WGET) Research Group investigated the efficacy of the 
addition of etanercept to standard therapy [126]. Patients with limited and severe disease, either 
newly diagnosed or relapsing, were enrolled. Standard treatment for limited and severe disease 
consisted of glucocorticoids, and methotrexate or cyclophosphamide, respectively; etanercept or 
placebo was randomly added to this as experimental treatment. Between the etanercept and 
placebo group, no significant differences were found in remission rates, disease flares, and disease 
activity, damage, or Quality of Life scores. Remarkably, during follow-up, six cases of cancer 
were identified in the etanercept group, whereas no such events were seen in the control group. 
No significant differences were found in the incidence and severity of other adverse events. 
The results of the etanercept study are surprisingly negative and seem to be in remarkable 
contrast with the data obtained from animal studies and clinical trials using infliximab. A 
discrepancy between the effect of etanercept and infliximab has been observed previously in 
another granulomatous disease, i.e. Crohn’s disease [108], and could potentially be explained 
from differences in the working mechanism of the drugs. Firstly, infliximab binds soluble and 
membrane-bound TNFα much better than etanercept, resulting in an increased capacity of 
infliximab to inhibit TNFα-mediated cytotoxicity and TNFα-induced endothelial cell activation 
[127]. Secondly, infliximab, but not etanercept, can induce an anti-inflammatory response by 
reverse signaling through membrane-bound TNFα [128]. Finally, infliximab and etanercept exert 
different effects on T-lymphocytes [129, 130] and monocytes [131]. 
Limitations to TNFα -inhibiting therapy 
From the studies on TNFα-inhibition in ANCA-associated vasculitis, as well as from similar 
studies performed in patients with other autoimmune diseases, several lessons can be drawn with 
respect to safety issues regarding this therapy. Generally, TNFα-inhibiting therapy can lead to 
infusion reactions, such as headache, irritation at the site of injection, dizziness, nausea, chest 
pain, dyspnoea, and pruritus. In addition, treatment with infliximab is associated with a higher 
rate of infections [91] [119], in particular with an increased risk of reactivation of tuberculosis 
[132]. In line with these findings, treatment of ANCA-associated vasculitis patients with 
infliximab resulted in infections in 22% of the patients [87]. However, in patients with Wegener’s 
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granulomatosis treated with etanercept [126], as well as in several controlled trials on infliximab 
in rheumatoid arthritis [90] and ankylosing spondylitis [93], the incidence of infection was similar 
in the treatment and control group. 
The role of TNFα in carcinogenesis is complex, and incompletely understood [133]. The effect 
of anti-TNFα therapy on the development of malignancies has been predominantly studied in 
rheumatoid arthritis, a disease that is associated with a higher incidence of malignancies [134]. In 
this disease, a large case series [135], a controlled retrospective study [136], a large prospective 
study [134], and a controlled trial [91] suggest that treatment with infliximab or etanercept makes 
patients more prone to the development or recurrence of cancer, in particular lymphomas. 
Conversely, Lipsky and colleagues found in a large prospective study that the incidence of 
malignancies in arthritis patients treated with infliximab was similar to background levels [90]. In 
the WGET trial, the treatment of Wegener’s granulomatosis with etanercept increased the 
incidence of solid cancer [126], whereas one out of 32 patients with ANCA-associated vasculitis 
was reported to have developed a B cell lymphoma during treatment with infliximab [87]. Thus, 
the link between TNFα-inhibition and malignancies should be investigated in more detail, before 
any conclusion can be drawn with respect to this issue. 
The high incidence of venous thromboembolic complications entails a new potential threat for 
patients with Wegener’s disease [137]. Bearing this in mind, it is of particular concern to gather 
information on the thrombogenic effects of TNFα-inhibiting therapy. Whereas TNFα is 
generally thought to be prothrombotic in vivo (reviewed in [138]), the putative anticoagulant effect 
of TNFα-inhibition is challenged by the finding that anti-TNFα can have a prothrombotic effect 
in chimpanzees [139]. In addition, it is shown that treatment with infliximab or etanercept can 
induce the formation of potentially prothrombotic anticardiolipin autoantibodies [140]. In the 
WGET-trial, however, no prothrombotic effect of etanercept was found [126]. 
Treatment with infliximab as well as etanercept has been associated with increased levels of 
autoantibodies and/or a lupus-like autoimmune disease (reviewed in [141]). This has been studied 
most extensively in patients with rheumatoid arthritis [90, 91, 140, 142-145], but anti-TNFα 
treatment was also shown to induce autoimmunity in ankylosing spondylitis [145], Crohn’s 
disease [121, 122], and mixed connective tissue disease [146]. In the WGET-trial [126], as well as 
in the infliximab study [87], the incidence of autoimmunity has not been reported. Nevertheless, 
although the development of autoantibodies in these patients only very rarely leads to a –usually 
mild– lupus-like syndrome, that resolves after discontinuation of anti-TNFα therapy, treatment-
induced autoimmunity remains an issue of concern.  
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Conclusion 
Taken together, in vitro data support the notion that TNFα plays an important role in the 
pathogenesis of ANCA-associated vasculitis and NCGN. Consequently, TNFα bioactivity-
inhibiting therapy might be effective in this disease. This is further supported by several studies in 
animal models of crescentic GN, although caution should be taken when translating animal 
studies to the clinical situation. In the only controlled study on TNFα bioinhibition in ANCA-
associated vasculitis patients, addition of etanercept to standard immunosuppressive therapy did 
not lead to improvement, and was associated with the occurrence of serious side-effects. It 
remains to be seen whether other approaches will be effective. In future studies, patients that are 
refractory to current treatment strategies should be tested in a controlled fashion, and infliximab 
should be tested instead of etanercept as additional therapy to standard immunosuppressive 
regimens. The incidence of potential side-effects, such as infections, malignancies, 
thromboembolic complications, and autoimmunity, should be of specific concern. 
  
 
 Chapter 4 – Inhibition of  complement factor C5 
protects against anti-myeloperoxidase antibody-
mediated crescentic glomerulonephritis in mice 
Huugen D, van Esch A, Xiao H, Peutz-Kootstra CJ, Buurman WA,, Cohen Tervaert JW, 
Jennette JC, and Heeringa P. Kidney Int 2007; 71: 646-654 
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Abstract 
In mice, administration of murine anti-MPO IgG induces pauci-immune necrotizing crescentic glomerulonephritis. 
Recent studies in this model indicate a crucial role for complement activation in disease induction. Here, we 
investigated the effect of pretreatment or intervention with a C5-inhibiting monoclonal antibody (BB5.1) in the 
mouse model of anti-MPO IgG-induced glomerulonephritis. 
Mice received BB5.1 8 hours before or 1 day after disease induction with anti-MPO IgG and LPS. Mice were 
sacrificed after 1 or 7 days. Control antibody pretreated mice developed hematuria, leukocyturia and albuminuria and 
glomerulonephritis with a mean of 21.0 ± 8.8 % glomerular crescents and 12.8 ± 5.5 % glomerular capillary necrosis. 
BB5.1 pretreatment prevented disease development, as evidenced by the absence of urinary abnormalities, a marked 
reduction in glomerular neutrophil influx at day 1 and normal renal morphology at day 7. Importantly, BB5.1 
administration 1 day after disease induction also resulted in a marked attenuation of urinary abnormalities and a more 
than 80% reduction in glomerular crescent formation. 
 In conclusion, inhibition of C5 activation attenuates disease development in a mouse model of anti-MPO IgG-
induced glomerulonephritis. These results favor further investigations into the role of complement activation in 
human MPO-ANCA mediated glomerulonephritis, and indicate that inhibition of C5 activation is a potential 
therapeutic approach in this disease. 
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Introduction 
Wegener’s granulomatosis, Churg-Strauss syndrome, microscopic polyangiitis and pauci-immune 
necrotizing crescentic glomerulonephritis are small vessel vasculitides (SVV) characterized by 
vascular inflammation predominantly affecting the capillaries, the pre-capillary arterioles and the 
post-capillary venules [2]. In many cases, renal and pulmonary involvement results in severe renal 
failure and pulmonary hemorrhage which may be fatal if left untreated. Current therapy consists 
mainly of immunosuppression with high-dose corticosteroids and cyclophosphamide during the 
induction phase and azathioprine in combination with low-dose steroids as maintenance therapy. 
However, considerable treatment-related morbidity and failure to induce or maintain remission 
underline the importance of less toxic and more effective therapies. 
 In many cases, SVV are associated with anti-neutrophil cytoplasmic autoantibodies (ANCA) 
[65]. The main autoantigens in ANCA-associated vasculitis are myeloperoxidase (MPO) and 
proteinase 3 (PR3), proteins that are predominantly stored in the azurophilic granules of resting 
neutrophils. In vitro studies suggest a crucial role for MPO-ANCA and PR3-ANCA in the 
pathogenesis of ANCA-associated SVV (reviewed in [13]) by showing that ANCA are capable of 
inducing degranulation and a respiratory burst in tumor necrosis factor alpha (TNFα-) pretreated 
neutrophils, resulting in damage of bystander endothelial cells [15]. Definite proof of the 
pathogenicity of MPO-ANCA came with the development of an experimental animal model of 
anti-MPO induced necrotizing crescentic glomerulonephritis (NCGN) that involves the transfer 
of mouse MPO-reactive splenocytes or IgG into MPO-competent mice [43]. These mice 
developed NCGN with pathological features similar to human anti-MPO-associated 
glomerulonephritis. Further support for MPO-ANCA pathogenicity is provided by a recently 
developed rat model, in which immunization of WKY rats with human MPO led to the 
generation of anti-human MPO antibodies that cross-reacted with rat MPO and caused a mild 
form of NCGN [49]. 
In the mouse model of anti-MPO IgG-induced NCGN, we recently showed that circulating 
neutrophils are crucial in disease development [147], and demonstrated that disease severity was 
markedly aggravated by the addition of bacterial lipopolysaccharide (LPS) as a proinflammatory 
stimulus [105]. Moreover, the disease enhancing effects of LPS could be attenuated, but not fully 
prevented, by pretreatment of the animals with a TNFα bioactivity-inhibiting monoclonal 
antibody. The partial response on TNFα-bioinhibition observed in this study, as well as the 
ambiguous results obtained from human studies on anti-TNFα therapy in patients with ANCA-
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associated vasculitis [87, 126], suggests that other factors are likely to be more critically involved 
in the induction of anti-MPO mediated NCGN. Recent experiments in mouse strains deficient 
for various factors of the complement system have indicated a crucial role for the alternative 
pathway of complement activation in disease induction [148]. More specifically, in these studies it 
was found that factor B as well as C5 deficient mice are completely protected from anti-MPO 
antibody induced NCGN, whereas C4 deficient mice are not. These observations prompted us to 
investigate whether targeting complement factor C5 is a possible therapeutic strategy for 
intervention. To this end, the present study was designed to examine the effects of a C5-
inhibiting monoclonal antibody in the mouse model of anti-MPO IgG-induced NCGN. 
Methods 
MICE 
Mpo-/- mice, backcrossed to a C57BL/6 background for six times, were genotyped using PCR-
amplified DNA from tail clippings [61]. Wildtype (WT) female C57Bl/6 (8-12 weeks of age) mice 
were obtained from Harlan (Horst, the Netherlands). Mice were kept according to University of 
Maastricht animal facility regulations, and all experiments were approved by the local Animal 
Care and Experimentation Committee. 
PURIFICATION OF MURINE MPO 
Murine MPO (muMPO) was purified from WEHI-3 cells as described previously [105]. Purity 
was checked by sodium dodecyl sulfate polyacrylamide gel electrophoresis. 
PREPARATION OF POLYCLONAL MOUSE ANTI-MOUSE MPO IGG 
Mpo-/- mice were immunized with murine MPO as reported previously [105]. On day 42, mice 
were bled. Anti-MPO antibody titers were monitored by enzyme-linked immunosorbent assay 
(ELISA) as described previously [105]. IgG was isolated from pooled sera by 50% ammonium 
sulfate precipitation followed by protein G column affinity chromatography. IgG-containing 
fractions were concentrated by ultrafiltration (Centriplus; Millipore, Amsterdam, The 
Netherlands) and dialyzed against PBS. Protein concentrations were determined using the 
bicinchoninic acid protein assay kit (Pierce, Rockford, IL). The anti-MPO titer of each batch was 
checked by ELISA as described above, using a sample of anti-MPO IgG with previously 
established pathogenicity as a reference. 
  63 
anti-C5 treatment in anti-MPO IgG-induced NCGN 
INDUCTION OF GLOMERULONEPHRITIS WITH ANTI-MPO IGG AND 
LIPOPOLYSACCHARIDE 
C57BL/6 mice received a dose of 100 µg/g body weight of sterile-filtered (0.2 µm filter; 
Schleicher & Schuell, Dassel, Germany) anti-MPO IgG by intraperitoneal injection. Previously, 
we showed that the administration of LPS considerably aggravated anti-MPO IgG-induced 
disease resulting in a more vigorous disease model [105]. Therefore, all mice received a single 
intraperitoneal injection with 0.5 µg/g body weight LPS (Escherichia coli, serotype 026-B6l; 
Sigma, St. Louis, MO), one hour after the administration of anti-MPO IgG. 
ANTI-C5 TREATMENT 
To inhibit C5 function, we used the mouse anti-murine C5 moAb BB5.1. This is a murine IgG1 
antibody that blocks C5a-activity as well as the formation of C5b-9 in vivo [149]. ENA-1 (anti-
human E-selectin [150]) was used as isotype control. 
In a first experiment, C57BL/6 mice were pretreated with an intraperitoneal injection of 1 mg of 
sterile-filtered BB5.1 (n=9) or isotype control antibody (n=9) 8 hours prior to disease induction 
with anti-MPO IgG and LPS, to investigate the effect of C5 inhibition in the induction phase of 
disease. Mice were sacrificed after one day (n=4/group) or after 7 days (n=5/group) to evaluate 
disease development. 
In the next experiment, we investigated whether intervention with BB5.1 after the induction of 
disease would lead to attenuation of anti-MPO IgG-induced NCGN. Disease was induced with 
anti-MPO IgG and LPS as in the first experiment, but this time, 1 mg of BB5.1 or control 
antibody was given 1 day after disease induction. Mice were sacrificed at 7 days after disease 
induction (n=5-6/group) 
In all mice, circulating anti-MPO IgG was monitored by ELISA as described above, using a 
serum pool from MPO-immunized MPO-knockout mice as reference. 
LABORATORY AND PATHOLOGICAL EVALUATION OF DISEASE 
At several timepoints during disease development, urine samples were tested by dipstick (Bayer, 
Mijdrecht, the Netherlands) for hematuria and leukocyturia and scored on a 0-4+ scale. At the 
timepoints indicated, mice were placed in metabolic cages for 16 hours to obtain urine for the 
determination of albuminuria by ELISA (Bethyl, Inc., Montgomery TX). Blood urea nitrogen 
(BUN) and creatinin levels were determined in sera collected at the time of sacrifice by an 
enzymatic degradation assay on a Synchron LX20 PRO (Beckman Coulter Inc., Fullerton CA). 
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Tissue samples were taken from both kidneys and processed for light microscopy, 
immunofluorescence, and immunohistochemistry. For light microscopy, renal tissue samples 
were fixed in 4% formaldehyde and embedded in paraffin. Sections (1.5 µm) were cut and 
hematoxylin/eosin, periodic acid-Schiff (PAS), and Martius yellow-brilliant crystal scarlet-soluble 
blue (MSB) staining were performed according to standard procedures. For each animal, the 
amount of crescents was determined in 100 consecutive glomerular cross sections. Only 
glomeruli that had two or more layers of cells in Bowman’s space were considered crescentic. 
Similarly, a glomerular necrosis score was determined for each animal by evaluating segmental or 
global glomerular capillary necrosis in 100 consecutive glomerular cross sections. Analysis was 
performed in a blinded fashion by two independent investigators. 
Phenotypic analysis of the inflammatory cell infiltrate was performed on 4-µm cryostat sections 
fixed in 100% acetone at room temperature. The following primary antibodies were used: rat 
anti-mouse CD45 (clone MP33), rat anti-mouse neutrophils (clone NIMP-R14) [78], rat anti-
mouse CD68 (macrophages, clone FA11 [79]), and rat anti-mouse CD3 (clone KT3). 
Endogenous peroxidase activity was blocked with 0.05% H2O2 in PBS. Rabbit anti-rat IgG-PO 
and goat anti-rabbit IgG-PO (both DakoCytomation) were used as appropriate secondary and 
tertiary antibodies, respectively. Antibody binding was visualized using 3-amino-9-ethylcarbazole 
(AEC) with H2O2 as substrate. Sections were counterstained with hematoxylin. Glomerular cell 
infiltrates were determined by counting the number of positive cells in 30 glomerular cross 
sections per kidney section. 
The presence of complement proteins was determined by immunofluorescence using the 
following primary antibodies: polyclonal digoxigenin- (dig-) labeled rabbit-anti-mouse C1q 
(generously provided by Prof. dr. MR Daha, Leiden, the Netherlands [151]), monoclonal rat-anti-
mouse C4 (clone 16D2; HBT, Uden, the Netherlands), monoclonal rat-anti-mouse C3 (clone 
11H9; HBT), and rabbit anti-mouse C5 (HBT) . FITC-labeled sheep-anti-dig IgG (Roche 
Diagnostics, Almere, the Netherlands), ALEXA 568-labeled goat-anti-rat IgG, and ALEXA 568-
labeled goat-anti-rabbit (Invitrogen, Breda, The Netherlands) supplemented with 5% normal 
sheep serum were used as conjugates. Deposition of mouse IgG was detected by rabbit anti-
mouse IgG-Alexa Fluor 488 (Invitrogen). 
STATISTICAL ANALYSIS 
Data are expressed as mean ± SD and were analyzed by two-tailed Student’s t-test using 
Graphpad Prism 4.03 for Windows (Graphpad Software, San Diego CA). Because of their non-
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Gaussian distribution, albuminuria data were compared by the two-tailed Mann-Whitney U test. 
In both cases, p-values ≤ 0.05 were considered statistically significant. 
Results 
INHIBITION OF C5 ACTIVATION PREVENTS NECROTIZING CRESCENTIC 
GLOMERULONEPHRITIS INDUCED BY ANTI-MPO IGG AND LPS 
Urinalysis  
Upon administration of anti-MPO IgG and 0.5 µg/g LPS, mice in both groups developed similar 
levels of circulating MPO-ANCA (data not shown). Control-pretreated mice developed 
hematuria and leukocyturia that lasted from day one until sacrifice on day 7 (Figure 4-1a, b). 
Urinary albumin concentrations were within normal range on day 1 post-induction (mean 48 
(range, 10-145) µg/16h), but were markedly increased on day 7 (mean 1600 (range, 430-3300) 
µg/16h, Figure 4-1c). In contrast, urine samples of mice pretreated with anti-C5 antibody 
displayed only minimal amounts of blood and leukocytes throughout the experiment (Figure 4-
1a, b), and albuminuria was within normal range. (day 1: mean 45 (range, 6-100) and day 7: mean 
23 (range, 14-42) µg/16h; Figure 4-1c). At sacrifice, creatinine and blood urea nitrogen levels 
were within normal range in all mice. 
 
Figure 4-1: Pretreatment with anti-C5 moAb inhibits 
induction of (a) hematuria, (b) leukocyturia, and (c) 
albuminuria induced by anti-MPO IgG and LPS. Open 
squares: control pretreatment; filled triangles: anti-C5 
pretreatment. The mean albumin level in urine samples 
from untreated C57bl/6 (n=5) mice was 43 (range 26-79) 
µg/16 hours. * p<0.05. 
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Light microscopy 
In mice pretreated with control antibody, the administration of anti-MPO IgG and LPS induced 
a focal and segmental crescentic glomerulonephritis on day 7 in all subjected mice. Although the 
majority of glomeruli appeared unaffected, glomerular crescent formation and necrosis were 
frequently observed. The mean percentage of crescentic glomeruli was 21.0 ± 8.8, whereas 12.8 ± 
5.5% of glomeruli showed fibrinoid necrosis (Figure 4-2). Crescents were cellular, and they were 
partly segmental (9% of the total number of glomeruli) and partly global (13% of total). 
Accompanying the crescentic glomerulonephritis, there was mild tubulo-interstitial inflammation, 
which in some cases was accompanied by mild tubular atrophy. Arterioles and larger blood 
vessels were unaffected. 
 
Figure 4-2: Pretreatment with anti-C5 moAb prevents development of NCGN induced by anti-MPO IgG and LPS. 
a: Overview of renal cortical tissue from a control antibody pretreated mouse, 7 days after administration of anti-
MPO IgG and LPS, representing the focal and segmental nature of the glomerulonephritis. Glomerular crescents are 
indicated by arrowheads. b: Overview of renal cortical tissue from an anti-C5 moAb treated mouse, 7 days after 
administration of anti-MPO IgG and LPS, displaying normal renal morphology. c: Detail of a glomerulus with a 
large cellular crescent from a mouse that received anti-MPO IgG and LPS after pretreatment with control antibody. 
d: Detail of a glomerulus from a mouse that received anti-MPO IgG and LPS after pretreatment with anti-C5 moAb, 
displaying normal morphology e: Effect of pretreatment with anti-C5 moAb on glomerular crescent formation 
expressed as a percentage of glomerular crescents in individual mice. f: Effect of pretreatment with anti-C5 moAb on 
glomerular necrosis expressed as a percentage of glomeruli with capillary necrosis in individual mice. Horizontal lines 
represent mean percentages in each group. a-d Periodic acid Schiff’s stain. Magnification: a,b x200; d,e x630. 
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In contrast, glomerular crescents and fibrinoid necrosis were completely absent in mice 
pretreated with C5-inhibiting antibody (Figure 4-2). In addition, no tubulo-interstitial 
inflammation or tubular atrophy could be found in these mice. Phenotypic analysis of the 
inflammatory cell infiltrate on day 7 revealed that anti-C5 pretreatment significantly inhibited 
glomerular influx of CD45+ leukocytes, CD3+ T-cells, FA11+ macrophages, and NimpR14+ 
neutrophils (Table 4-1). 
Table 4-1: Immunophenotyping of intraglomerular inflammatory cell infiltrate at 7 days after pretreatment with anti-
C5 moAb (BB5.1) or isotype control moAb (ENA-1). 
 
Control-pretreatment* 
(n=5) 
Anti-C5 pretreatment* 
(n=5) 
p-value 
CD45+ leukocytes 3.2 ± 0.59 1.2 ± 0.21 0.0004 
CD3+ T-cells 0.45 ± 0.11 0.13 ± 0.05 0.0011 
FA11+ macrophages 2.3 ± 0.62 0.68 ± 0.32 0.002 
NIMP-R14+ neutrophils 0.41 ± 0.12 0.22 ± 0.09 0.03 
* Number of cells (mean ± SD) per glomerular cross-section 
 
To gain more insight into the mechanism by which anti-C5 antibodies affect disease development 
in the mouse model of anti-MPO IgG-induced NCGN, we investigated the effect of anti-C5 
pretreatment on early glomerular neutrophil influx. Compared to the control antibody, anti-C5 
antibody pretreatment significantly reduced the number of neutrophils per glomerular cross-
section in mice one day after disease induction with anti-MPO IgG and LPS (2.5 ± 0.66 vs. 0.79 
± 0.27 /gcs, p<0.005; Figure 4-3). 
 
Figure 4-3: Pretreatment with anti-C5 moAb significantly 
reduces early glomerular neutrophil influx. a: Glomerulus 
from a mouse that had received anti-MPO IgG and LPS and 
was pretreated with control antibody demonstrating marked 
segmental infiltration of neutrophils as detected by 
immunohistochemistry. b: Glomerulus from a mouse that had 
received anti-MPO IgG and LPS and was pretreated with anti-
C5 moAb, demonstrating strongly reduced neutrophil 
infiltration. c: Quantification of glomerular neutrophil influx 
one day of administration of anti-MPO IgG and LPS in mice 
that were pretreated with control antibody (white bar) or anti-
C5 moAb (black bars). gcs, glomerular cross section; 
magnification a,b x630. ** p<0.01. 
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Immunofluorescence 
Immunofluorescence staining for complement factors C1q, C3, and C4 in anti-MPO/LPS treated 
and untreated wildtype mice sacrificed at day one showed sparse glomerular staining for C1q and 
weak mesangial staining for C3 in all mice (Figure 4-4). Also, mesangial C4 deposits were 
observed. The intensity and pattern of C1q, C3, and C4 staining was similar to that observed in 
untreated C57Bl/6 mice (Figure 4-4). In contrast, glomerular capillary staining for C1q, C3, and 
C4 was detected in renal sections from mice one day after induction of heterologous anti-GBM 
glomerulonephritis (Figure 4-4). In these mice, staining for C5 demonstrated moderate granular 
glomerular deposits. However, such deposits were not detected in untreated C57Bl/6 mice and 
anti-MPO/LPS treated mice. Immunofluorescence staining for IgG revealed only scant deposits 
of IgG in glomeruli in all mice (data not shown). 
 
Figure 4-4: Immunofluorescence staining for complement proteins in untreated wildtype C57bl/6 mice and in mice 
one day after injection with anti-MPO IgG and LPS or heterologous rabbit anti-glomerular basement membrane 
(GBM) antibodies. Representative glomeruli stained for C1q, C3, C4, and C5 are shown. In wildtype mice and mice 
sacrificed one day after injection of anti-MPO IgG and LPS sparse glomerular staining for C1q, weak mesangial 
staining for C3 and mesangial deposits of C4 were observed. In contrast, in mice sacrificed one day after injection of 
rabbit anti-GBM antibodies, capillary staining for C1q, C3 and, C4 was found. For C5, moderate granular glomerular 
deposits were observed in renal sections of mice subjected to accelerated sheep anti-GBM nephritis whereas no 
glomerular staining was detected in untreated C57Bl/6 mice and anti-MPO/LPS treated mice. Magnification all 
pictures x400.  
  69 
anti-C5 treatment in anti-MPO IgG-induced NCGN 
INHIBITION OF C5 ACTIVATION AFTER DISEASE INDUCTION ATTENUATES 
NECROTIZING CRESCENTIC GLOMERULONEPHRITIS INDUCED BY ANTI-MPO IGG 
AND LPS 
Urinalysis  
We next investigated whether anti C5-treatment was also beneficial when administered one day 
after the induction of disease with anti-MPO IgG and LPS. We previously demonstrated that at 
this timepoint, considerable glomerular neutrophil influx is already present [105]. Moreover, at 
the start of intervention, mice in both groups had similar levels of circulating anti-MPO 
antibodies and had developed hematuria and leukocyturia to a similar extent (Figure 4-5a, b). As 
shown in Figure 4-5a, the extent of hematuria declined in mice treated with a single dose of 
BB5.1, and was absent on day five. At the time of sacrifice on day 7, three out of six BB5.1-
treated animals were still free from hematuria, whereas hematuria persisted in control-treated 
animals. 
 
Figure 4-5: Intervention with anti-C5 moAb 
attenuates (a) hematuria, (b) leukocyturia and (c) 
albuminuria induced by anti-MPO IgG and LPS. 
Open squares: control treatment; Filled triangles: 
anti-C5 treatment. ** p<0.01. 
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Anti-C5 treatment also had a pronounced effect on leukocyturia. In control antibody-treated 
mice, leukocyturia increased during the time course of the experiment, whereas this increase was 
absent in mice treated with anti-C5 antibody (Figure 4-5b). In both groups, albuminuria was 
quantified in urine samples obtained on day 1 and day 7 post-induction. As shown in Figure 4-5c, 
urinary albumin levels on day 1 were within normal range in both groups. On day 7 however, a 
significant increase in albuminuria was detected in control antibody-treated mice, whereas in anti-
C5 antibody-treated mice urinary albumin levels were only minimally elevated (mean 212 (range, 
45-633) µg/16h in anti-C5 antibody-treated mice vs. 1596 (range, 705-2552) µg/16h in control 
antibody-treated mice, p<0.01). 
Light microscopy 
On day 7, all control antibody-treated mice had developed a focal and segmental NCGN, with a 
mean of 13.9 ± 4.5% crescentic glomeruli, and 11.8 ± 3.4% of glomeruli displaying capillary 
fibrinoid necrosis. The development of NCGN was however markedly attenuated in the anti-C5 
antibody-treated mice, showing a mean of 1.9 ± 0.8% glomerular crescents, and 1.5 ± 1.2% of the 
glomeruli containing capillary fibrinoid necrosis (Figure 4-6). 
Also, treatment with the C5-inhibiting antibody led to a significant reduction in glomerular influx 
of CD45+ leukocytes as well as CD3+ T-cells and FA11+ macrophages on day 7 (Table 4-2). In 
both groups, glomerular influx of NIMP-R14+ neutrophils on day 7 was low and the difference 
between the groups did not reach statistical significance. (Table 4-2) Staining for complement 
proteins in these groups of mice were similar to those of the pretreatment study. There were no 
differences in C1q, C3, C4, and C5 staining between BB5.1-treated and control-treated mice, and 
the intensity and pattern in both groups were similar to the untreated wildtype C57bl/6 mice 
(data not shown). 
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Figure 4-6: Intervention with anti-C5 moAb attenuates development of NCGN induced by anti-MPO antibodies and 
LPS. a: Overview of renal cortical tissue from a control antibody treated mouse 7 days after administration of anti-
MPO IgG and LPS representing the focal and segmental nature of the induced glomerulonephritis . Glomerular 
crescents are indicated by arrowheads. b: Overview of renal cortical tissue from an anti-C5 moAb treated mouse 7 
days after administration of anti-MPO IgG and LPS . One glomerular crescent is observed (arrowhead). c: Detail of 
a glomerulus with a cellular crescent from a mouse that received anti-MPO IgG and LPS and was treated with 
control antibody. d: Detail of a glomerulus with a small cellular crescent from a mouse that received anti-MPO IgG 
and LPS and was treated with anti-C5 moAb. e: Effect of treatment with anti-C5 moAb on glomerular crescent 
formation expressed as a percentage of glomerular crescents in individual mice. f: Effect of treatment with anti-C5 
moAb on glomerular necrosis expressed as a percentage of glomeruli with capillary necrosis in individual mice. 
Horizontal lines represent mean percentages in each group. a-d Periodic acid Schiff’s stain. Magnification: a,b x200; 
d,e x630. *** p<0.001. 
 
Table 4-2: Immunophenotyping of intraglomerular inflammatory cell infiltrate at 7 days after treatment with anti-C5 
moAb (BB5.1) or isotype control moAb (ENA-1). 
 
Control-treatment* 
(n=5) 
Anti-C5 treatment* 
(n=6) 
p-value 
CD45+ leukocytes 3.2 ± 0.76 1.7 ± 0.19 0.0011 
CD3+ T-cells 0.51 ± 0.20 0.14 ± 0.06 0.0017 
FA11+ macrophages 1.85 ± 0.30 0.9 ± 0.18 0.0001 
NIMP-R14+ neutrophils 0.37 ± 0.09 0.27 ± 0.08 n.s. 
*Number of cells (mean ± SD) per glomerular cross-section; n.s.: not significant 
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Discussion 
In the present study, we demonstrate that mice pretreated with BB5.1, a moAb that inhibits 
activation of complement factor C5, are completely protected from disease induced by anti-MPO 
IgG and 0.5 µg/g bacterial LPS. Control-pretreated mice developed focal segmental NCGN to a 
degree comparable with our previous observations [105]. Importantly, we also demonstrate that 
intervention with BB5.1 after the onset of disease, at a time that important signs of disease, such 
as hematuria, leukocyturia and glomerular influx of neutrophils, are already present, was also 
effective, as evidenced by a more than 80% reduction in the percentage of crescentic glomeruli 
and a more than 85% reduction in albuminuria on day 7. 
Our study is the first to show that C5-inhibition prevents disease development in an animal 
model of ANCA mediated NCGN. These results are in line with two other studies on immune-
mediated glomerular injury showing involvement of the terminal complement pathway in a 
mouse model of lupus nephritis [152] and glomerulonephritis induced by cryoglobulins [153]. 
According to the currently prevailing theory on the pathogenesis of ANCA mediated vasculitis 
(reviewed in [18]), ANCA-induced activation of primed neutrophils is crucial to disease 
development. ANCA-activated neutrophils adhere to susceptible vascular endothelium, where 
they release oxygen radicals and lytic granule constituents, leading to local inflammation. 
Although this theory has proven very useful, it does not explain the critical involvement of 
complement in ANCA-induced disease. 
Complement system activation can occur through the classical pathway, which is dependent on 
immune complexes (ICs), through the mannose-binding lectin (MBL) pathway, or through 
alternative pathway activation. Because of the paucity of ICs in renal biopsies from patients with 
ANCA-associated NCGN, it seems unlikely that the classical pathway plays an important 
pathogenic role. Immune deposits have however been found in fresh skin lesions from WG 
patients, suggesting their involvement in the initial phase of disease development [62]. Moreover, 
IC depositions were found in over 50% of renal biopsies from ANCA-associated vasculitis 
patients [154] and their presence was associated with higher levels of proteinuria. This association 
does however not reveal whether IC positivity is the cause of more severe disease manifestations, 
or whether it is merely the result of more severe disease. Finally, we previously reported that 
levels of circulating MPO in mice are increased upon treatment with LPS which could potentially 
lead to the formation of circulating MPO/anti-MPO immune complexes in our model. (8) 
However, whether circulating immune complexes are formed and whether these participate in 
disease induction is unknown at present and warrants further investigation. In this respect, it is 
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important to note that C4-deficient mice which are unable to activate the classical complement 
pathway, are not protected from disease induced by anti-MPO IgG [148]. Moreover, in our 
present study, glomerular depositions of IgG and C1q were scanty and not different from those 
observed in untreated mice. Together, these results suggest that disease development in the 
mouse model of anti-MPO IgG-induced NCGN is not dependent on activation of the classical 
pathway of complement activation. 
Involvement of the MBL pathway of complement activation has been demonstrated in several 
forms of glomerulonephritis, including IgA nephropathy and lupus nephritis [155]. However, 
whether MBL pathway activation contributes to ANCA mediated SVV is largely unknown and 
has not been thoroughly investigated. A recent study showed that in patients with ANCA-
associated vasculitis, genotype frequencies of polymorphic variants in the MBL gene are not 
different from those observed in the normal population (Kamesh L, Heward JM, Williams JM, et 
al. Kidney Blood Press Res 28:176, 2005, abstract). Moreover, mice deficient for C4, one of the 
key components of the MBL cascade, are not protected from disease induction in the model of 
anti-MPO IgG-induced NCGN [148]. Together, these data indicate that involvement of the MBL 
pathway in ANCA mediated SVV is unlikely. 
The initiating event in the alternative pathway of the complement cascade is the spontaneous 
generation of the C3 convertase, C3bBb. This complex is however very unstable, and its proper 
functioning is therefore dependent on the stabilizing effect of the binding of properdin. 
Interestingly, it has been shown that properdin is one of the proteins that is released by activated 
neutrophils [156]. Stabilizing the C3 convertase and consequent potentiation of the complement 
cascade might therefore be an important additional deleterious effect of neutrophil activation in 
ANCA-associated vasculitis. However, very little is known about the C3-binding and activating 
properties of ANCA. In one study, ANCA-positive sera were found to facilitate the binding of 
complement factor C3c, as well as the formation of C5b-9, on neutrophils [157]. Bearing in mind 
the results of our study, this potential mechanism of direct ANCA-induced complement 
activation certainly merits further investigations. 
The enzymatic activity of MPO and other neutrophil lysosomal constituents may provide an 
alternative –or additional– link between MPO-ANCA and complement activation. It has been 
shown that C5 can acquire neutrophil chemotactic activity upon treatment with an enzyme stored 
in the lysosomal granules of granulocytes, but the nature of this enzyme remains unclear [158]. 
Interestingly, C5 acquires C5b-like activity upon treatment with hypochlorite and hypochlorite-
modified amines, either from an exogenous source [26], or as the enzymatic product of MPO 
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released from activated neutrophils [27]. Since the majority of MPO-ANCA do not inhibit MPO-
activity, but actually prevent the inhibition of MPO-activity by its natural inhibitor, ceruloplasmin 
[29], it is conceivable that release of MPO, in the presence of MPO-ANCA, leads to MPO-
induced activation of the terminal complement pathway. It is however unclear in these studies 
whether, during the formation of the C5b-like complex, also a protein with C5a-like properties is 
formed. In addition, this mechanism does not provide an explanation for the critical role of 
alternative pathway activation in anti-MPO IgG-induced NCGN [148] 
Upon activation, C5 is spliced into two cleavage products. The C5b molecule is involved in the 
generation of C5b-9, the end product of the terminal complement pathway. The C5a molecule is 
a powerful chemoattractant for neutrophils, and has considerable neutrophil activating potential. 
Since BB5.1 inhibits C5a-activity as well as the formation of C5b-9 [149], its effect on anti-MPO 
IgG-induced NCGN can theoretically be caused by the inhibition of C5a activity, inhibition of 
C5b-9 formation, or both. 
Very little is known about the role of C5b-9 in ANCA-associated glomerulonephritis. On 
neutrophil smears, it has been demonstrated that ANCA-positive sera are capable of binding C3 
which, in some cases, resulted in the formation of C5b-9 [157]. It is however unclear whether this 
mechanism also plays a role in vivo. Alternatively, C5a activity could play a critical role in the 
pathogenesis of MPO-ANCA associated vasculitis. C5a has strong neutrophil-attracting 
capability, and we previously showed that, in the mouse model of anti-MPO IgG-induced 
NCGN, neutrophils are crucial for disease development [147]. In our current study, we observed 
that anti-C5 pretreatment led to a significant decrease in early glomerular neutrophil influx on day 
one. This is in line with several studies showing that C5a strongly promotes the adhesion of 
neutrophils to endothelial cells [159, 160]. Being a strong neutrophil activator, C5a might induce 
the adherent neutrophils to subsequently undergo an oxidative burst and release their granular 
enzymes. Interestingly, C5a is also a strong inducer of properdin release by neutrophils [156], and 
might thus be part of a positive feedback loop stabilizing the alternative pathway convertase, 
thereby increasing inflammation [161] 
It has previously already been shown by our group that neutrophils play a pivotal role in the 
pathogenesis of anti-MPO IgG-induced NCGN [147]. However, whereas macrophages 
importantly contribute to glomerular lesions in this, as well as in a previous [105] study, it is as yet 
unclear as to what extent these cells are involved in the pathogenic process. It has been shown 
that monocytes, being the circulating precursors of macrophages, are activated in humans with 
active ANCA-associated disease [162], and in vitro studies have revealed that ANCA themselves 
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might be at least partly responsible for this [163]. Moreover, macrophages have frequently been 
shown to be the predominant cell type in glomerular lesions of patients with ANCA-associated 
vasculitis [164, 165] (reviewed in [166]). These studies do however not unequivocally prove a role 
for monocytes and macrophages in ANCA-disease. Therefore, although in our study significantly 
less glomerular macrophages are observed in experimental mice pretreated with anti-C5, and 
although the activating effect of C5a on monocytes and macrophages is well-known, additional 
studies are required to reveal whether the observed reduction in macrophage influx is 
pathogenetically involved in the effect of anti-C5 treatment in this disease model.  
Murine anti-MPO IgG induced NCGN is in many ways similar to MPO-ANCA associated 
NCGN observed in humans. As in human disease, immune complexes are scarce or absent in the 
mouse model [43, 105], and murine anti-muMPO IgG activates TNFα-primed murine 
neutrophils [105]. The results of the present study together with the observations that murine 
anti-MPO induced NCGN is dependent on an intact alternative pathway complement system 
indicate a previously unsuspected role for complement activation in ANCA associated diseases. 
Clearly, these results require confirmation and translation to the human situation. 
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Abstract 
Anti-neutrophil cytoplasmic autoantibodies specific for myeloperoxidase (MPO) are associated with small-vessel 
vasculitis in humans. The administration of polyclonal IgG, isolated from murine MPO-immunized MPO-deficient 
(Mpo-/-) mice, causes vasculitis in wildtype (WT) mice. Using splenocytes from murine MPO-immunized Mpo-/- mice, 
we generated and characterized a panel of 11 mouse anti-mouse MPO monoclonal antibodies (moAbs). Whereas 
most of them cross-react with rat MPO, only one moAb shows weak cross-reactivity with human MPO. Inhibition 
ELISA revealed that their epitopes are restricted to three immunodominant regions on the murine MPO molecule. 
In several combinations, alone or with a priming dose of bacterial lipopolysaccharide (LPS), the anti-MPO moAbs 
do not cause glomerulonephritis in WT mice. However, two clones severely aggravated mild crescentic 
glomerulonephritis induced by the administration of a low dose of anti-glomerular basement membrane (GBM) IgG, 
as reflected by increased hematuria, albuminuria, and histopathological damage, and more severely impaired renal 
function. Together, these results underline the pathogenicity of the anti-MPO immune response, and provide an 
interesting tool to study the role of epitope specificity and isotype in the pathogenesis of anti-MPO IgG-induced 
NCGN. 
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Introduction 
Small vessel vasculitides (SVV) are diseases that are characterized by destructive inflammation of 
the arterioles, capillaries and postcapillary venules [2]. Although any organ can be affected, renal 
and pulmonary involvement typically lead to severe morbidity, and may be fatal if left untreated. 
In many patients, the presence of SVV is associated with elevated titers of anti-neutrophil 
cytoplasmic autoantibodies (ANCA). The autoantibodies are predominantly specific for 
myeloperoxidase (MPO-ANCA) or proteinase 3 (PR3-ANCA), proteins that are stored in the 
lysosomal granules of polymorphonuclear granulocytes (PMNs) and monocytes, and that have an 
important bactericidal function [20]. Since the discovery of ANCA, several studies have shown 
that ANCA-titers correlate with disease activity and predict relapse and therefore, ANCA 
detection is considered to be an important tool in the diagnosis and follow-up of patients with 
ANCA-associated SVV [7, 66-68, 167]. 
Since the discovery of ANCA, their role in the pathogenesis of ANCA-associated disease has 
been subject of investigation. It has been shown in vitro that ANCA can activate TNFα-primed 
PMNs, and this has led to a theory on the pathogenesis of ANCA-associated SVV (reviewed in 
[18]), in which ANCA-activated neutrophils adhere to and damage endothelium of susceptible 
blood vessels, leading to local vascular inflammation. Although many other animal studies 
(reviewed in [168]) already strongly supported this notion, definite evidence for pathogenicity of 
MPO-ANCA was provided by Xiao et al., showing that the adoptive transfer of splenocytes or 
the passive transfer of purified IgG from murine MPO-immunized MPO-deficient (Mpo-/-) mice 
to immune-deficient or wildtype (WT) mice resulted in pauci-immune necrotizing crescentic 
glomerulonephritis that was similar to human MPO-ANCA associated glomerulonephritis [43]. 
Since then, it has been shown that neutrophils play a key role in the passive transfer model of 
anti-MPO IgG-induced NCGN [147], and that proinflammatory stimuli aggravate disease [105]. 
In the mouse model of anti-MPO IgG-induced NCGN, disease is induced by the passive transfer 
of polyclonal anti-MPO IgG, obtained from sera of MPO-immunized Mpo-/- mice. It is 
conceivable that in this mixture of antibodies with different epitope specificities and isotypes, 
only a subpopulation contributes to its pathogenic effect. In this study, we describe the 
development and characterization of a panel of mouse anti-MPO monoclonal antibodies 
(moAbs) that can be used to study the role of idiotype and isotype in murine anti-MPO IgG-
induced NCGN. In addition, we show that two of those moAbs are pathogenic in the context of 
a mild local proinflammatory environment induced by the administration of a low dose of anti-
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glomerular basement membrane (GBM) antibodies. Our study confirms the pathogenicity of the 
anti-MPO immune response, and provides an interesting tool to study the involvement of 
epitope restriction and isotype in the pathogenesis of anti-MPO IgG-induced NCGN. 
Material and Methods 
MICE 
Mpo-/- mice, backcrossed to a C57Bl/6 background for six times, were genotyped using PCR-
amplified DNA from tail clippings [61]. Wildtype female C57Bl/6 (8-12 weeks of age) mice were 
obtained from Harlan (Horst, the Netherlands). Mice were kept according to University of 
Maastricht animal facility regulations, and all experiments were approved by the local Animal 
Care and Experimentation Committee. 
GENERATION AND CHARACTERIZATION OF ANTI-MPO MOABS 
Immunization and generation of hybridomas 
To obtain anti-MPO IgG-producing hybridomas, Mpo-/- mice were immunized with MPO 
isolated from the murine promyelocytic cell line WEHI-3 as described previously [105]. Mice 
received an intraperitoneal dose of 10 µg murine MPO in 100 µl sterile-filtered PBS and an equal 
volume of Complete Freund’s Adjuvant (Sigma, Zwijndrecht, The Netherlands) on day 0, 
followed by two booster injections of 10 µg murine MPO in Incomplete Freund’s Adjuvant 
(Sigma) on day 21 and 35. on day 43, 10 µg of murine MPO in PBS was administered, and at day 
48, the animals were sacrificed, the spleens were harvested, and a single-cell suspension was made 
by pressing the cells through a sterile nylon gaze. Subsequently, cells were resuspended in RPMI 
Medium 1640 with GlutaMAX™-I (Invitrogen, Breda, The Netherlands), enriched with 20% 
fetal calf serum, 1% penicillin/streptamycin (Gibco), HAT (0.1 mM hypoxanthine, 0.4 µM 
aminopterin, 16µM thymidine; Invitrogen), and 0.1% β-mercaptoethanol, and fused with the 
HAT-sensitive cell line SP20 by co-culturing them in the presence of polyethylene glycol (Serva, 
Heidelberg, Germany). Anti-MPO moAb-producing clones were selected by enzyme-linked 
immunosorbent assay (ELISA) as described previously [105] with minor modifications. Briefly, 
microtiter plates were coated overnight with murine MPO (0.5 µg/ml), blocked with 1% bovine 
serum albumin (BSA), and incubated with undiluted supernatants. Depending on the required 
isotype, this was followed by incubation with alkaline phosphatase-conjugated goat-anti-mouse 
antibodies specific for IgG1, IgG2a, or IgG2b (BD Pharmingen, Alphen aan den Rijn, the 
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Netherlands). 4-nitrophenyl phosphate (pNPP) was used as substrate, and wells were analyzed 
spectrophotometrically at 405 nm. Each anti-MPO IgG-producing clone was subcloned 3-5 
times. Once the clones were monoclonal, they were grown in Hepes-buffered RPMI Medium 
1640 with GlutaMAX™-I enriched with 1% low-IgG fetal calf serum (Perbio), and 1% 
penicillin/streptomycin. Anti-MPO IgG was isolated from the supernatants by protein G column 
affinity chromatography, after concentration by ultrafiltration, using a 50 kD Amicon filter 
(Millipore, Amsterdam, the Netherlands). IgG-containing fractions were pooled and dialyzed 
against PBS, and protein concentrations were determined using the bicinchoninic acid (BCA) 
protein assay kit (Pierce, Rockford, IL) according to the manufacturer’s instructions. Affinity of 
the moAbs to murine MPO was determined by ELISA as described above. The isotype of each 
moAb was determined using a mouse isotyping test kit (HBT, Uden, the Netherlands), according 
to the manufacturer’s instructions. A portion of each moAb was biotinylated using standard 
techniques.  
Inhibition ELISA 
To study epitope specificity of the anti-MPO moAbs, we utilized a home-made inhibition 
ELISA. Briefly, 96-well microtiter plates were coated with murine MPO (0.5 µg/ml) and blocked 
with BSA. In order to determine the capacity of each moAb (moAb A) to inhibit binding of 
another moAb (moAb B) to its antigen, the plates were then co-incubated with a fixed dilution of 
biotinylated moAb B and a two-fold serial dilution of moAb A. To detect the inhibitory effects of 
competing moAbs, the biotinylated moAb B was used at the highest dilution giving a maximum 
OD value by direct ELISA. Non-biotinylated moAb B and an isotype control were used as 
positive and negative inhibiting controls, respectively. After washing, plates were incubated with 
peroxidase-labeled streptavidin (Jackson ImmunoResearch, Cambridgeshire, UK). O-phenylene 
diamine was used as substrate, and plates were read at 490 nm. 
Determination of species specificity 
Specificity of the generated antibodies for murine MPO, as well as cross-reactivity with rat MPO 
was determined by immunohistochemistry on WT, Mpo-/-, and rat spleen sections. Sections were 
acetone-fixed and air-dried, before incubating them with biotinylated anti-MPO moAbs. 
Endogenous peroxidase activity was blocked with 0.05% H2O2 in PBS, and sections were 
incubated with peroxidase-conjugated streptavidin. Antibody binding was visualized using AEC 
as substrate, and the slides were counterstained with hematoxylin. Staining intensity was 
determined semi-quantitatively, using a 0-3+ scale. 
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Cross-reactivity of the antibodies to human MPO was determined by indirect 
immunofluorescence (IIF) on ethanol fixed neutrophils (Inova, San Diego CA, USA) and a direct 
ELISA on human MPO (Calbiochem, San Diego CA, USA), using fluorescein isothiocyanate 
(FITC-) labeled rabbit anti-mouse IgG (DakoCytomation, Glostrup, Denmark) and alkaline 
phosphatase-labeled goat anti-mouse IgG (Jackson ImmunoResearch), as respective conjugates. 
INDUCTION OF DISEASE 
Sheep anti-mouse GBM serum was kindly provided by Dr. E. Steenbergen, Dept of Pathology, 
University Medical Center Nijmegen, the Netherlands. IgG was isolated by 50% ammonium 
sulfate precipitation followed by protein G column affinity chromatography. IgG-containing 
fractions were pooled and dialyzed against PBS. Protein concentrations were determined using 
the BCA protein assay kit. 
In all in vivo experiments, the administered solutions were sterile-filtered before injection (0.2 µm 
filter; Schleicher & Schuell, Dassel, Germany). Disease was induced by the intravenous 
administration of 1mg sheep anti-mouse GBM IgG, dissolved in PBS, followed after 10 minutes 
by an intraperitoneal injection of 1 mg anti-MPO moAb or isotype control. As IgG2a isotype 
control, we used clone OX-27 (mouse anti-rat MHC class I moAb). As IgG2b isotype control, 
mouse anti-TNP moAb (generously provided by M.R. Daha, Leiden, the Netherlands) was used 
[169]. 
In a separate series of experiments, we investigated whether intraperitoneal administration of a 
single anti-MPO moAb, a combination of several moAbs, or moAbs administered in the context 
of a systemic proinflammatory response induced by the intraperitoneal administration of 0.5µg/g 
lipopolysaccharide (LPS), resulted in NCGN. 
LABORATORY AND PATHOLOGICAL EVALUATION OF DISEASE 
At several timepoints during disease development, urine samples were tested for hematuria using 
dipsticks (Bayer, Mijdrecht, the Netherlands), and scored on a 0-4+ scale. On the evening prior 
to the timepoints indicated, mice were placed in metabolic cages for 16 hours to acquire urine for 
the determination of albuminuria by ELISA (Bethyl, Inc., Montgomery TX). Blood urea nitrogen 
(BUN) levels were determined in sera collected at the time of sacrifice by an enzymatic 
degradation assay on a Synchron LX20 PRO (Beckman Coulter Inc., Fullerton CA, USA). 
After sacrifice, tissue samples were taken from both kidneys and processed for light microscopy, 
immunohistochemistry, and immunofluorescence. For light microscopy, renal tissue samples 
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were fixed in 4% formaldehyde and embedded in paraffin. Sections (1.5 µm) were cut and 
hematoxylin/eosin (HE) and periodic acid-Schiff (PAS) staining was performed. For each animal, 
the amount of crescents was determined in 100 consecutive glomerular cross sections. Only 
glomeruli that had two or more layers of cells in Bowman’s space were considered crescentic. 
Similarly, for each animal a glomerular PAS-score was determined by counting the mean number 
of quarters containing PAS-positive material in 100 consecutive glomerular cross sections. 
Analysis was performed in a blinded manner. 
The number of infiltrating leukocytes was determined by immunohistochemistry on 4 µm 
cryostat sections fixed in 100% acetone at room temperature, using rat anti-mouse CD45 and 
peroxidase-labeled rabbit anti-rat IgG (DakoCytomation) as primary and secondary antibody, 
respectively. Endogenous peroxidase activity was blocked with 0.05% H2O2 in PBS. Antibody 
binding was visualized using 3-amino-9-ethylcarbazole (AEC) with H2O2 as substrate. Sections 
were counterstained with hematoxylin. Glomerular cell infiltrates were determined by counting 
the number of positive cells in 30 glomerular cross sections per kidney section. 
By immunofluorescence, glomerular cross-sections were stained for the presence of sheep IgG 
and mouse IgG, using FITC-labeled rabbit anti-sheep IgG (Jackson ImmunoResearch) and Alexa 
Fluor 488-labeled rabbit anti-mouse IgG (Molecular Probes, Leiden, The Netherlands), 
respectively. Serum anti-MPO titers were measured in an ELISA as described previously [105], 
using alkaline phosphatase-labeled goat anti-mouse IgG antibodies as conjugate. 
STATISTICAL ANALYSIS 
Data are expressed as mean ± SD and were analyzed by two-tailed Student’s t-test using 
Graphpad Prism 4.03 for Windows (Graphpad Software, San Diego CA, USA). Because of their 
non-Gaussian distribution, albuminuria data are compared by two-tailed Mann-Whitney U test. 
In both cases, p-values ≤ 0.05 were considered statistically significant. 
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Results 
GENERATION AND CHARACTERIZATION OF ANTI-MPO MOABS 
We generated and characterized eight anti-MPO hybridomas producing moAbs of the IgG1 
isotype, two IgG2a moAbs, and one IgG2b moAb. Specificity for mouse MPO was determined 
by ELISA on purified murine MPO, and confirmed by immunohistochemistry on WT and Mpo-/- 
spleen sections (Figure 5-1), showing specific staining of neutrophils in WT spleen (Figure 5-1a), 
and absence of any staining in Mpo-/- tissue (Figure 5-1b). As shown in Table 5-1, several of the 
moAbs cross-reacted with rat MPO as determined by immunohistochemistry on rat spleen 
sections, whereas only one moAb (4H9) showed weak cross-reactivity with human MPO by 
ELISA. 
Table 5-1: Anti-MPO moAbs, isotypes, cross-inhibition, and cross-reactivity 
Clone Isotype Cross-inhibited by Group Cross-reactivity 
with rat MPO 
Cross-reactivity 
with human MPO 
8F4 IgG1 4H9 A + – 
2D4 IgG1 8F4, 4H9, 6G4 A +++ – 
4H9 IgG1 8F4, 6G4, 8F11 A ++ + 
1F1 IgG1 3B1, 1H4, 6G4, 
6D1, 8F11 
B + – 
1H4 IgG1 3B1, 1F1, 6G4, 
6D1, 8F11 
B + – 
3B1 IgG1 1H4, 1F1, 3F7, 
6G4, 6D1, 8F11 
B + – 
3F7 IgG1 4B3, 6G4 C – – 
4B3 IgG1 3F7, 6G4, 6D1 C – – 
6G4 IgG2a 4H9, 1F1, 3B1, 
1H4, 8F11 
A/B + – 
8F11 IgG2a 4H9, 1F1, 3B1, 
1H4, 6G4 
A/B +++ – 
6D1 IgG2b 1F1, 3B1, 1H4 B – – 
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Figure 5-1: Specificity and cross-reactivity of anti-murine MPO antibodies. Immunohistochemical (a-c) staining of 
WT (a), Mpo-/- (b) and rat (c) spleen sections with anti-MPO moAb (clone 8F4 (a and b) and clone 2D4 (c)). Original 
magnification x200. Immunofluorescence double labeling of clone 8F4 (d, green) and a rat moAb specific for murine 
neutrophils (clone NIMP-R14; e; red) on WT spleen sections demonstrated co-localization of MPO with neutrophils 
(f, overlay of pictures d and e) 
INHIBITION ELISA 
In order to determine epitope specificity of the generated moAbs, we used an inhibition ELISA, 
based on the assumption that binding of a moAb to its antigen inhibits binding of another moAb 
with specificity for a (partly) overlapping epitope. Generally, the inhibition studies revealed a 
pattern of grouped reciprocal inhibition. In other words, if moAb A inhibits (biotinylated) moAb 
B, moAb B also inhibits (biotinylated) moAb A, but this reciprocal inhibition only occurs if both 
antibodies are part of one group, recognizing epitopes that are at least partly overlapping. 
Roughly, the generated panel of antibodies could be divided into three groups, whereas inhibition 
occurred within, but not between the groups. A representative example of an inhibition ELISA, 
showing the binding of biotinylated 8F4 to be inhibited by clone 4H9, but not by the other 
clones and normal mouse IgG, is presented in Figure 5-2. 
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PATHOGENICITY OF ANTI-MPO MOABS 
Anti-MPO moAbs do not induce NCGN in the context of an LPS-induced 
systemic proinflammatory stimulus 
We have previously shown that NCGN could be induced by administration of polyclonal anti-
MPO IgG alone [43], and was markedly aggravated by bacterial lipopolysaccharide [105]. In this 
study we therefore first investigated the pathogenic effect of the anti-MPO moAbs alone, or in 
the context of a systemic proinflammatory environment induced by the administration of 0.5 
µg/g LPS. None of the generated moAbs, applied in several dosages, alone or in several 
combinations of IgG1, IgG2a and/or IgG2b clones, had the capacity to induce NCGN. 
Mild anti-GBM glomerulonephritis is severely aggravated by anti-MPO 
moAbs 
It is already known that a polyclonal anti-MPO immune response can enhance the pathogenicity 
of anti-GBM antibodies [45, 170, 171]. Therefore, we conducted a series of experiments to 
evaluate the pathogenicity of our anti-MPO moAbs in the context of a local proinflammatory 
stimulus provided by the intravenous administration of anti-GBM IgG. 
In mice injected with polyclonal anti-MPO IgG and LPS [105], we observed that anti-MPO 
IgG2a and IgG2b titers decreased faster than the IgG1 titer (Figure 5-3). We hypothesized that 
this was due to the predominant involvement of IgG2a and IgG2b antibodies in the induction of 
NCGN by polyclonal anti-MPO IgG. Therefore, we chose to study the effects of 6D1, an anti-
MPO moAb of the IgG2b isotype, and 6G4, an IgG2a moAb, on mild GN induced by 1 mg 
sheep anti-GBM IgG. 
As shown in Figure 5-4, administration of 6D1 as well as 6G4 caused a marked increase in early 
albuminuria (37.4 (range 7.4-82.8) and 14.2 (range 5.0-40.5) mg/16h in mice receiving 6D1 and 
6G4, respectively; p<0.05 compared to the respective control groups) and hematuria. At this time 
Figure 5-2: Representative example of the inhibition 
ELISAs summarized in Table 5-1. Reactivity of clone 8F4 
is dose-dependently inhibited by clone 4H9 and 
unbiotinylated 8F4 but not by the other clones generated 
and normal mouse IgG 
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point, albuminuria in mice treated with isotype control antibodies was significantly less severe 
(5.4 (range 0.22-20.7) and 2.7 (range 0.30-5.7) mg/16h in mice receiving IgG2b and IgG2a 
isotype control, respectively). On day 7, the animals that had received 6D1 or 6G4 still had 
considerable hematuria, whereas this was absent in both control groups (Figure 5-4c). In 
addition, the animals in both experimental groups still had high levels of albuminuria (30.9 (range 
9.0-56.4) and 16.3 (range 8.8-25.1) mg/16h in mice receiving 6D1 and 6G4, respectively). The 
administration of IgG2b isotype control resulted in mild albuminuria on day 7. In contrast, 
IgG2a isotype control antibody treatment induced albuminuria to a level comparable to the level 
observed after the administration of 6G4 (Figure 5-4d). 
 
 
Figure 5-3: Titer of different anti-MPO IgG subclasses in C57Bl/6 mice on several timepoints after the 
administration of polyclonal anti-MPO IgG and LPS [105]. Whereas IgG1, IgG2a and IgG2b are equally present in 
polyclonal IgG obtained by immunizing Mpo-/- mice with murine MPO (d), IgG2a (b) and IgG2b (c) anti-MPO titers 
decrease faster than the IgG1 (a) anti-MPO titer after injection of polyclonal IgG in combination with LPS. In all 
sera, including the original pool, IgG3 anti-MPO was not detected (results not shown). Black down-pointing triangle 
(▼): anti-MPO IgG subclass titer in the polyclonal pool, prior to administration; black squares (■): serum anti-MPO 
subclass titer one day after intraperitoneal administration of polyclonal anti-MPO IgG; black up-pointing triangle 
(▲): serum anti-MPO subclass titer six days after intraperitoneal administration of polyclonal anti-MPO IgG; black 
diamond (♦): normal mouse serum (negative control). Results are depicted as mean ± SD of five animals. In Figure 
d, the IgG subclass titers in polyclonal anti-MPO IgG prior to administration (the black down-pointing triangles in 
Figure a-c) are plotted to validate the differences in Figure a-c 
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After sacrifice on day 7, kidneys were harvested for histopathological and immunohistochemical 
analysis. As shown in Figure 5-5, both 6D1 and 6G4 severely aggravated mild NCGN induced by 
a low dose of sheep anti-GBM IgG, whereas their isotype controls only caused mild 
histopathological alterations. The difference was most remarkable between 6D1 and its IgG2b 
isotype control: no crescent formation and only minimal glomerular PAS-positivity was 
discernable in the mice that had received IgG2b isotype control whereas in mice that had 
received 6D1 13.6% (range 8-17%) crescentic glomeruli and a glomerular PAS-score of 1.13 
(range 0.74-1.48; p<0.0001 compared to isotype control) were observed (Figure 5-6). 
 
 
Figure 5-4: Urinalysis. On day 1 (a, b) and day 7 (c, d), hematuria (a, c) and albuminuria (b, d) were assessed by 
dipstick analysis and albumin ELISA, respectively. On day 1 and 7, anti-MPO moAbs 6G4 and 6D1 caused severe 
hematuria and albuminuria in combination with anti-GBM IgG. On day 7, mice that received IgG2a isotype control 
antibody also had considerable proteinuria. Black bars: anti-MPO moAbs; white bars: isotype controls 
 
The IgG2a anti-MPO moAb 6G4 also increased disease severity (Figure 5-5). After sacrifice on 
day 7, mice that had received anti-GBM IgG and 6G4 had on average 26% (range 18-36%; 
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p<0.0001 compared to isotype control) crescentic glomeruli, and a glomerular PAS-score of 1.65 
(range 1.18-1.87; p<0.0001; Figure 5-6). Surprisingly however, the animals that had received 
IgG2a isotype control and anti-GBM IgG also developed some renal morphological 
abnormalities (Figure 5-5). In this group, on average 1.2% (range 0-2.0%; p<0.001 compared to 
6G4) of all glomeruli were crescentic, and the average glomerular PAS-score was 0.44 (range 
0.26-0.64; Figure 5-6; p<0.001 compared to 6G4). 
 
Figure 5-5: Anti-MPO moAbs 6G4 (IgG2a, fig a, c, d) and 6D1 (IgG2b, fig f, h, i) severely increase glomerular 
damage in comparison to their isotype controls (b and e, and g and j, respectively) upon administration of a low 
dose of anti-GBM IgG. Whereas administration of anti-GBM IgG and isotype control induces only mild glomerular 
PAS-positivity and crescent formation, the addition of 6G4 or 6D1 results in severe renal damage, characterized by 
the deposition of PAS-positive material and the formation of crescents (arrows). PAS staining, original magnification 
x200 (a, b, f, g); x400 (c-e, h-j) 
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To investigate whether the observed differences in histopathological damage were also reflected 
in renal function, we determined BUN levels in all mice sacrificed at day 7, using sera obtained at 
the time of sacrifice. As can be seen in Figure 5-7, 6G4 and 6D1 significantly increased BUN 
levels in combination with anti-GBM IgG, whereas their respective isotype controls caused only 
mild renal function disturbance. 
Immunofluorescence staining of renal cross-sections for sheep IgG revealed a glomerular linear 
capillary pattern on t=3h as well as on t=7 days, that was equally intense in all groups sacrificed at 
the same timepoint (results not shown). At t=3h, a diffuse glomerular mesangial granular staining 
pattern was observed upon staining for mouse IgG. This was slightly more intense in mice that 
had received 6G4 or 6D1, compared to mice that had received isotype control. Also on day 7, 
probably due to “trapping” of IgG in the damaged glomeruli, the fluorescence intensity for 
mouse IgG tended to be somewhat higher in the experimental groups than in the controls. 
 
 
Figure 5-6: Anti-MPO moAbs 
6G4 and 6D1 severely increase 
the percentage of crescentic 
glomeruli (a) and the mean 
glomerular PAS-positivity (b) 
in combination with a dose of 
anti-GBM IgG that is only 
mildly nephritogenic in 
combination with an isotype 
control 
Figure 5-7: Increased blood 
urea nitrogen (BUN) levels in 
mice treated with anti-MPO 
moAbs 6G4 and 6D1 in 
combination with anti-GBM 
IgG 
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As determined by ELISA and using a total IgG-specific conjugate, no difference was observed in 
anti-MPO titers between mice receiving 6G4 and mice receiving 6D1, in sera obtained after 3h, 
24h, and 7 days. As expected, no anti-MPO IgG could be detected in mice receiving isotype 
control moAb (results not shown). 
Discussion 
The pathogenicity of polyclonal mouse anti-murine MPO IgG has been well established in the 
mouse model of anti-MPO IgG-induced NCGN [43, 105, 147]. In this model, as well as in 
human ANCA-associated vasculitis, it is largely unknown whether there is a subset of ANCA, 
having a specific isotype and/or recognizing a specific epitope, which is responsible for their 
pathogenic effect. In this study, we describe the generation and characterization of a panel of 
mouse moAbs specific for murine MPO, and we show that two of the generated clones are 
severely pathogenic in the context of a mild anti-GBM glomerulonephritis. Our results provide 
additional evidence for the pathogenicity of anti-MPO IgG. In addition, our study shows that 
these moAbs are important tools for further investigations into the role of isotype and/or 
epitope-related functions of autoantibodies in the pathogenesis of anti-MPO IgG-induced 
NCGN.  
We employed a combination of inhibition ELISAs to obtain an indication of epitope specificity 
of the generated moAbs. The results from these assays suggest that the moAbs recognize 
epitopes that are located on three immunoreactive locations on the murine MPO-molecule. This 
is in line with studies in humans ([172-176], for a review, see [177]), suggesting that MPO-ANCA 
recognize a restricted number of epitopes on human MPO. 
Next, we investigated whether the generated anti-MPO moAbs were cross-reactive with human 
and rat MPO. Only one of the generated moAbs (4H9) showed weak cross-reactivity with human 
MPO, indicating that, despite a reported 85% amino acid similarity between mouse and human 
MPO [178], the immunoreactive regions of murine MPO are not found on its human 
counterpart. This result is however in line with the observation that all mouse anti-human MPO 
moAbs, as well as the vast majority of polyclonal MPO-ANCA derived from human sera, do not 
cross-react with rat MPO [179]. Conversely, in the study presented here, all except one of the 
generated anti-MPO moAbs showed cross-reactivity with rat MPO. Apparently, mice and rats are 
phylogenetically related to such an extent, that the murine immunogenic sites are preserved on 
the rat MPO molecule. 
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In previous studies, we showed that administration of polyclonal anti-MPO IgG causes NCGN 
[43], which is aggravated by bacterial LPS [105]. However, the anti-MPO moAbs generated in 
this study did not cause NCGN when administered alone, in combinations, and/or in 
combination with LPS. This is in contrast with mouse models of autoimmune arthritis [180-182] 
and pemphigus vulgaris [183, 184], in which both polyclonal and monoclonal autoantibodies 
induce disease in the recipient animals. 
It is unclear why the anti-MPO moAbs in our study, alone or in various combinations, with or 
without LPS, do not exert the same in vivo effect as polyclonal anti-MPO IgG. One possibility is 
that we might not yet have selected a clone recognizing a pathogenic epitope. Alternatively, 
pathogenicity might be restricted to a monoclonal antibody with a highly specific combination of 
proper isotype and epitope specificity. Since we selected only two IgG2a and one IgG2b moAb, a 
pathogenic anti-MPO moAb might be having either of those isotypes, but another epitope 
specificity. 
The administration of an IgG2a or IgG2b anti-MPO moAb led to severe aggravation of mild 
anti-GBM disease, as determined by severe urinary abnormalities, histopathological damage, and 
loss of renal function after 7 days. These results are in line with a study in rats revealing an 
aggravating effect of rabbit anti-rat MPO IgG on anti-GBM glomerulonephritis [170], and with 
two studies demonstrating that administration of anti-GBM IgG results in more severe disease if 
the recipient animals are first immunized with human MPO [45, 171]. In these studies however, 
the observed effect was exerted by polyclonal antibodies, whereas in our study, we describe an 
effect of monoclonal anti-MPO antibodies. 
 Anti-MPO IgG2a and IgG2b titers are rapidly declining upon the administration of polyclonal 
anti-MPO IgG in combination of LPS, whereas the anti-MPO IgG1 titer remains high. This 
suggests that in polyclonal anti-MPO IgG, IgG2a and IgG2b are responsible for disease 
development. Apart from a more rapid clearance of anti-MPO IgG2a and IgG2b from the sera 
of mice injected with polyclonal anti-MPO-IgG, there are several other reasons to assume a 
predominant role of IgG2a and IgG2b autoantibodies in MPO-ANCA-mediated disease. Firstly, 
preliminary data show that in the mouse model of anti-MPO IgG-induced NCGN, deficiency of 
both Fcγ receptors FcγRI and FcγRIII is required to prevent polyclonal anti-MPO IgG-induced 
disease development [185]. A similar pattern is observed in a model of murine experimental 
autoimmune hemolytic anemia, in which the pathogenicity of various isotype switch variants of a 
murine moAb causing hemolytic anemia is studied in several FcγR-deficient mouse strains [186]. 
In this study, pathogenicity of the IgG2a and IgG2b isotype-switch variants is only fully 
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prevented in common gamma-chain (FcRγ) deficient mice, that do not express the FcγRI as well 
as the FcγRIII receptor. This is in accordance with the observations in murine polyclonal anti-
MPO IgG-induced NCGN [185], and provides indirect support for the pathogenicity of anti-
MPO IgG2a and IgG2b. However, the exact role of the IgG isotype remains to be determined, 
using IgG1 clones with exactly the same epitope specificity as 6B1 and 6G4. 
Another pathogenicity-determining characteristic determined by the isotype of a moAb, lies in its 
capacity to activate complement. In the mouse model of anti-MPO IgG-induced NCGN, it has 
been shown that activation of the alternative complement pathway is pivotal in disease 
development [148, 187]. It would therefore be interesting to study the complement-activating 
potential of moAbs that share a similar idiotype, but have different isotypes. In this respect, it has 
been shown in the mouse model of hemolytic anemia described above, that IgG2a and IgG2b, 
but not IgG1 isotype-switch variants bind complement factor C3 in vivo [188]. Whether anti-
MPO IgG2a and/or IgG2b are also better activators of the complement pathway than anti-MPO 
IgG1, is as yet unknown. 
An unexpected observation in our study was the mild increase in disease severity induced by the 
administration of control IgG2a after the injection of anti-GBM antibodies, when compared to 
the control group receiving IgG2b. Additional studies are necessary to explain the observed 
effect of this irrelevant IgG2a moAb on anti-GBM glomerulonephritis. 
In conclusion, the study presented here describes the generation and characterization of a panel 
of moAbs specific for mouse MPO. The generated clones are not pathogenic in combination 
with LPS, but an IgG2a and an IgG2b anti-MPO moAb severely aggravate mild anti-GBM 
glomerulonephritis. Thus, a new murine model is provided that can be used to specifically 
address the importance of several antibody effector functions related to isotype, idiotype, and 
possibly to other antibody properties, in the development of anti-MPO IgG-induced NCGN. 
Studying this model may help us to obtain a better understanding of the pathophysiology of 
human MPO-ANCA associated vasculitis and glomerulonephritis. 
  
 
 Chapter 6 – MPO is critically involved in the 
induction of  organ damage after renal ischemia 
reperfusion 
Submitted as part of: Robert A. Matthijsen, Dennis Huugen, Nicole T. Hoebers, Bart de Vries, 
Carine J. Peutz-Kootstra, Yasuaki Aratani, Jan Willem Cohen Tervaert, Wim A. Buurman and 
Peter Heeringa. Myeloperoxidase is critically involved in the induction of organ damage following 
renal ischemia reperfusion. 
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Abstract 
Injury induced by renal ischemia and reperfusion (IR) is one of the factors that are still complicating not only renal 
transplantation surgery, but also a variety of other clinical conditions. Myeloperoxidase (MPO) is a neutrophil 
enzyme that is not only involved in host defence, but also in several immune-mediated inflammatory syndromes. In 
the present study, we utilized a murine model of renal IR injury to evaluate the role of MPO in this condition.  
Renal IR injury was applied in wildtype (WT) and myeloperoxidase-deficient (Mpo-/-) mice by unilateral clamping for 
40 minutes, followed by removal of the contralateral kidney and 24 hours of reperfusion. Blood urea nitrogen (BUN) 
levels were determined to evaluate the extent or renal damage, and immunohistochemistry was utilized to investigate 
neutrophil influx and renal deposition of MPO. 
24 hours after reperfusion, the mean BUN level in Mpo-/- mice was 31.4 ± 3.9, compared to 42.8 ± 5.2 in WT mice 
(p=0.003). In addition, renal neutrophil influx was significantly lower in Mpo-/- compared to WT mice (28.2 ± 7.6 vs. 
40.4 ± 5.2 cells per high-power field, p<0.02). 
From the data presented here, we conclude that MPO might play a hitherto unrecognized role in renal IR injury in 
humans. Finally, we discuss several potential mechanisms through which this versatile enzyme might be involved in 
renal IR. 
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Introduction 
In clinical medicine, complications arising from organ ischemia and reperfusion (IR) are common 
phenomena, complicating the treatment of severely injured or ill patients and influencing the 
outcome of various clinical conditions. Our understanding of the pathophysiology of IR induced 
organ damage is limited, and this impairs the development of new and effective therapies. 
In renal IR injury, cellular injury is one of the potential targets that has received much interest 
over the last decades. It is induced by ischemia and aggravated upon reperfusion, and forms a 
potent trigger for the activation of an extensive inflammatory response, illustrated by the 
production of various cytokines such as TNF-α and the interleukins 10, 12 and 18 [189, 190], the 
infiltration and activation of polymorphonuclear neutrophils (PMNs) in the affected area, as well 
as the expression or deposition of various components of the innate immune response, such as 
complement factors [191]. Under healthy conditions, the cells and proteins orchestrate a well-
mounted attack on invading micro-organisms, but when faced with extensive IR injury, they 
seem to lack sufficient means of control. 
MPO is a 140 kD heme protein that is predominantly stored in the lysosomes of monocytes and 
in the azurophilic granules of resting PMNs [20]. It is one of the enzymes that are released upon 
neutrophil activation, and its capacity to catalyze the formation of hypochlorite (HOCl) out of 
hydrogen peroxide (H2O2) and chloride ions makes it a powerful tool in the bactericidal 
armament of these cells [20]. However, there are also clinical studies indicating a potentially 
harmful effect in immune-mediated inflammatory syndromes, such as multiple sclerosis [192, 
193], acute coronary syndrome [194], and renal disease (reviewed in [19]). In addition, a 
considerable line of research indicates that MPO and MPO-derived oxidants are involved in the 
pathogenesis of atherosclerosis, possibly through catalyzing the oxidation of low-density [195-
199] and high-density [200] lipoproteins.  
It can be concluded from these studies that MPO can have both beneficial and detrimental 
effects in a variety of immune-mediated diseases. However, although the immune system is 
generally thought to be also involved in renal IR, the role of MPO in this is as yet unknown. 
More information regarding this issue might teach us more about the pathophysiological 
mechanisms that are responsible for renal IR, and provide potential targets for therapeutic 
intervention. Thus, in this chapter, we investigated the role of MPO in a mouse model of renal 
unilateral ischemia reperfusion injury, by comparing disease severity in wildtype (WT) and MPO-
deficient (Mpo-/-) mice with respect to various disease parameters. Our results show that that in 
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this model, MPO-mediated cytotoxicity is in part responsible for the development of renal 
damage resulting from ischemia and reperfusion. The potential mechanisms through which MPO 
might exert this effect on murine and human renal IR are discussed. 
Methods 
MICE 
Mpo-/- mice, backcrossed to a C57BL/6 background for six times, were genotyped using PCR-
amplified DNA from tail clippings [61]. Wildtype male C57Bl/6 (11 weeks of age) mice were 
obtained from Charles River Breeding Laboratories (Heidelberg, Germany). Mice were kept 
according to University of Maastricht animal facility regulations, and all experiments were 
approved by the local Animal Care and Experimentation Committee. 
EXPERIMENTAL PROCEDURE 
Experiments were carried out as previously described, with minor modifications [201]. At the 
start of the experiments, mice (n=5-6 per group) were anesthetized with sodium pentobarbital 
(100 mg/kg i.p.). Body temperature was maintained at 39°C by a heating pad until animals 
recovered from anesthesia. Under aseptic conditions a 1.0-cm long midline abdominal incision 
was made and ischemia was induced by applying a non-traumatic vascular clamp to the left renal 
pedicle for 40 min. Subsequently, the wound was covered with cotton soaked in sterile PBS. 
Immediately after removal of the clamp, the left kidney was inspected for restoration of blood 
flow and the contralateral kidney was removed. This provided us with a model of renal 
transplantation that allowed us to study the effect of renal IR unaffected by changes caused by 
the acute disruption of renal function prior to reperfusion, as would be the case if a contralateral 
nephrectomy were performed before the application of ischemia. The wound was closed in two 
layers, and animals were sacrificed 2 or 24 hours after reperfusion. In mice that were to be 
sacrificed after 24 hours, 0.25% bupivacaine was applied topically for postoperative pain 
management. At the time of sacrifice, plasma was collected and the left kidney was harvested for 
immunohistochemical and immunofluorescence analysis. 
LABORATORY AND PATHOLOGICAL EVALUATION OF DISEASE 
In mice sacrificed after 24 hours, blood urea nitrogen (BUN) levels were determined by an 
enzymatic degradation assay on a Synchron LX20 PRO (Beckman Coulter Inc., Fullerton CA), in 
sera collected at the time of sacrifice. Renal neutrophil influx was determined using a rat anti-
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mouse neutrophil antibody (clone NIMP-R14 [78]) on 4 µm snap-frozen tissue sections. After 
incubation with the primary antibody, endogenous peroxidase activity was blocked with 0.05% 
H2O2 in PBS, and rabbit anti-rat IgG-PO and goat anti-rabbit IgG-PO (both DakoCytomation) 
were then used as secondary and tertiary antibodies, respectively. Antibody binding was 
visualized using 3-amino-9-ethylcarbazole (AEC) with H2O2 as substrate. Sections were 
counterstained with hematoxylin, and juxtamedullary neutrophil influx was quantified by 
counting the average number of NIMP-R14-positive cells in 10 adjacent high-power fields, 
located around the medulla. 
To determine colocalization of renal MPO deposits with the localization of PMNs, renal cross-
sections were double-stained with a biotinylated mouse moAb specific for murine MPO (clone 
8F4 [105]) and NIMP-R14, using Alexa Fluor 488-labeled streptavidin and Alexa 568-labeled 
goat-anti-rat IgG (both obtained from Invitrogen, Breda, The Netherlands) as respective 
conjugates. No significant staining was detected in slides incubated with control rat IgG (NIMP-
R14) or mouse IgG (8F4). 
Plasma MPO levels were determined by in-house catching ELISA as described previously [105]. 
Briefly, microtiter plates were coated with Fcγ fragment-specific goat anti-mouse IgG (Jackson 
ImmunoResearch), incubated for 48 hours at 4°C, and blocked with 1% BSA in PBS. Plates were 
then incubated with an anti-murine MPO-specific moAb clone 8F4), followed by incubation with 
appropriately diluted plasma samples. Next, the plates were incubated with polyclonal rabbit anti-
human MPO (DakoCytomation, Glostrup, Denmark) and alkaline phosphatase-labeled 
polyclonal goat anti-rabbit IgG as primary and secondary detection antibody, respectively. 4-
Nitrophenyl phosphate (pNPP) was used as substrate, and results were analyzed 
spectrophotometrically at 405 nm. Concentrations were calculated from a standard curve of 
purified murine MPO (range, 2.5-100 ng/ml). 
STATISTICAL ANALYSIS 
Data are expressed as means ± SD and were analyzed by unpaired two-tailed Student’s t-test, 
using Graphpad Prism 4.01 for Windows (Graphpad Software, San Diego CA). P-values < 0.05 
were considered statistically significant. 
Results 
To investigate the effect of MPO-deficiency on renal function deterioration induced by renal IR 
injury, we determined BUN levels in plasma obtained at the time of sacrifice, 24 hours after 
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reperfusion and contralateral nephrectomy. As shown in Figure 6-1, Mpo-/- mice displayed a 
markedly less pronounced increase in BUN levels, when compared to WT controls (mean, 31.4 ± 
3.9 vs. 42.8 ± 5.2 mmol/l in Mpo-/- and WT mice, respectively, p=0.003). This was accompanied 
by a lower degree of renal influx of NIMP-R14-positive PMNs, as determined by 
immunohistochemistry (Figure 6-2, Figure 6-3, d and h). Whereas WT mice had on average 40.4 
± 5.2 NIMP-R14-positive cells per high-power field, the mean number of PMNs in Mpo-/- mice 
was 28.2 ± 7.6 per high-power field (p<0.02, Figure 6-2). 
 
  
 
To investigate whether MPO-positivity was restricted to PMNs, or whether also extracellular 
MPO could be found, double-staining with NIMP-R14 and 8F4 was performed. As displayed in 
Figure 6-3, sequestrated PMNs in WT mice were predominantly positive for the NIMP-R14 
antigen as well as MPO. A small amount of MPO-positivity did however not merge with 
positivity for NIMP-R14, suggesting that extracellular MPO was present in the lesions as well. As 
expected, no MPO positivity was found in the kidneys of Mpo-/- mice (Figure 6-3). 
 
  
Figure 6-1: MPO-deficient mice are partly 
protected from loss of renal function 
induced by renal ischemia perfusion, as 
reflected by a smaller increase in blood 
urea nitrogen (BUN) level after 24 hours. 
Untreated WT and Mpo-/- mice had 
similar BUN levels; the solid line 
indicates the mean BUN level in 
untreated mice (n=5). 
Figure 6-2: Juxtamedullary 
sequestration of NIMP-R14-
positive PMNs is attenuated in 
mice deficient for MPO. 
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Apart from the generation of reactive oxygen species, activation of PMNs also induces the 
release of their granule constituents such as MPO. Indeed, in plasma obtained from WT mice 24 
hours after reperfusion, we found significantly elevated levels of circulating MPO compared to 
untreated WT mice (mean, 24.2 ± 2.3 and 11.4 ± 2.8 ng/ml in IR and control mice, respectively; 
p<0.0001; Figure 6-4). 
 
Figure 6-3: Immunofluorescence (a-c and e-g) and immunohistochemistry (d and h) pictures of renal tissue stained 
for PMNs (NIMP-R14, red, a and e) and MPO (8F4, green, b and f). In WT mice, renal deposition of MPO largely 
colocalizes with NIMP-R14 (c), whereas no MPO is detected after renal IR in Mpo-/- mice (g). 
 
Discussion 
Many of the mechanisms responsible for renal failure after a period of ischemia followed by 
reperfusion are as yet unknown. In the present study we show that MPO-deficient mice are partly 
protected from IR-induced renal failure. Therefore, we postulate that this enzyme plays a hitherto 
unrecognized role in the pathogenesis of this syndrome. 
MPO is a neutrophil enzyme that is predominantly stored in the azurophilic granules of PMNs. 
Its capacity to catalyze the formation of HOCl out of H2O2 and chloride-ions is well-documented 
(for a review, see [20]). It has also been demonstrated in vitro that MPO mediates CD11b/CD18 
(MAC-1) dependent adhesion of PMNs [21], and that this specific binding of MPO to 
CD11b/CD18 results in PMN activation [22]. Finally, the role of MPO as an antigen in vasculitis 
and glomerulonephritis mediated by MPO-specific anti-neutrophil cytoplasmic autoantibodies 
(ANCA) is nowadays firmly established [18].  
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In our present study, we showed that the protective effect of MPO-deficiency, as measured by a 
decrease in BUN levels, is accompanied by a decrease in IR-induced renal influx of PMNs. 
Bearing in mind the in vitro role of MPO in CD11b/CD18-mediated PMN adhesion and 
activation [21, 22], it is tempting to postulate that the protective effect of MPO-deficiency is 
mediated by its effect on PMN adhesion and/or activation. In line with this hypothesis, Rabb 
and colleagues showed a protective effect of CD11b/CD18 blockade in a rat model of acute 
renal failure [202]. However, the role of MPO in PMN adhesion in vivo is as yet unclear, and also 
the role of PMNs in renal IR injury is not undisputed ([201, 203-205], and reviewed in [206]). 
Thus, PMN influx and CD11b/CD18 seem to play an intriguing but complicated role in renal IR, 
and it is as yet unclear whether MPO has a modifying effect on their action. 
 
  
 
Apart from its effect on PMN adhesion and activation, MPO could also be involved in other 
pathways that play a role in the pathogenesis of renal IR. Firstly, there is convincing in vitro 
evidence that MPO also plays a role in apoptosis [23-25]. Over the years, a massive body of 
literature has emerged describing activation of apoptotic pathways in renal IR (reviewed in [207] 
and [208]). Moreover, inhibition of apoptosis through administration of the anti-apoptotic agent 
IGF-1 or ZVAD-fmk (a caspase inactivator) [209], repletion of guanosine [210], or 
administration of a p53 inhibitor [211] has been shown to preserve renal function after renal IR. 
We are currently testing the hypothesis that in our study, a decrease in MPO-mediated apoptosis 
is one of the mechanisms through which Mpo-/- mice are protected from injury caused by renal 
IR.  
Figure 6-4: Renal IR leads to 
an increase in circulating MPO 
levels 24 hours after 
reperfusion. 
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Secondly, a direct activating effect of MPO on complement factor C5 [26, 27] provides a 
potential mechanism through which MPO plays a role in renal IR injury. It has been shown that 
inhibition of C5b-9 (MAC) formation [212], as well as treatment with a C5a receptor antagonist 
[201] attenuates disease in mouse models of renal IR. However, data on a direct effect of MPO 
on complement system activation are restricted to in vitro studies [26, 27]. 
MPO has been studied as a possible pathogenic factor in a number of other mouse models. In a 
study on myocardial ischemia, MPO-deficient mice are partly protected against leukocyte influx 
and myocardial rupture, and have a better post-ischemic left-ventricular function [213]. It is 
suggested that the effect of MPO in this model is mediated by its oxidizing effect on 
plasminogen activator inhibitor-1 (PAI-1), resulting in a decreased plasmin activity in Mpo-/- mice. 
Alternatively, MPO might be involved in myocardial IR injury via the generation of cytotoxic 
aldehydes [214]. Nevertheless, it remains to be determined whether these mechanisms also play a 
role in renal IR injury. 
Whereas myocardial IR injury is attenuated in MPO-deficient mice, MPO-deficiency is actually 
detrimental in murine atherosclerosis [215] and murine experimental autoimmune encephalitis 
[216]. Moreover, Mpo-/- mice also display an increased infarct size in a murine model of cerebral 
IR injury [217]. It is suggested in these studies that MPO-mediated, oxidative inactivation of 
proinflammatory molecules [215], or increased proliferation of antigen-specific T-cells in Mpo-/- 
animals [216] are responsible for the observed effects. Alternatively, as discussed by Nauseef 
[218], MPO might by protective in these models via the terminating effect of the MPO-H2O2-
halide system on the NADPH-oxidase pathway [219]. However, the role of these mechanisms in 
the pathogenesis of renal IR injury remains obscure. 
In conclusion, the study presented here provides evidence that MPO plays a detrimental role in 
murine renal IR injury. We are currently trying to unravel if this effect is caused by the role of 
MPO in PMN adhesion and activation, apoptosis, complement pathway activation, plasmin 
activity, the generation of toxic aldehydes, and/or other, as yet unknown, factors. 
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Wegener’s Granulomatosis, Churg-Strauss Syndrome, microscopic polyangiitis, and idiopathic 
pauci-immune necrotizing crescentic glomerulonephritis (NCGN), have many characteristics in 
common. First, their diagnosis is based histopathologically on a sterile inflammation 
predominantly affecting the arterioles, venules and capillaries of the circulatory system. Second, 
their presence is often accompanied by elevated levels of anti-neutrophil cytoplasmic 
autoantibodies (ANCA), predominantly specific for proteinase 3 (PR3) or myeloperoxidase 
(MPO). Therefore, these diseases are collectively called ANCA-associated small-vessel 
vasculitides [2]. 
The close association between the presence of ANCA and vasculitis has led many researchers to 
investigate their role in the pathogenesis of this disease. In the presented thesis, we try to 
elucidate the effects of MPO-ANCA –the autoantibodies– as well as MPO –the autoantigen– in 
renal inflammation. To this end, we utilized the mouse model of anti-MPO IgG-induced 
glomerulonephritis, as discussed in the next paragraph. In addition, we used the mouse model of 
renal ischemia reperfusion injury to obtain a more profound insight into the role of MPO in the 
pathophysiology of (renal) inflammation in a broader sense. 
Translation of in vitro observations to in vivo evidence for 
MPO-ANCA pathogenicity 
As discussed in Chapter 1, a considerable body of in vitro studies generally points towards a 
mechanism in which the development of full-blown ANCA-associated vasculitis relies on three 
key players (Figure 7-1). The first player is the polymorphonuclear neutrophil (PMN), being the 
most prominent source of MPO, PR3, and other potential ANCA antigens. The second is a 
proinflammatory environment, typically created in vitro by adding a priming concentration of 
TNFα to the system. This “pre-activates” the PMNs, leading to the upregulation of adhesion 
molecules and, importantly, to an increased expression of the ANCA antigens on the outer 
membrane of circulating PMNs and monocytes. ANCA then act as the third player when they 
bind to primed PMNs, resulting in their activation and the release of lytic granule constituents 
and reactive oxygen radicals (reviewed in [18]). The adherence of activated PMNs to susceptible 
endothelium then initiates an inflammatory cascade that ultimately results in symptomatology as 
clinically observed. 
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Figure 7-1: Representation of ANCA-mediated neutrophil responses that are putatively involved in the pathogenesis 
of ANCA-associated small vessel vasculitis. (a) Proinflammatory cytokines and chemokines (e.g. tumor necrosis 
factor α), released as a result of local or systemic infection, cause upregulation of endothelial adhesion molecules 
(e.g. selectins, ICAM-1, and VCAM) and prime the neutrophil. (b) Neutrophil priming causes upregulation of 
neutrophil adhesion molecules (CD11b) and translocation of the ANCA antigens from their lysosomal 
compartments to the cell surface. (c) Engagement of the F(ab’)2 portion of ANCA with ANCA antigens on the cell 
surface, and interaction of the Fc part of the antibody with Fc receptors, activates the neutrophil, causing increased 
neutrophil–vessel wall adherence and transmigration. (d) ANCA-mediated neutrophil activation also triggers reactive 
oxygen radical production and possibly causes neutrophil degranulation, with consequent release of proteolytic 
enzymes, leading to vasculitis. 
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To test the hypothesis that ANCA-induced activation of primed neutrophils underlies pauci-
immune NCGN, the first requisite is an animal model that convincingly proves the pivotal role 
of ANCA in the pathogenesis of ANCA-associated vasculitis. In Chapter 1, several rodent 
models addressing this issue are discussed. Although these models generally support the 
suggested hypothesis, they do not prove unequivocally that ANCA cause vasculitis and 
glomerulonephritis. In 2002, Xiao and colleagues showed that the adoptive transfer of IgG from 
murine MPO (muMPO) immunized MPO-knockout (Mpo-/-) mice to wildtype (WT) mice 
resulted in a mild vasculitis and glomerulonephritis, with remarkable similarity to human MPO-
ANCA associated disease [43]. In addition, it has recently been shown that the immunization of 
WKY rats with human MPO induces the generation of anti-human MPO antibodies that cross-
react with rat MPO and cause a mild form of NCGN [49]. Together, these studies do not only 
prove that MPO-ANCA cause vasculitis and glomerulonephritis, but also provide an exquisite 
opportunity to further explore the mechanisms involved. 
 
As described above, the transfer of anti-MPO IgG to WT mice only induces mild NCGN. In 
Chapter 2, we show that bacterial lipopolysaccharide (LPS), being a model proinflammatory 
stimulus, increases the severity of NCGN induced by anti-MPO IgG in a dose-dependent 
fashion. This provided us with a disease model that not only more closely resembled human 
MPO-ANCA associated NCGN, but that was also excellently suitable to investigate the effect of 
therapeutic intervention on various parameters of disease severity. 
We investigated several factors that might be mediating the observed effect of LPS. First, we 
showed that LPS increases the anti-MPO IgG-induced early (day 1) glomerular influx of PMNs, 
as well as the late (day 6) influx of several types of leukocytes, in a synergistic fashion. Second, 
systemic administration of LPS resulted in an immediate, transient increase in serum TNF-α 
levels, as well as circulating MPO levels. Third, we were able to confirm ANCA-induced 
activation of PMNs in the mouse model by showing that incubation of murine TNFα-pretreated 
peritoneal exudate cells (predominantly PMNs) with anti-MPO IgG results in a modest but 
significant increase in superoxide production. Together, these results strongly suggest that in 
mice, the LPS-induced release of TNFα and/or MPO augments anti-MPO IgG-induced 
activation of PMNs, thus leading to more severe disease. The activated PMNs then adhere to the 
glomerular endothelium, ultimately resulting in glomerulonephritis. Importantly, however, we 
also showed that pretreatment of the animals with a TNFα-inhibiting monoclonal antibody 
(moAb) attenuates, but not fully prevents, disease development. This indicates that other –
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TNFα-independent– mechanisms might be more crucially involved in the pathogenesis of anti-
MPO IgG-induced disease. 
In order to prove that anti-MPO IgG-induced activation of primed PMNs causes 
glomerulonephritis, it is necessary to not only provide evidence for the role of anti-MPO IgG 
and priming, but also for a crucial role of PMNs in the pathogenesis of anti-MPO IgG-induced 
NCGN. We addressed this issue by investigating the effect of neutrophil-depletion in the mouse 
model of anti-MPO IgG-induced disease. In line with the hypothesis, pretreatment of animal 
with the neutrophil-depleting moAb NIMP-R14 [78] completely inhibited disease development 
upon administration of anti-MPO IgG [147]. 
 
In Chapter 3, we review in vitro and animal studies, as well as clinical data on TNFα and TNFα-
bioactivity inhibition in ANCA-associated vasculitis, and discuss the potential benefit that 
patients with ANCA-associated vasculitis might have from TNFα bioactivity-inhibiting therapy. 
As already briefly discussed in chapters 1 and 2, in vitro studies as well as various animal models 
strongly suggest an important role for TNFα-induced neutrophil priming in the pathogenesis of 
ANCA-associated vasculitis. In human ANCA-associated disease, however, the therapeutic 
potential of TNFα inhibition is still controversial. The results from a large, but uncontrolled, 
study on the effect of infliximab in the treatment of ANCA-associated disease were promising, 
although major side-effects occurred [87]. However, the first controlled trial on the use of 
etanercept in this disease was disappointing, since no benefit of adding etanercept to standard 
therapy could be seen [126]. Moreover, also in this trial major side-effects occurred in the group 
receiving etanercept. 
 
In summary, it can be concluded from the mouse studies that, in a fully homologous system, anti-
MPO IgG, an inflammatory environment and PMNs indeed act together in causing full-blown 
NCGN. However, TNFα plays a less crucial role in the involved mechanisms than could be 
expected from in vitro observations. Clinical trials, demonstrating that ANCA-associated disease 
can perpetuate and relapse during TNFα-inhibiting therapy, support this notion, although firm 
conclusions should not yet be drawn from the available data. To substantiate the hypothesis that 
ANCA-induced activation of primed neutrophils causes vasculitis, we should therefore look for 
mechanisms that facilitate the pathogenic activity of ANCA in a TNFα-independent fashion. 
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MPO-ANCA associated vasculitis and the complement 
system 
Since ANCA-associated vasculitis is typically characterized by a paucity of immune complexes, it 
is generally assumed that the complement system does not play an important role in the 
pathogenesis of this disease. Contrary to this, several studies did find a considerable degree of 
immune complex depositions in skin lesions [62] as well as in renal biopsies [154] from ANCA-
associated vasculitis patients. Immune complexes were also found in a rat model of MPO-ANCA 
associated glomerulonephritis at an early stage of disease, but not at later timepoints [47]. It is 
suggested from these studies that the deposition of immune complexes is an important initial 
trigger in the development of vascular lesions, but that they have disappeared by the time that 
biopsies are generally taken. To summarize, from the clinical data presented thus far, no firm 
conclusions can be drawn with respect to the importance of immune complex depositions and 
the complement system in the pathogenesis of ANCA-associated disease. 
 
 
 
One of the advantages of the mouse model of anti-MPO IgG-induced glomerulonephritis, is that 
it allows the investigation of a seemingly infinite number of proteins, not only through the 
employment of neutralizing or depleting moAbs, but also by studying disease development in 
Figure 7-2: The complement system can 
be triggered through the classical and 
lectin pathway, both of which are 
dependent on the presence of 
complement factor C4, and through the 
alternative pathway, which is dependent 
on complement factor B. Generally, 
complement pathway activation leads to 
the formation of a C3 convertase, 
ultimately resulting in the generation of 
C5b-9 (the MAC-complex) and C3a and 
C5a, which are both powerful 
chemoattractants. 
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transgenic mice. Utilizing this approach, Xiao and colleagues recently investigated the role of the 
complement system (Figure 7-2) in anti-MPO IgG-induced NCGN. Much to their surprise, they 
found that disease development was completely inhibited in C3-depleted mice, as well as in 
transgenic mice deficient for complement factor C5 or factor B. Conversely, C4-deficient mice 
were not protected from disease induced by anti-MPO IgG [148]. It can be concluded from these 
experiments that alternative complement pathway activation, but not activation of the classical or 
lectin pathway, is somehow crucially involved in disease development. 
The pivotal role of complement in anti-MPO IgG-induced NCGN, makes this system a 
potentially highly interesting therapeutic target. This issue is addressed in Chapter 4, in which we 
show the effect of a C5-inhibiting moAb (BB5.1 [149]) on the development of disease induced by 
the administration of anti-MPO IgG and LPS. As could be expected from the studies in 
complement-deficient mice, pretreatment with anti-C5 moAb completely prevented disease 
development upon administration of anti-MPO IgG and LPS, as measured by urinary, 
histopathological, and early (day 1) and late (day 7) immunohistochemical parameters. 
Importantly, however, we also studied the effect of anti-C5 treatment one day after disease 
induction, when hematuria, leukocyturia, and glomerular PMN influx are already present. This 
intervention resulted in a considerable decline in urinary abnormalities, as well as a more than 
80% decrease in the percentage of glomeruli containing crescents and/or fibrinoid necrosis. The 
response to anti-C5 treatment was also reflected in several immunohistochemical parameters of 
glomerular inflammation. Immunofluorescence staining did not provide a clear answer with 
respect to the mechanism responsible for the anti-C5 effect. However, we hypothesize that 
properdin release from activated PMNs is involved in this process. Properdin is an important 
stabilizer of C3bBb, the alternative pathway C3 convertase, and therefore, its release would 
increase complement system activation, resulting in the generation of C3a and C5a, both strong 
chemotactic and PMN-activating factors. Thus, a positive feedback loop is created, in which C3a 
and C5a attract and activate new PMNs, resulting in the release of more properdin, so that more 
C3bBb is stabilized (Figure 7-3) [161]. 
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Figure 7-3: Proposed mechanism through which the complement system is involved in the pathogenesis of MPO-
ANCA associated small vessel vasculitis. The C3 convertase C3bBb is stabilized by properdin released from ANCA-
activated PMNs. This induces activation of the terminal complement pathway, which entails the generation of C5a, a 
powerful chemoattractant and activator of PMNs. 
 
The observation that C4-deficient mice are not protected from anti-MPO IgG-induced NCGN 
[148], might lead to the conclusion that immune complexes are not involved in its pathogenesis. 
However, it has been shown in murine heterologous nephrotoxic nephritis, a model in which 
disease development is generally thought to be mediated by immune complexes, that C1q-
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deficiency does not protect against disease [220]. Moreover, depending on the mouse strain used, 
C1q-deficiency might even lead to an aggravated response in the mouse model of heterologous 
[220] and accelerated [221] nephrotoxic nephritis. Obviously, there are many differences between 
the pathogenic mechanisms involved in nephrotoxic nephritis and anti-MPO IgG-induced 
glomerulonephritis, but it can be learned from those experiments that immune complex 
pathogenicity might under some circumstances be independent from classical pathway activation. 
It is conceivable that deposits of MPO/anti-MPO complexes are in part responsible for the 
initial glomerular sequestration of PMNs, and that the alternative complement pathway has an 
aggravating role [222]. Direct evidence for this mechanism is however lacking in (human) 
ANCA-associated vasculitis. 
 
Our study does not only provide important new insights into the pathogenesis of anti-MPO IgG-
induced NCGN, but it is also of interest from a clinical point of view. In an animal model of 
MPO-ANCA associated vasculitis that has many features in common with its human 
counterpart, we showed that C5-inhibition prohibits all pathogenic effects of anti-MPO IgG, not 
only when initiated prior to disease induction, but also in an intervention setup. Interestingly, C5-
inhibiting therapy is also already available for humans. Eculizumab is a recombinant humanized 
moAb that inhibits cleavage of C5 and thus prevents the formation of the chemotactic mediator 
C5a as well as the generation of CD5b-9 [223, 224]. It has recently been shown to be effective 
and safe in the treatment of paroxysmal nocturnal hemoglobinuria [225]. Pexelizumab, another 
C5-inhibiting moAb [226], has been tested mainly in patients undergoing coronary artery bypass 
grafts, and the safety of long-term administration of this drug is as yet undetermined. Therefore, 
it would be very interesting to determine whether complement pathway activation is involved in 
the pathogenesis of human (MPO-) ANCA associated vasculitis as well. Ultimately, such a 
finding could lead to a study into the effect of anti-C5 treatment in a clinical trial. 
Anti-MPO monoclonal antibodies in the mouse model of 
anti-MPO IgG-induced NCGN 
In the mouse model of anti-MPO IgG-induced NCGN, disease is induced with polyclonal anti-
MPO IgG, isolated from the sera from MPO-immunized Mpo-/- mice. Consequentially, it might 
be consisting of several isotypes, and specific for several epitopes on the MPO-molecule. In 
Chapter 5, we describe the development and characterization of a panel of monoclonal anti-
MPO antibodies. By immunohistochemistry we show that some of the generated moAbs cross-
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react with rat MPO, and enzyme-linked immunosorbent assay (ELISA) and indirect 
immunofluorescence reveal that only one of the generated anti-mouse MPO moAbs is weakly 
cross-reactive with human MPO. The epitopes recognized by the generated moAbs are roughly 
clustered in three regions on the murine MPO-molecule, as determined by inhibition ELISA. 
Although it is not sure whether our panel of moAbs is exhaustive, our results are in accordance 
with studies on epitope specificity in human MPO-ANCA associated vasculitis ([173-176], 
reviewed in [177]). 
To our surprise, none of the generated moAbs, applied in several dosages, alone or in several 
combinations of IgG1, IgG2a and/or IgG2b clones, had the capacity to induce NCGN, either 
with or without LPS. The reason for this lack of pathogenicity is unknown. In our opinion, it is 
unlikely that the generation of new clones will yield moAbs with an epitope specificity that is 
importantly different from the moAbs that are already available. However, it is possible that the 
moAbs are only pathogenic in a specific combination of several isotypes and/or idiotypes, or that 
pathogenicity of a moAb relies on a specific combination of isotype and idiotype. 
Whereas we could not show pathogenicity of the generated anti-MPO moAbs by themselves or 
in combination with a systemic proinflammatory stimulus created by the administration of LPS, 
two of the generated clones (one of the IgG2a and one of the IgG2b isotype) were severely 
pathogenic in the context of a mild immune complex glomerulonephritis, induced by the 
injection of sheep antibodies against the murine glomerular basement membrane (anti-GBM 
IgG). A similar effect was already shown in two rat studies [45, 170], and recently, it has also been 
shown in mice that the presence of a polyclonal immune response against murine MPO 
aggravates anti-GBM glomerulonephritis [171]. However, in those studies, the anti-MPO effect 
was not exerted by moAbs, but by a polyclonal immune response. 
The results of our study underline the pathogenicity of the anti-MPO immune response. 
However, it is as yet unclear as to what extent the described aggravating effects of the anti-MPO 
moAbs is restricted to the two tested clones. Investigation of the role of specific isotypes requires 
the generation of sets of clones from different isotypes, but recognizing exactly the same epitope. 
Similarly, to study whether the effect is epitope-specific, it would be necessary to establish sets of 
clones from the same isotype, recognizing different epitopes. However, after the administration 
of polyclonal anti-MPO IgG, we observed that serum anti-MPO IgG2a and IgG2b titers 
decreased more rapidly than serum anti-MPO IgG1. We therefore hypothesize that anti-MPO 
IgG pathogenicity may predominantly be caused by antibodies of the IgG2a or IgG2b isotype. 
Clearly, additional experiments are required to answer to this question. The generated panel of 
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monoclonal autoantibodies might however provide interesting information concerning the role 
of immune complexes, complement binding, Fc-receptor involvement, and interference of the 
moAb with the enzymatic activity of MPO, in the pathogenesis of anti-MPO IgG-induced 
NCGN. Finally, although we did not yet perform experiments into this direction, it could be 
worthwhile to investigate the effect of an anti-MPO moAb, F(ab) fragment, or F(ab)2 fragment 
in combination with polyclonal anti-MPO IgG. In such an experiment, the moAb might very well 
aggravate disease, but it is also conceivable that the binding of non-pathogenic monoclonal 
antibodies (or antibody fragments) prevents the binding of pathogenic polyclonal anti-MPO IgG, 
and thus might lead to attenuation of disease. 
The role of MPO in renal inflammation 
Although similar in many ways, vasculitis patients positive for PR3-ANCA clearly differ from 
patients with MPO-ANCA (reviewed in [5]). This suggests that, apart from being an antigen, 
MPO might play an additional –functional– role in the pathogenesis of MPO-ANCA mediated 
disease. This is further supported by the finding that MPO-ANCA inhibit the binding of MPO to 
ceruloplasmin, its natural inhibitor, and thus promote the ongoing activity of MPO [28, 29]. In 
Chapter 6, we investigated the role of MPO in renal inflammation, by employing a mouse model 
of renal ischemia/reperfusion (IR) injury. By showing that MPO-deficient mice are partly 
protected from IR-induced renal failure, we demonstrate that this enzyme plays a hitherto 
unrecognized role in this model. Although it is as yet unknown what the mechanism is behind 
the deleterious effect of MPO in IR-induced renal inflammation, we discuss the possibility that 
this effect is mediated by apoptosis [23-25], activation of complement factor C5 [26, 27], and/or 
effects on coagulation and fibrinolysis [213, 227]. It has been shown in vitro that MPO might be 
involved in CD11b/CD18 integrin-mediated PMN adherence and activation [21, 22]. In line with 
this, we observed a decrease in IR-induced adhesion of PMNs in Mpo-/- mice. Although the 
function of these cells in renal IR is as yet incompletely understood, a role for MPO in PMN 
adhesion in vivo might provide an attractive explanation for the protective effect of MPO-
deficiency in renal IR injury and several other animal models of inflammation, and is currently 
being investigated. However, it remains to be investigated as to what extent the activity of MPO 
itself plays a role in the pathophysiology of MPO-ANCA-associated vasculitis. It might be 
worthwhile in this respect to see whether treatment with the MPO-inhibitor 4-aminobenzoic acid 
hydrazide or indomethacin [228] reduces disease in the mouse model. 
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Speculations on the development of ANCA-associated 
vasculitis  
An important limitation of the discussed animal model is consequential to the artificial way in 
which the anti-MPO immune response is elicited: they are not suitable to study the origin of the 
autoimmune response to MPO. In this respect, infection [69-72, 229] and other environmental 
factors such as silica ([230-233], reviewed in [234]) have long been suggested to play a role in the 
induction of the ANCA response. This might also be the case for MPO-ANCA, although there is 
little support for this view from clinical as well as experimental studies. In addition, as discussed 
in the introduction of this thesis, future studies will have to establish the value of the theory of 
autoantigen complementarity [32] as a mechanism contributing to the initiation of the anti-PR3, 
and possibly the anti-MPO autoimmune response. 
It is possible that any factor responsible for the initiation of an anti-MPO immune response, is 
also responsible for its perpetuation. However, if such a trigger is temporary, as would probably 
be the case when disease onset is consequential to an infection, as suggested by some researchers 
[32, 69-72], an explanation should be found for the continuation of ANCA-production after 
termination of the triggering factor. In this respect, it might be interesting to note that in 
preliminary experiments in our mouse model, we found increased numbers of periglomerular 
class II major histocompatibility complex and CD11c-positive dendritic cells (DCs). This is in 
line with observations by Krüger and colleagues, who identified similar depositions of CD11c-
positive cells in a mouse model of nephrotoxic nephritis, and were able to show that these cells 
could act as dendritic cells in vitro [235].  
Although far from proven, the presence of functionally active dendritic cells in the glomerular 
infiltrates would make it defendable to propose a hypothesis in which the cause of ongoing 
production of ANCA lies within the inflamed glomeruli themselves. Support for this mechanism 
is provided by a study showing that the administration of apoptotic PMNs can lead to the 
development of ANCA [54]. In addition, ANCA have been shown to disturb normal apoptosis 
of TNFα-primed PMNs, leading to a decreased phagocytosis by macrophages [236]. This might 
cause secondary necrosis, which is a highly inflammatory event, potentially leading to the 
maturation and activation of dendritic cells [237]. Alternatively, it has been shown by Harper and 
colleagues that the opsonization with ANCA of apoptotic PMNs actually increases their uptake 
by macrophages, but that this occurs in a proinflammatory fashion, leading to an increased 
release of IL-1 and IL-8 [17]. Irrespective of the cause of inflammation however, it is conceivable 
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that in a phlogistic milieu, characterized by the presence of activated, apoptotic and/or necrotic 
PMNs, DCs, and T-cells, DCs might process MPO in such a way, that it results in the activation 
of T-cells and the generation of autoimmunity. In this respect, it has already been shown that 
mice injected with DCs that are loaded in vitro with the cardiac autoantigen MYHC-α, develop 
autoimmune myocarditis if the DCs were appropriately activated with LPS and a costimulatory 
anti-CD40 antibody [238]. Moreover, a similar mechanism of activation of T-cells by lesional 
DCs has already been suggested to play a role in murine autoimmune diabetes [239] and human 
autoimmune thyroiditis [240]. Also in ANCA-associated disease, generation of autoantibodies at 
the site of inflammation has been proposed previously [100, 241], and is supported by the 
presence of ANCA in broncho-alveolar lavage fluid of patients [242]. However, it remains a 
challenge to prove a role for this phenomenon in vivo. A better understanding of the 
pathophysiology behind the perpetuation of ANCA production has not only gained priority after 
the discovery of MPO-ANCA pathogenicity in rodent models [43, 49], but those models also 
offer an exiting opportunity to investigate this issue in an in vivo setting. 
Conclusion 
The development of the mouse model of anti-MPO IgG-induced vasculitis has led to a series of 
studies that largely confirmed the hypothesis derived from in vitro studies, that MPO-ANCA are 
pathogenetically involved in MPO-ANCA associated vasculitis through their capacity to activate 
TNFα-primed PMNs. Unexpectedly however, the complement system has recently been shown 
to be crucially involved in disease pathogenesis. Additional studies will have to reveal the 
responsible mechanism. Nevertheless, if the results obtained in the mouse model also apply to 
human (MPO-) ANCA-associated disease, this does not only call for a modification of the 
current hypothesis, but also implies an exciting opportunity for novel therapeutic strategies. The 
therapeutic value of a panel of murine MPO-specific moAbs, as well as mounting data on the 
versatile functions of MPO in vivo, remain to be established. Finally, although considerable 
progress has been made in this field as well, it is as yet a challenge to elucidate the mechanisms 
that are responsible for the derangement of the immune system underlying the formation of an 
autoimmune response. 
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De ziekte van Wegener, microscopische angiitis, het syndroom van Churg-Strauss en “pauci-
immune rapidly progressive crescentic glomerulonephritis”, een vorm van glomerulonefritis die 
wordt gekenmerkt door zijn snelle progressie en het vrijwel afwezig zijn van immuuncomplexen, 
zijn ziekten die gekenmerkt worden door steriele inflammatie van met name de kleine 
bloedvaten. De organen die het meest frequent aangetast zijn, zijn de nieren, de longen, en het 
KNO-gebied, maar feitelijk kan de ziekte in ieder orgaan optreden. Het beloop kan zeer ernstig 
zijn, en leiden tot ernstig disfunctioneren van het getroffen orgaan. De huidige standaardtherapie 
bestaat uit diverse middelen die alle op een vrij aspecifieke manier de afweer onderdrukken. De 
effectiviteit ervan schiet frequent tekort, en bovendien kan de behandeling gepaard gaan met 
ernstige bijwerkingen. 
Een fenomeen dat deze “kleine vaten-vasculitiden” met elkaar gemeen hebben, is hun associatie 
met de aanwezigheid van anti-neutrofiel cytoplasmatische autoantilichamen (ANCA). Zoals de 
naam al suggereert, zijn dit antilichamen die lichaamseigen antigenen herkennen, in het bijzonder 
eiwitten die zich bevinden in het cytoplasma van neutrofiele granulocyten. Hoewel de 
antilichamen gericht kunnen zijn tegen diverse eiwitten, zijn ANCA in de meeste patiënten met 
bovenstaande ziekten specifiek voor proteïnase 3 (PR3) of myeloperoxidase (MPO). 
Tot voor kort bestond tussen de aanwezigheid van ANCA en vasculitis alleen een associatie, en 
kon in vivo niet aangetoond worden dat de autoantilichamen ook daadwerkelijk vasculitis en 
glomerulonefritis veroorzaakten. In 2002 is echter aangetoond dat muizen waarbij antilichamen 
gericht tegen muisMPO worden ingespoten vasculitis ontwikkelen, die wordt gekenmerkt door 
de aanwezigheid van rode en witte bloedcellen en eiwit in de urine, tekenen van 
nierfunctiestoornissen in het bloed en ontstekingen in de nieren en longen, die erg lijken op de 
afwijkingen die gevonden worden bij mensen met (MPO-) ANCA geassocieerde vasculitis. Deze 
ontdekking wierp niet alleen een geheel nieuw licht op het ontstaan van deze ziekte, maar 
creëerde ook de mogelijkheid om in dit muismodel andere factoren te onderzoeken die mogelijk 
betrokken zijn bij de pathogenese, en om potentiële nieuwe therapieën te testen. In dit 
proefschrift worden experimenten beschreven –vooral uitgevoerd in het hierboven beschreven 
muismodel– , waarmee we wilden uitzoeken waarom anti-MPO antilichamen glomerulonefritis 
veroorzaken in muizen, welke factoren daarbij betrokken zijn, en hoe we dit kunnen beïnvloeden. 
We denken dat deze muizen een goed model zijn voor de pathogenese van MPO-ANCA 
geassocieerde glomerulonefritis in mensen; het uiteindelijke doel is dan ook om het ontstaan van 
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deze ziekte bij mensen beter te begrijpen, en een therapie te ontdekken die beter (dat wil zeggen, 
effectiever, en met minder bijwerkingen gepaard gaand) werkt dan de huidige behandeling. 
In hoofdstuk 1 wordt een introductie gegeven over ANCA-geassocieerde vasculitiden, in het 
bijzonder MPO-ANCA geassocieerde vasculitis en glomerulonefritis. Tevens worden kort een 
aantal andere diermodellen van ANCA-geassocieerde ziekte besproken, aan de hand van hun 
plus- en minpunten. Uitgebreider wordt ingegaan op het hierboven beschreven muismodel, 
waarin het merendeel van onze studies zijn verricht. 
In hoofdstuk 2 wordt beschreven wat de rol is van proinflammatoire stimuli in het muismodel 
van anti-MPO antilichaamgeïnduceerde glomerulonephritis. Er zijn een aantal redenen om te 
veronderstellen dat ontstekingseiwitten belangrijk zijn in het ontstaan van MPO-ANCA 
geassocieerde ziekte bij mensen, en in deze studie tonen we aan dat dit in ieder geval opgaat voor 
muizen. Bovendien laten we zien dat het tevoren inactiveren van één van die eiwitten –tumor 
necrosis factor-alfa, TNFα– leidt tot significant minder anti-MPO antilichaamgeïnduceerde 
nierschade, maar de ziekte niet helemaal voorkómt. Dit heeft implicaties voor het potentiële nut 
van anti-TNFα behandeling van mensen met ANCA-geassocieerde ziekte, een onderwerp dat 
verder wordt uitgewerkt in hoofdstuk 3. De conclusie van deze uitgebreide review van in vitro, in 
vivo, en klinische studies naar de rol van TNFα (/-inhibitie) in ANCA-geassocieerde vasculitis, is 
dat ook deze behandeling niet altijd voldoende effectief is, en nog met veel bijwerkingen gepaard 
gaat. 
Hoofdstuk 4 behandelt de rol van het complementsysteem in het muismodel van anti-MPO 
antilichaamgeïnduceerde glomerulonefritis. Dit is een groep van eiwitten die samen belangrijk zijn 
voor de verdediging van het lichaam tegen schadelijke invloeden. Het blijkt echter dat sommige 
onderdelen van het complementsysteem ook een dermate belangrijke plaats hebben in het 
ontstaan van ziekte in het muismodel, dat deficiëntie ervan –hetzij in genetisch veranderde 
muizen, hetzij ten gevolge van het inspuiten van de muizen met een “complement-remmer”– het 
ontstaan van ziekte voorkómt. De meest interessante ontdekking uit onze studie was dat het 
tevoren inactiveren van één specifiek eiwit van het complementsysteem (factor C5) ziekte niet 
alleen kan voorkómen, maar dat het inspuiten van muizen die al ziek zijn met een factor C5-
remmer ook leidt tot een reductie van anti-MPO antilichaamgeïnduceerde nierschade van meer 
dan 80%. Aangezien er al middelen bestaan die factor C5 in mensen kan remmen, heeft deze 
ontdekking mogelijk belangrijke consequenties voor de behandeling van mensen met MPO-
ANCA geassocieerde vasculitis in de toekomst. 
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In hoofdstuk 5 beschrijven we de ontwikkeling van een set muisMPO-specifieke monoklonale 
(dat wil zeggen, slechts bindend aan één specifiek stukje van het MPO-molekuul) antilichamen. 
Doel hiervan was te onderzoeken of er een bepaald type anti-MPO antilichaam verantwoordelijk 
is voor het ontstaan van ziekte. Echter, hoewel we elf MPO-specifieke antilichamen hebben 
gegenereerd, bleek geen enkele daarvan op zichzelf of in combinatie met elkaar ziekte te 
veroorzaken in muizen. Wel bleken sommige van de antilichamen in staat om een milde vorm 
van glomerulonefritis, geïnduceerd met antilichamen gericht tegen de glomerulaire 
basaalmembraan, te verhevigen. De betekenis hiervan voor de humane ANCA-geassocieerde 
vasculitis is nog niet helemaal duidelijk; in de toekomst zullen de verkregen antilichamen mogelijk 
van nut zijn bij verder onderzoek naar subtypespecifieke effecten van antilichamen in auto-
immuunziekten. 
Behalve het antigeen waar MPO-ANCA specifiek voor zijn, is MPO ook een zeer veelzijdig 
neutrofiel eiwit, met bepaalde eigenschappen en functies. Hoewel er weinig onderzoek naar is 
gedaan, bestaan er wel indirecte aanwijzingen dat MPO zelf een rol speel t in de pathogenese van 
MPO-ANCA geassocieerde vasculitis. Omdat het niet mogelijk is dit uit te zoeken in ons 
muismodel, proberen we in hoofdstuk 6 de eigenschappen van MPO nader te onderzoeken in 
een muismodel van renale ischemie-reperfusieschade. Dit is een model waarin kan worden 
onderzocht hoe zuurstofgebrek in de nier, gevolgd door het herstel van de circulatie (zoals dat 
bijvoorbeeld optreedt bij een niertransplantatie) tot schade leidt. Het blijkt dat de afwezigheid van 
MPO muizen beschermt tegen renale schade geïnduceerd door ischemie gevolgd door reperfusie. 
Mogelijk oefent MPO dus ter plaatse van een ontsteking een toxisch effect uit op de omgeving. 
Het is mogelijk dat iets dergelijks ook een rol speelt bij (MPO-) ANCA geassocieerde 
glomerulonefritis, maar onze resultaten staan in opvallend contrast met studies waarin MPO-
deficiëntie juist leidt tot meer schade na de inductie van bijvoorbeeld atherosclerose of een 
bepaalde vorm van encefalitis. 
In hoofdstuk 7 worden de voorgaande hoofdstukken nogmaals in een ruimer perspectief 
besproken, en wordt kort ingegaan op de vraag hoe het menselijk lichaam mogelijk wordt 
aangezet tot de productie van ANCA. 
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Nu ook het feest vastere vormen aan begint te nemen, wordt het tijd om me bezig te gaan 
houden met de meest verantwoordelijke taak van een promovendus: het schrijven van een 
dankwoord dat íedereen behelst die –op directe of meer indirecte wijze– een bijdrage aan dit 
proefschrift heeft geleverd. 
 
Peter, een goed proefschrift is afhankelijk van de uitvoering, maar vooral ook van de kwaliteit van 
het project en de begeleiding. Ik hoop dat dit proefschrift ook voor jou aantoont dat deze 
ingrediënten in meer dan voldoende mate aanwezig waren in onze samenwerking. Ik wil je bij 
deze bedanken voor de leerzame en gezellige tijd die ik onder jouw hoede heb gehad. Tenslotte 
wens ik je veel succes toe in Groningen, en ik hoop dat we contact houden. Jan Willem, bedankt 
voor het vertrouwen, en voor het mede in het oog houden van de grote lijnen. Onze discussies 
hielpen me realiseren dat er niet alleen muizen, maar ook mensen met ANCA-gemedieerde 
vasculitis bestaan! 
Anita, zonder jouw ervaring, kwaliteiten, energie, toewijding, mentale steun, gemopper, en niet in 
het minst je vrijdagse kookkunsten, zou dit boekje waarschijnlijk nog niet half zo dik zijn geweest. 
Ons project vereiste een hoge mate van teamwork, en ik denk dat niemand méér geschikt was 
voor ons team dan jij. Bedankt dat je de samenwerking hebt willen afronden door mijn paranimf 
te zijn. En ik kan me heel goed voorstellen dat jullie je eerste dochter niet ELISA hebben 
genoemd! 
De lijst van collega’s die verder betrokken zijn geweest bij het onderzoek en bij de vele 
interessante zijpaadjes die we zijn ingeslagen lijkt eindeloos, en ik hoop dat ik de mensen die ik nu 
ongetwijfeld vergeet niet te hard voor het hoofd stoot. Het enthousiasme waarmee iedereen heeft 
geholpen was indrukwekkend, en daar ben ik iedereen erg dankbaar voor. Een bijzonder woord 
van dank aan Bram, Jan, Ad, Pieter, Anita, de rest van het secretariaat, het lab Algemene 
Immunologie, José, Maria (ik ben je enorme steun tijdens de laatste maanden niet vergeten!), 
Petra, Ruud, Luciënne, Kim, Henk, Marcella, Marjan, Marjan, de mensen van het PLAN, Menno, 
Anique, Anna, Vicky, Bart, Robert, Astrid, Gerard, Wilfred, Heinz, Silvie, Ariane, Mariska, 
Carine, Saskia, Nadine, Paulien: jullie hebben mijn jaren als aio allemaal op je eigen manier 
beïnvloed, waren nooit te beroerd om een stapje extra te zetten (soms meer stapjes als dat eens 
nodig was …), en/of mij met allerhande adviezen bij te staan. Eric Steenbergen, een speciaal 
woord van dank voor jou en je groep: zonder jullie hulp zou de beginfase van het project er een
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stuk magerder uitgezien hebben! Moh Daha, bedankt voor de zinvolle discussies en suggesties. 
Helaas hebben we niet alle plannen in de praktijk kunnen brengen, maar een gesprek met u 
leverde altijd weer een geheel nieuwe blik op de materie. Tom, bedankt voor de diverse keren dat 
je ons controlecoupes hebt gestuurd. Finally, I would like to thank Professor Jennette and Hong 
Xiao for the inspiring and fruitful collaboration with their group. 
 
Ik ben ervan overtuigd dat relativeringsvermogen in het leven van een promovendus onmisbaar 
is. Gelukkig was er de afgelopen periode een grote hoeveelheid vrienden beschikbaar om dit in de 
praktijk te brengen, om frustraties te delen, een biertje te drinken, wat te sporten, wat te eten, of 
gewoon maar wat te vertellen. Arthur, als er iemand was die me altijd begreep was jij het wel. We 
spreken elkaar de laatste tijd wat minder frequent, maar keer op keer blijkt dat dit de kwaliteit van 
het contact niet beïnvloedt. Koen, na onze gemeenschappelijke middelbare schooltijd werd de 
(geografische) afstand tussen ons eerst een stuk groter, maar de laatste paar jaar zijn onze paden 
op miraculeuze wijze weer steeds meer parallel gaan lopen. Bedankt voor alle gesprekken, het mij 
ertoe overhalen toch nog enige lichamelijke arbeid te verrichten in de vorm van een aantal 
halsbrekende potjes squash, en niet te vergeten je hulp de afgelopen tijd met alle promotiezaken. 
Ik ben dankbaar dat je mijn paranimf wil zijn. 
Martijn en Steven, jullie bleken al snel meer dan zomaar twee collega-aio’s. Jullie grenzeloze 
relativeringsvermogen, humor, betrokkenheid, enthousiasme, energie, en natuurlijk het door jullie 
geïnitieerde en (zeker na de komst van Twan) al snel legendarische “kook-klupje”, leverden de 
broodnodige afleiding, en de energie om er de volgende dag weer met frisse moed tegenaan te 
gaan. Martijn, ik ben blij dat je mijn collega bent gebleven; ik ben ervan overtuigd dat je 
uiteindelijk je doel zult bereiken, en wens je veel succes op het pad ernaartoe. 
Matthias, Daniëlle, Jeroen, Judith, Linda, Natasja, Kitty, Suzanne, Marjo, Jeroen, Jeroen, Maura, 
Dorien, Frank, Jaap, Joost, Nicole, Rianne: de meesten van jullie waren minder bij het project zelf 
betrokken, maar jullie wisten altijd voor de broodnodige ontspanning te zorgen! Joost, leuk dat je 
ook in het onderzoek bent gestapt! 
 
Pap, mam, jullie hebben me áltijd, en in álles wat ik me iedere keer weer in mijn hoofd haalde, 
gesteund. Jullie enthousiasme, geduld en begrip hebben me geholpen te worden wie ik nu ben, en 
dit boekje is daar mede een gevolg van. Bedankt voor alles.  
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Babs en Nienke, het is een drukke tijd geweest, en af en toe dreigden jullie daar de dupe van de 
worden. Gelukkig maakten jullie me daar altijd attent op voordat de boel uit de hand liep. Dank 
voor jullie “down to earth” zijn, en voor jullie steun bij alles. 
Nadiya, your coming into my life was the greatest and most unexpected result of my time as a 
PhD-student. You were the one missing piece in the jigsaw of my life; thank you for all your 
support, your warmth, your enthusiasm, and for being who you are. We have been dreaming 
together now for almost three years and I hope that we will complement each other for many 
more. 
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